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70. Fig. 70: AGE specific fluorescence spectra of native HSA (H), 91 
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Abstracl 
Natural antioxidants from plant products have been reported to possess free radical 
scavenging properties and prevent oxidative damage without causing unwanted effects. 
Among various classes of chemicals present in the plants, phenolic compounds have 
tremendous health promoting effects as antioxidants. The phenolic compounds exhibit 
considerable free radical scavenging activities through their electron-donating and metal 
ion chelating properties. Since some antioxidants may act as inhibitors of glycation. in 
the first phase of stud\. \Nc evaluated in-vitro antioxidant activities of three 
phytochemicals: thymoyuinone (TQ), thvniol (TL) and eugenol (EU) by determining 
reducing po\~er. ferric reducing antioxidant power (FRAP). metal chelating activity, 
DPPH and AAPJ I radical scavenging assays. The phytochemicals were also found to 
have properties of chelating ferrous ions. Based on these data. it is clear that the TQ, TI. 
and EU contained high antioxidant activity and chelating properties. The all three 
phytochemicals were found to possess strong radical-scavenging and redox abilities as 
evidenced by model antioxidant assays including DPPH and FRAP. To evaluate whether 
the tested phytochemicals could affect glycation induced generation of ROS, cytochrome 
c reduction assay was employed. A significant decrease in the generation of superoxide 
radical was observed in the presence of these phytochemicals. This seemingly indicates 
that the phytochemicals either scavenge superoxide anion radicals or chelate transition 
metals leading to less free radical production, or they nia\ have both effects. The 
protective effect of these ph\tochemicals on AAPH-induced RBC hemolysis was 
observed in a dose dependent manner. EU possesses lower IC5, value as compared to TL 
and TQ as shown by higher inhibition of RBC hemolysis. Similarly. reducing power and 
FRAP value was found to be higher in case of EU as compared to TL and TQ. The order 
of antioxidant activity of these compounds was same in all antioxidant parameters tested 
viz. TQ<'I'L<EU. Among three phytochemicals, EU had the most powerful antioxidant 
and radical scavenging activity followed by TL and TQ which is related to their structure. 
TQ has weak electron donating groups contributing to less electron density to the 
benzene ring. However, electron density is found to be higher in TL and EU because of 
presence of hydroxyl group attached to benzene ring. Among EU and TL. EU has two 
electron donating groups viz. methoxy group (—OCH3) and allyl group (—CH,-
CH=CH,) at ortho- and para- position respectively which are more reactive sites as 
compared to meta- position while TL has %+eak electron donating groups at ortho- and 
meta- position (methyl and isopropyl) respectively. Hence it can he concluded that EU 
having maximum electron density showed best antioxidant activity among the three 
phvtochemicals. 
Non-enzymatic glycation. the reaction of glucose and other reducing sugars with amino 
group of proteins, produces Amadori or early glycation products, while longer exposure 
results in irreversible advanced glycation end products (AGEs). Glycation involves non-
enzymatic covalent attachment of carbonyl groups of glucose with N-terminal and lysyl 
side chain c-amino groups to form unstable Schiff base adduct that rapidly progresses to a 
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stable ketoamine derivative, the Amadori product. I lereatter, the reactions become more 
varied and complicated leading to the formation of AGEs. AGE formation is greatly 
accelerated in hyperglycaemic conditions and many studies so for have demonstrated the 
formation and role of AGFs in various diseases including diabetes. Glycation alters 
protein conformation and induces protein cross linking that eventually ensues in 
aggregation. Modifications of structural as well as circulatory proteins by glycation have 
drawn much attention because of their potential role in the etiopathogenesis of various 
diseases. 
As the glycation is a dose and time dependent process, in the second phase, a 
comparative study of HSA denaturationldegradation induced b) glucose for extended 
time period was performed. The structural perturbations in the glycated HSA samples 
were analyzed by UV absorbance. tryptophan fluorescence, circular dichroism, FTIR and 
gel electrophoresis techniques. The studies revealed remarkable structural and 
biophysical changes in LISA upon glycation by glucose up to 28 days. Estimation of 
ketoamine, carbonyl and free amino groups revealed that glycation induces 
conformational and structural changes in HSA. UV spectra of glycated HSA showed 
hyperchromicity as observed on da) 14 and post incubation hypochromicity thereafter. 
These changes are indicative of positional change of aromatic acids of HSA upon its 
glycation. The tryptophan fluorescence of FISA showed the same pattern as observed in 
UV spectra presumably involving same aromatic amino acids are involved in both 
spectral analysis. Glycation causes unfolding of protein leading to exposure of aromatic 
amino acids towards solvent system resulting in hyperchrornicity and gain in tryptophan 
fluorescence. I lowever, on further incubation up to 28 days causes shielding of aromatic 
amino acids contributing to hypochromicity and loss of fluorescence intensity. The 
significant observation in the tryptophan fluorescence was a blue shift on glycation. The 
results reiterate the earlier observation and suggest conformational changes in glycated 
LISA. The fluorescence intensity of AGEs was also found to be increased in glycated 
USA samples compared to native HSA. 
The Far-UV CD spectrum of glycated HSA showed a loss of helical structure as shown 
by a decrease in the negative ellipticity at 208 and 222 nm. The interaction between 
native and glycated HSA was confirmed by FTIR spectral analysis as well. Glycation of 
protein has been shown to result in the protein degradation and/or cross-linking and the 
observed alterations in the electrophoretic behavior of HSA incubated with glucose 
apparently results from such effects. Glvcated IISA migrated as highly diffuse band with 
the increase in incubation time and showed the presence of aggregates. I Iowever, native 
HSA migrated as a single band of 6GkD molecular %%eight. Next, colorimctric estimations 
were carried out to support the biophysical analysis. Ketoamine level at 7 days of 
incubation was found to be significantly higher in glycated HSA as compared to native 
-SA, which showed negligible ketoamine content. Levels of carbonyl groups were also 
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elevated in giNcated HSA, an important marker of both glycation and oxidative stress. 
Number of free amino groups in glvcated HSA samples was found to he decreased as 
compared to native USA. On the basis of above observations we can inter that 
incubations with glucose for up to 28 days resulted in a time dependent modification of' 
USA. Thus, prolonged exposure of HSA to glucose exerts greater deleterious effects on 
its structure and formation of aggregates. 
Hyperglycaemia and accumulation of AGES due to non-enzymatic glycation of proteins 
in tissues and serum have important roles in diabetic complications. Moreover. Amadori 
product is the principal form of gl>cation mediated modification in proteins. Recent 
investigations have shown that elevated concentrations of' Amadori products play a 
substantial role in diabetes-related complications. Although there have been important 
advances in the control of the hyperglycaemia of diabetes by means of diet, 
hypoglycaemic drugs, insulin and islet transplantation. The long term complications of 
diabetes such as cataract, nephropathy. retinopathy and atherosclerosis are still leading 
causes of death. These complications are a direct result of protein alteration which results 
in irreversible tissue damage. Thus, inhibition of the formation of AGE is believed to 
play a role in the prevention of diabetes-related complications. Designing a drug having 
anti-AGE activity is a challenge due to the complexity of reaction involved in the 
formation of AGE. The most studied and successful agent has been a nucleophilic 
hydrazine compound viz. aminoguanidine (AG) has shown promising results in-vitro and 
in animal models in terms of inhibition of ACE formation. A number of other agents such 
as pyridoxaminc, carnosine, taurine and phenyl thiazolium bromide have also been 
investigated in several studies and have shown promising results. However, except 
pyridoxamine. none has progressed as yet to the stage of clinical trials. Although some 
recent studies highlighted the antiglycating potential of a few natural sources, namely 
garlic, green tea and tomato adequate work has not yet been done. Thus there is a need 
for developing new antiglycating agents combining higher levels of efficacy. selectivity 
and safety in humans. Therefore, the identification of antiglycation compounds is 
attractine considerable interest. Many dietary agents, particularly spices, are a major part 
of traditional medicine that has been practiced to control many chronic ailments including 
diabetes. 
Q. I L and EL are commonly used commodities of diet and'or traditional medicine. 
Therefore, inhibitory effect of varying concentrations of IQ, 'fl and L•U on glycation to 
HSA induced by glucose was evaluated up to 28 days in-vitro. The interaction of LISA 
with glucose in presence of these phytochernicals was studied by absorbance, 
fluorescence and 1='IlR techniques. Both hyperchromicity and hlpochromicity was found 
to he decreased in presence of aminoguanidine (AG) and at all concentrations of TQ. Ti. 
and EU. Eugenol (0.6 µ1v1) sho\\cd highest reduction in hyper and hypochromicity in 
comparison to other formulations of its group. The reduction in conformational changes 
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due to gl)catiun in presence of G and ph\tuchcmicats sere c' ident at all time points. It 
indicates that the TO. TL and I:l inhibit the - lycation of I ISA as observed h) a reduction 
in the by herchromicil\ at ? and 14 days and decrease in h\rochromicity at 2-1 and 28 
daNs. Fluorescence spectra of' IISA also exhibited the same pattern as observed in 11V 
spectra. The characterization stud\ of' A(iF'.s \%as perlurtned using A(iF.-specific 
fluorescence and tluantitation h\ free I' sine side chains. Our results indicated that these 
ph%tochemicah at all comcentratir'in inhibit the gtivcation of' IISA as observed by a 
reduction in the formati~in of fluorescent :AGEs at 1.1. 21 and 28 days of incubation. 
Further. firntation of nest peaks on addition of AG. TQ. 'I1. or IJl in the infra-red region 
confirms the interaction ofthese ph\tochemicafs \\ith IISA as ohser\ed by IF 1k spectra. 
ketoamincs are carl non-enr\matic gl~cation adduct; and are important precursors of 
AGEs and h~drox 1 radicals. Inhibition of ketoamine formation in gl%cated IISA in 
presence of AG or \ ar\ ing concentrations of 1 Q. I L and EU \\as observed significantly 
at 7 days. Middle concentration of It tasted i.e. 0,6 ft\I sho ed maximum inhibition of 
ketoamine ti>rrnation hence. helpful in reducing the formation of gl cation induced 
rnterntediar eomptumis. heto:unine• \\ere concerted to protein hound carbonyl groups 
is a protein enediol reaction. Elie generation of' carbonvI groups serves as a marker of 
protein gM'eoxiddtidn. I he presence of' .\G and these phytochemicals in glycated I ISA 
sienificantly reduce the level of earbon\I content at ?. 14. 2I and 28 days. Further these 
ph\tochemicals reduced the amount of modified lysine side chains as compared to the 
control. Free radical generation during gl cation %%as confirmed h) quantitation of 
superoxide radicals in presence and absence of A6. '10. 'I'L. [Li and 501). The results 
indicate that earl. LI)cation i enerates free radicals 'shich "crc quenched significantly by 
the'e rhuochemicals and ,\(i. Studies s%ith these ph\tochemicals showed inhibition of' 
different parameters in gl cated IISA samples shossing a definite role of ROS in the 
modi f ication of el\ sated I ISA and AGE formation. 
Recent e%idences suggest that increased oxidative damage as \\ell as reduction in 
antioxidant capacity could he related to the complications in patients sith t)pe-2 
diabetes. Thus, the studs seas extended further to e'aluate the antioxidati e and 
antigl'cetive role of' TO (30 µh•1). II. t 0 }t\111 and [1 (0.6 µ\•1) in diabetic patients '\ith 
secondar% complicmn)n;. We ohser\ed the changes in \1D.\. protein carhon\l. I RAP. 
glutathione ((iSHt IC'els. protein crosslinking arid. or fragmentation in sera of these 
patients incubated in hcd.mad and absence of these ph\tochemicak for 21 dais. Sera of 
health\ individual \\ ithout any treatment served as cororoI. \lalondialdehvde (\1DA i and 
protein carbonyl levels \sere evaluated to determine the lipid and protein damage in 
serum. TRAP %alue and glutatl►ione lesel «as taken as the indicator of total antioxidatiott 
potential. \iF):A and carbon%) content \5 as found si gnificantl increased s hich strongly 
supported the increased osidatke damage in case of' diabetic patients as compared to 
healthy subjects. In-sitro treatment \sith these ph tochemicals sho%\ed a significant 
xx 
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decrease in their level in tvpc-2 diabetic patients. The Ie' cI of reduced L'Iutathiune as 
signiticantl' to er in the t\pe- diabetic patients as compared to normal subjects. On the 
in-vitro treatment %\ith pit'\tochemicals there was increase in its level in tspe-2 diabetic 
patients. hR;1P \ aloe in serum vas also lc Bred si,nificantl%. in t}pe-2 diabetic patients. 
Ph'tochentical treatment ameliorates I R.\P value. Decrease in M1).\ and carhonvl 
content %%ith a concomitant increase in (JSI I and I R.A1' levels on in-vitro treatment with 
ph\tochem lea Is \acre 1i1und to be more pronounced in thr case of eucertol at 0.6 It  
tollo ed h% th%mol ( (1 uM and th'moquinone (3(1 µ\11. 
Scrum profile of diabetic patient ;hos%s extensive I-ISA cross-linking. fragmentation and 
aggregate formation as observed h,- Jill'uson of band but the sera incubated ith TQ. TL 
and L- 1 exhibited inhibition of HST\ cross-linkink. trapmcntation and aggregate 
formation. Amongst the three ph%tochemicals. 1:U at the 0.6 uN1 concentration could 
inhibit diffusion of hand better than :0 }IM-1 of lQ and TL. The intake of these 
ph\tochenmicals may be helpful in diabetes related complications. 
:\II the three ph)tochernicals described in the present stud) have etunulati%e effect of 
antioxidant and anticl~catiun acti\ ities that might contribute to eliecti%e action. 
I to e er. the in-s itro results rat 	not reflect the effects of these agents in-v iv o as they 
undersgo biotranstormatioti process followed h\ the li%er first pass eftcct, which 
invariahlk atkct the content, activitN and bioavailabilit) of these compounds. Ilcnee, 
hirther investigations are needed to address these issues- Various substances included in 
(lie present stud\ are na turall) occurring. This fact and the results of the present stud) 
indicate the possihilit\ of therapeutic use of these phvtochemnicals k r the prevention of 
diabetic complications. .-\n important therapeutic factor %\orth of consideration is to 
administer the photochemical to diabetic patients. This is essential because it has been 
proposed that once the progress of excessive gkcation Iras begun, subsequent 
remediation ofht -perggtkcaemia'could not prevent diabetes related complications. 
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Introduction 
Glycation is a non-enzymatic reaction of the amino groups of amino acids, peptides, and 
proteins with carbonyl group of reducing sugars resulting in the formation of complex 
brown pigments and protein-protein crosslinks. It is occurring slowly but continuously in 
cells of all living organisms. It was first studied under defined conditions by Louis 
Camille Maillard in the early 1900s (Maillard and Gautier, 1912). Thus it came to be 
known as the Maillard reaction (Fig. i). Exact realization of the importance of Maillard-
like reactions in-vivo began in the mid-1970s when studies was done on haemoglobin A1c 
(HbA1 ,), a naturally occurring minor human haemoglobin that is elevated in diabetics 
(Bookchin and Gallop, 1968). HbAi, was known to be a post-translational adduct of 
glucose with the N-terminal valine amino group of the 3 chain of hemoglobin, in which 
the glucose was thought to be attached via non-enzymatically formed Schiff base 
structure. We found that measurement of the elevation of HbA 1 , in diabetics allowed 
assessment of the degree of glucose control integrated over several weeks (Koenig et al., 
1976). Later on. the significance of the complex, late stage Maillard processes was 
recognized as mediators of several complications in diabetes (Bunn et al., 1978) and 
aging (Monnier and Cerami, 1981). The Maillard reaction is actually a complex series of 
reactions and is sub-divided into three main stages: early, intermediate, and late. 
Early Stage: 
The nucleophilic addition reaction between a carbonyl group from a reducing sugar (e.g. 
glucose, fructose, galactose, mannose etc) and a free amino group is initiated with the 
reversible formation of an adduct known as Schiff base by conversion of the aldehydic 
carbon—oxygen double bond of the sugar to a carbon—nitrogen double bond with the 
amine. This reaction occurs over a period of hours. The Schiff base is a 
thermodynamically unstable form in relation to the equilibrium cycled pyranose or 
furanose forms. Therefore, the Schiff base gives rise to an enaminol intermediate by 
rearrangement and, subsequently, to a relatively stable ketoamine compound/Amadori 
compound and heyns product in case of fructose. Since this reaction does not require the 
participation of enzymes, the variables which regulate it in vivo are the degree and 
duration of hyperglycemia, the half-life of the protein, its reactivity in terms of free 
amino groups, and cellular permeability to glucose. In in vivo conditions, the Amadori 
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product reaches equilibrium after approximately 15-20 days and, through irreversible 
links, accumulates on both short-lived and long-lived proteins (Lapolla et al., 2005). 
Intermediate Stage: 
In the second stage. the Amadori compound further undergoes a series of dehydration and 
fragmentation reactions generating a variety of carbonyl compounds with some formation 
of initial cross-linked protein species. Carbonyl compounds are generally more reactive 
than the original carbohydrate and act as propagators by reactions with free amino 
groups. Among the most active enhancers of the reaction are a-dicarbonyls such as 
methylglyoxal, glyoxal, glucosones, deoxyglucosones and dehydroascorbate (Thornalley 
et al., 1999). 
Late Stage: 
In the late stage, these propagators again react with free amino groups and, through 
oxidation, dehydration and cyclization reactions, form yellow-brown, often fluorescent, 
insoluble. irreversible compounds, usually called Advanced Glycation End-Products 
(AGEs), sometimes known as "melanoidins", which accumulate on long-lived proteins 
and cause damage and extensive protein cross-linking. AGEs are characterized by a wide 
structural and physicochemical diversity. 
Reducing sugars other than glucose can participate in glycation and do so much faster 
than glucose, which is the least reactive of all sugars. This may explain why glucose has 
been selected as the major metabolic sugar during evolution (Bunn and Higgins, 1981). 
Glucose is the major metabolic sugar present in our body. Even in euglycemic normal 
individual the level of glucose in plasma is between 65 mg/dl to 100 mg/dl. Therefore 
even in non-diabetic euglycemic individuals' plasma and other proteins are regularly 
interacting with glucose and result in formation of glycated end products such as AGEs. 
Wolffenbuttel et al., (1996) suggested that modification of hemoglobin by advanced 
glycosylation end products would be a better index for long term glycemia in diabetic 
patients. While glycation can be detected in physiologic conditions like aging, the 
reactions are considerably faster and more intensive in the pathophysiologic conditions 
like the uncontrolled diabetes mellitus associated with persistently elevated blood glucose 
concentration (Thornalley, 2003). In addition to the multiple pathologies mediated by the 
in-vivo generated AGEs, various exogenous sources such as diet and smoking may also 
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add significantly to the damage caused by those generated in the body (Koschinsky ci al.. 
1997). 
Recent data showed that, in spite of the fact that sugars are the main precursors of AGE 
compounds, numerous intermediary metabolites, i.e. alpha-oxoaldehydes, also creatively 
participate in non-enzymatic gtkcation reactions. Such intermediary products are 
generated during glycolysis (methylglyoxal) or along the polyolic pathway and can also 
be formed by autoxidation of carbohydrates (glyoxal). As compared to glycation 
reactions involving molecules like nucleic acid and lipids, protein glycation has been 
studied extensively showing numerous structural alterations including exposure of thiols, 
protein compaction, cross linking, fragmentation and susceptibility to proteolysis (Seidler 
and Seibel, 2000). Glycation by various sugars of a limited number of amino groups in 
proteins like hemoglobin, albumin and low density lipoproteins induce number of 
alterations in proteins and loss of biological activity (Turk, 2001). These include 
conformational alterations, exposure of hydrophobic residues and thiols, loss in allosteric 
sensitivity (Bunn and Briehl, 1970), ligand binding (McDonald et al.. 1979) and receptor 
recognition. In diabetes mellitus, protein glycation and glucose auto-oxidation may 
generate free radicals, hich in turn catalyzes lipid peroxidation (Baynes. 1991). 
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Fig. 1: Glycation of a protein by glucose and subsequent formation of AGEs (Ahmed, 
2005). 
3 
Introduction 
ADVANCED GLYCATION END PRODUCTS (AGEs): 
AGEs are complex, heterogenous molecules that cause protein cross-linking. exhibit 
browning and generate fluorescence. The formation of AGEs in-vitro and in-vivo is non-
enzymatic and dependent on the turnover rate of the chemically modified target, time and 
sugar concentration. Persistent hyperglycemia induces abnormal changes such as increase 
of advanced glycation end products (AGEs) formation, increase of polyol pathway flux, 
and activation of protein kinase C isoforms (Brownlee, 2001; Evans et al., 2002). Protein 
modification with AGE is irreversible, as there are no enzymes in the body that would be 
able to hydrolyze AGE compounds. These structures then accumulate during the lifespan 
of the protein on which they have been formed. For example, tens crystalline proteins 
(Stevens el al.. 1978). insulin (Dolhofer and Wieland, 1979). proteins of erythrocyte 
membrane (Miller et al., 1980), bovine serum albumin (Arakawa and Timasheff, 1982), 
human serum albumin (Shaklai et al.. 1984). enzymes (Coradello et al.. 1982), high and 
low density lipoproteins (Kirstein et al., 1990), peripheral nerve myelin (Greene, 1983), 
elastin (Baydanoff ei al.. 1987) and immunoglobulin G (Newkirk ei al., 2003). 
CLASSIFICATION OF AGES: 
AGEs are usually grouped into fluorescent, non-fluorescent compounds and cross linking 
AGEs. Some authors also grouped them into toxic and non-toxic AGEs. Toxic AGEs 
seem to derive from glycolaldehyde or glyceraldehyde and their structures remain to be 
elucidated (Sato et al., 2006). Many AGEs fluoresce under UV light and are capable of 
intra and inter-molecular cross-linking, but not all share these properties (Wautier and 
Schmidt, 2004). On the basis of these two properties AGEs can be classified into three 
categories (Fig. 2). 
1. Fluorescent AGE crosslinks:— Protein-protein crosslinks by these structures in-vivo 
are thought to be responsible for a major share of the deleterious effects of AGEs in 
diabetes and aging. Along with brown colour, fluorescence is one of the qualitative 
properties classically used to estimate these AGEs. For example, pentosidine, 
crossline, pentodilysine, vesperlysine A, B and C. Pentosidine was first isolated and 
identified FRom dura mater collagen and has since been identified in many tissues 
(Sell et al., 1991). 
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2. Non-fluorescent AGE crosslinks:- Although their ease of detection makes them 
useful markers of AGE formation, the fluorescent AGE cross-links are thought to 
account for only one percent or less of the total cross-linking structures formed under 
physiological conditions (Dyer et al.. 1991). Thus, the major AGEs responsible for 
protein-protein cross-linking in-vivo are non-fluorescent structures that have not yet 
been conclusively identified. The structure of three common examples of this class 
are imidazolium dilysines, alkyl formyl glycosyl pyrrole and arginine-Ivsine 
imidazole. 
3. Non-crosslinking AGEs:- Besides the cross-linking AGEs, a number of non-
crosslinking AGEs have been reported under physiological conditions. They may 
have deleterious effects as precursors of cross-links or as biological receptor ligands 
causing a variety of adverse cellular and tissue changes. Pyrraline, 
carboxymethyllysine and imidazolones are examples of non-crosslinking AGEs. 
AUTOXIDATIVE GLYCATION AND GLYCOXIDATIO\N: 
Oxidation processes are important in the formation of many AGEs (Lapolla et al.. 2005). 
Two routes have been proposed for AGEs formation. The first involves auto-oxidation of 
free sugar. Monosaccharides, like glucose, exist in equilibrium with their enediol, which 
can undergo autoxidation in the presence of transition metals to form an enediol radical 
(Wolff and Dean, 1987). This radical reduces molecular oxygen to generate the 
superoxide radical (02 ) and becomes oxidised itself to a dicarbonyl ketoaldehyde that 
reacts with protein amino groups forming a ketoimine. This is referred to as autoxidative 
glycation and is outlined in Fig. 3(a). Ketoimines are similar to. although more reactive, 
than Amadori products and participate in AGE formation. 
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(a) Fluorescent Cross-linking AGEs 
Pentosidine 
(b) Non-Fluorescent Cross-linking AGEs 
rnleia 
1'rvtcia 
Imidazolium dilysines 
(111 
Alkyl tormyl glycosyl pyrrole 
rR+~ 
Il\ 	 Pmkin 
N 
It 	 it 
Arginine-lysine imidazole 
(c) Non-Cross-linking AGEs 
lit' -0 
(11,011 
Pyralline 
I I ,.(' --  a 	Pn+rin 
Carboxymethyllysine 
Fig. 2: Chemical structure of (a) Fluorescent cross-linking AGEs, (b) Non-fluorescent 
cross-linking. AGEs, (c) Non-cross-linking AGEs (Ahmed, 2005). 
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The second mechanism involves autoxidation of Amadori products to AGEs as shown in 
Fig. 3(b). Protein-bound products of the Amadori pattern, in the presence of molecular 
oxygen and transition metals, are oxidized and give origin to highly reactive protein-
enediols generating protein-dicarbonyIs and superoxide radical. The protein dicarbonyl 
compounds can participate in AGE formation and referred to as glycoxidation products. 
Once formed, the superoxide radicals can be converted to highly reactive hydroxyl 
radical via the fenton reaction. ROS such as O[, H202. and 'OH may contribute to these 
reactions. which require trace levels of catalytic redox-active transition metal ions. The 
process also includes oxidative steps and is therefore called glycoxidation (Bousova et 
al., 2005; Elgawish et al., 1996; Yim et al., 1995) 
RECEPTORS FOR AGES (RAGE) 
A number of AGE receptors (RAGE) have been identified in macrophages, endothelial 
and several other types of cells (Skolnik etal., 1991). Phagocytic cells expressing RAGE 
internalize and digest AGE modified proteins and therefore these receptors are implicated 
in protein turnover, tissue remodeling and inflammation (Schmidt et al., 2001; Vlassara, 
2001). Expression of RAGE is enhanced in certain cells during diabetes and 
inflammation. Interaction of AGE with their cellular receptors generates intracellular 
oxidative stress resulting in the activation of the transcription factor NF-kB and 
subsequent gene expression which is relevant in diabetic complications (Zill et al., 2001). 
NF-kB modulates gene transcription for endothelin-1, tissue factor and thrombomodulin 
and generation of pro-inflammatory cytokines such as interleukin-la, interleukin-6 and 
tumor necrosis factor-u (Neumann et al., 1999). There is also enhanced expression of 
adhesion molecules including vascular cell adhesion molecule-I and intercellular 
adhesion molecule-1, in addition to other effects such as increased vascular permeability. 
The intracellular signaling pathways following activation of RAGE by AGEs are outlined 
in Fig. 4. The importance of oxidative stress, following binding of AGEs with RAGE in 
endothelial cells was demonstrated by a study which showed that NF-kB and haem-
oxygenase messenger RNA, both markers of oxidative stress, become activated. The 
same study also showed increased oxidative stress in animals after infusion of AGEs 
(Yan et al.. 1994). 
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BIOLOGICAL EFFECTS OF AGE FORMATION: 
AGEs are formed in excess during aging, diabetes mellitus and renal failure (Schleicher 
et al., 1997). AGE modifications influence the structural as well as functional properties 
of proteins. Due to AGE modifications. several enzymes alter their activity. 
Methylglyoxal-modified serum albumin exhibits impaired esterase activity compared to 
unmodified albumin (Ahmed and Thornalley, 2005). Moreover cystein proteases like 
cathepsins are inhibited by methylglyoxal modification at active site of cysteins (Zeng 
and Davies, 2005). Glycated and crosslinked proteins exhibit an increased resistance to 
proteasomal protein degradation, and hence results in markedly enhanced biological half-
life (Bulteau et al., 2001). In contrast to intracellular proteins, collagen in the 
extracellular matrix (ECM) has a relatively long biological half-life and is directly 
exposed to high levels of glucose outside the cell. Indeed, modified collagen becomes 
more resistant to degradation by metalloproteinases which cause accumulation of AGE-
modified collagens in the ECM which mediate its stiffening leading to heart and vessel 
dysfunction (Badenhorst et al., 2003). Lens crystallins are also a long-lived target, 
leading to cataracts. Damage to DNA due to AGE formation may cause birth defects 
(Ulrich and Cerami, 2001). Thus AGEs appear to damage cells by three mechanisms 
(Fig. 5): 
The first is the modification of intracellular proteins/intracellular glycation including, 
most importantly, proteins involved in the regulation of gene transcription (Giardino et 
al., 1994; Shinohara et al., 1998). The second mechanism being, these AGE precursors 
can diffuse out of the cell and modify adjacent extracellular matrix molecules 
nearby/cross-link formation (McLellan et al., 1994) with changes signaling between the 
matrix and the cell causes cellular dysfunction (Charonis et al., 1990). The third 
mechanism being, these AGE precursors diffuse out of the cell and modify circulating 
proteins in the blood, such as albumin. These modified circulating proteins can then bind 
to AGE receptors and activate them, thereby causing the production of inflammatory 
:ytokines and growth factors, which in turn cause vascular pathology (Smedsrod et al., 
7; Vlassara et al., 1995). 
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Fig. 5: Harmful effect of AGEs (Lapolla et al., 2005). 
The major sways in which glycation changes protein functions are by: 
a) Inhibition of regulatory molecule binding 
b) formation of cross linkage of glycated protein 
c) trapping of glycated proteins by extracellular matrix 
d) decreasing the susceptibility of protein to proteolysis 
e) loss of biological activity of enzymes including malate dehydrogenase, 
glucose-6-phospahte dehydrogenase, glutathione reductase, glyceraldehyde-3- 
phospahte dehydrogenase, catalase and superoxide dismutase (Heath et al., 
1996). 
0 abnormality of nucleic acid function 
g) increased immunogenicity in relation to immune complex formation (Turk, 
2001). 
GLYCATION OF HUMAN SERUM ALBUMIN: 
Human serum albumin is a major protein component of the serum. Albumin contains 585 
amino acids and has a molecular weight of 66 kD. This globular protein contains 18 
tyrosines, six methionines, one tryptophan, 17 disulphide bridges, and only one Free 
cysteine, (Cysteine-34) (Sugio et al., 1999). Structurally it consists of 67% of the 
secondary structure which comprises 28 a-helical segments. Rest of the secondary 
structure consists of 10% n-turns and 23% extended peptide chain. The tertiary structure 
of HSA is arranged in heart shape in three homologous domains 1, I1, Ill (Fig. 6). It 
Inlroductio,r 
contains only one tryptophan located in domain 11 (Coussons et al., 1997; Weber, 1975). 
This highly soluble protein is present in human plasma at normal concentrations between 
35 and 50 gIL. Human serum albumin is a member of the multi-gene family of proteins 
that include u-fetoprotein and human-group specific component. In normal conditions, its 
half-life is about 20 days, and its plasma concentration represents equilibrium not only 
between its synthesis in the liver and its catabolism, but also its transcapillary escape. It is 
produced in the liver at a rate of nearly 0.7 mg/g of liver tissue per hour (Peters, 1970). 
Its production is under the control of insulin and somatotropin (Hutson et al., 1987). 
Albumin has several important physiological and pharmacological functions. It transports 
metals, fatty acids, cholesterol, bile pigments, and drugs. It is a key element in the 
regulation of osmotic pressure and distribution of fluid between different compartments. 
Its most striking property is its ability to bind an unusually broad spectrum of ligands 
(Brown. 1982). These include inorganic cations, organic anions, various drugs, amino 
acids, and perhaps most important. physiologically available hydrophobic molecules like 
bilirubin. hemin, and fatty acids. As a result, albumin is considered a multifunctional 
plasma transport protein. 
Albumin is also responsible for storage and transport of a large number of drugs in the 
plasma (Bhattacharya et al., 2000). It is also supposed to have a high affinity to metal 
ions such as Cu`' and Zn2.  and act as an antioxidant in the vascular compartment due to 
its scavenging of reactive oxygen and nitrogen species generated due to basal aerobic 
metabolism normally and formed at an increased rate during inflammation (Halliwell and 
Gutteridge, 1990). It is present in the serum in a soluble form and is a major contribute to 
80% of plasma colloid pressure (Lundsgaard-Hansen, 1986). 
It also acts as an important Acid-Base buffer in plasma. HSA non-enzymatically reacts 
with glucose to form a stable glycated albumin (Shaklai et al.. 1984). This process is 
especially elevated in Diabetes (Dolhofer and Wieland, 1980) due to increased glucose 
concentration in plasma. This process of non-enzymatic glycation proceeds in a glucose 
concentration, incubation period and temperature dependent manner (Baynes et al., 
1984). The principle site of glycation of HSA is lysine-525, but the lysine residues in 
positions 199, 281, and 439 are also susceptible to glycation. In addition there are six 
more residues that glycate but with much less efficiency (Shaklai et al.. 1984). 
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Fig. 6: Schematic Kira%%irsg of the I IS:% molecule. leach ,uhdomain is marked %%ith a 
different colour (ye1Ia%%.Ia: green. Ib: red. I[a: magenta, Ilb: blue, Ilia; and cyan IIlb). N- 
and C- termini are marked N and C, respectively. Arginine 117. lysine 351 and lysine 475 
which may be sites for binding long-chain fatty acids are colored white (Sugin et al.. 
1999). 
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The in-vitro exposure of protein to glucose results in the non- enzymatic covalent 
attachment of glucose to lysine side chains in a manner that observed in-vivo. HSA is 
typically three times more glycated than the rest of the population in conditions of 
hyperglycemia (Bourdon et al., 1999). In diabetes, USA may rise from 6-10% to 20-30% 
and hence serves as the indicator of glycation (Nakajou et al., 2003). HSA also represents 
the major and predominant circulating antioxidant in plasma known to be exposed to 
continuous oxidative stress (Soriani et al., 1994). Glucose and free radicals were found to 
impair the antioxidant properties of the serum albumin (Bourdon et al., 1999). Many 
studies show the presence of elevated levels of oxidized albumin, in patients with 
diabetes mellitus (Suzuki et al., 1992), aging (Era et al., 1995), patients with chronic 
hepatitis C (Rigamonti et al., 2003), oxidized albumin is a reliable marker of oxidative 
stress in hemodialysis patients (Mera el al., 2005) and many other diseases. 
INHIBITION OF GLYCATION: 
Body has several humoral and cellular defence mechanisms to protect tissues from 
deleterious effects of glycation reaction and AGE accumulation. These include the 
glyoxalase systems (I and II) that catalyses the deglycation of methylglyoxal to D-lactate 
(Thornalley, 1998). The discovery of deglycating enzymes has implications for the repair 
of protein damage by fructose (Monnier, 2005). A variety of plasma amines may react 
with sugar and Amadori carbonyl groups to reduce AGEs. Numerous compounds have 
been investigated for anti-glycation activity and the various sites where potential anti-
glycation or AGE compounds could act are outlined in Fig. 7. Currently several strategies 
are employed to control protein glycation. 
(i) Block free amino groups on proteins, preventing glycation by free sugars. 
However, the biological effect of reducing free protein amino groups is not 
known. 
(ii) Block carbonyl groups on reducing sugars, Amadori products and dicarbonyl 
intermediates (3-deoxyglucosone, methylglyoxal, etc.) effectively reducing 
glycation and/or AGE formation. Again, the effect of reducing available carbonyl 
groups in-vivo may not be desirable. 
14 
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(iii) Antibodies may be used to block Amadori products. This approach has the 
advantage of specificity compared to use of compounds that merely recognize 
carbonyl groups. 
(iv) Chelation of transition metals by ceruloplasmin may reduce glycation-derived 
free radicals. However, many transition metals have important physiological 
functions and their complete removal may have undesirable consequences. 
(v) Antioxidants may protect against free radicals derived ,ia autoxidative glycation, 
glycoxidation and AGEs. 
(vi) Enzymes (Amadoriases) may be used to deglycate Amadori products or inactivate 
intermediates such as 3-deoxyglucosone. 
(vii) AGE-cross-link breakers offer the potential of reversing diabetic complications 
although their precise mechanism of action is still unclear. 
(viii) RAGE blockers could prevent interaction of AGEs with RAGE to suppress the 
cellular and inflammatory changes associated with the development of diabetic 
complications. 
DIABETES: 
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia 
with disturbances of fat, carbohydrate and protein metabolism resulting from defects in 
insulin secretion and/or insulin action (Turko et al., 2001). The recent statistics indicate 
that the global prevalence of DM, estimated as 366 million in 2011, will increase up to 
522 million by 2030 (Whiting etal., 2011). Diabetes is the fifth leading cause of death in 
the US and the number of people with diabetes in the world is expected to approximately 
double between 2000 and 2030 (Wild et al.. 2004). India has world's largest number of 
diabetic subjects and the prevalence of diabetes and impaired glucose tolerance were 
12.1% and 14.0% respectively, with no gender difference (Ramachandran et al.. 2001). 
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The prevalence of diabetes in India is about three times higher in urban population 
compared to rural population and also the prevalence of diabetes varies widely across the 
nation, a very high prevalence (16.3%) was reported in Thiruvanathapuram in Kerala 
State in the year 1999, in the same year. a prevalence of 8.3 per cent was reported from 
Guwahati (Moebus eta!, 2010; Ramachandran et al., 2001). Depending on the etiology 
of DIM, factors contributing to hyperglycemia may include reduced insulin secretion, 
decreased glucose utilization and increased glucose production (Kasper el al., 2005). 
Distinct types of diabetes mellitus (DM) are caused by complex interactions of genetics, 
environmental factors and life style choices. In the United States, DM is the leading cause 
of end-stage renal disease, non-traumatic lower extremity amputations and adult 
blindness. 
CLASSIFICATION OF DIABETES: 
Classification of 1)M1 is on the basis of pathogenic process that leads to hyperglycemia. 
• Type I diabetes results from (3-cell destruction, usually leading to absolute insulin 
deticiencv . 
• Type 2 diabetes results from a progressive insulin secretory defect on the background 
of insulin resistance. impaired insulin secretion and increased glucose production. 
• Other specific types of diabetes due to other causes, e.g. genetic defects in (i-cell 
function, genetic defects in insulin action. diabetes of the exocrine pancreas (such as 
cystic fibrosis), endocrinopathies (e.g. acromegaly, hyperthyroidism) and drug or 
chemical induced (such as nicotinic acid, protease inhibitors) or due to infections (e.g. 
congenital rubella). 
• Gestational diabetes mellitus include impaired glucose tolerance during pregnancy. 
DIABETIC COMPLICATIONS: 
The complications of DM affect many organ systems and are responsible for the majority 
of morbidity and mortality related to the disease. One of the most prevalent metabolic 
syndromes world-wide, diabetes mellitus (DM), is characterized by hyperglycemia 
resulting in short-term metabolic changes in lipid and protein metabolism and long-term 
irreversible vascular and connective-tissue changes. These changes include diabetes-
specific complications such as retinopathy. nephropathy, neuropathy and complications 
17 
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of the macro-vasculature such as atherosclerosis; potentially resulting in heart disease, 
stroke and peripheral vascular disease (Hudson, 2002). 
In diabetic subjects, hyperglycemia is widely recognized as the major cause of diabetic 
secondary complications due to over generation of ROS (Fig. 8) (Palm et a(., 2003). 
Several hypotheses relating to hyperglycemia have been proposed. Four main hypotheses 
as shown in Fig. 9 are: (i) Increased polvol pathway flux. (ii) Increased advanced 
glycation end product (AGE) formation. (iii) Activation of protein kinase C isoforms, and 
(iv) Increased hexosamine pathway flux. 
1. Diabetic retinopathy: 
Diabetic retinopathy is one of the most important microvascular complications in 
diabetes and is a leading cause of acquired blindness among the people of occupational 
age (L'Esperance et al.. 1990). In a large population-based study, prevalence of any 
degree or proliferative retinopathy was highest in the younger-onset, insulin-taking 
diabetic patients and lowest in older-onset group not taking insulin (Klein et al.. 1984). 
The prevalence of diabetic retinopathy increases with duration of diabetes. 
Diabetic retinopathy involves both morphological and functional changes in the retinal 
capillaries, including basement membrane thickening, loss of pericytes, increased 
permeability and vascular dysfunction. AGEs have been detected in retinal blood vessel 
walls and contribute towards vascular occlusion and increased permeability of retinal 
endothelial cells causing vascular leakage (Beisswenger et al., 1995). AGEs exert their 
effect on microvascular endothelial cells and pericytes by upregulating levels of their 
RAGE messenger RNA (Tanaka et al.. 2000). AGEs may cause loss of pericytes and 
death of endothelial cells in diabetic retinopathy. The role of AGE in the development of 
diabetic retinopathy and the effect of the AGE-formation inhibitor. aminoguanidine, has 
been examined in animal models (Hammes ci ul., 1995). 
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2. Diabetic nephropathy: 
Diabetic nephropathy is a leading cause of end stage renal disease, and accounts for 
disabilities and the high mortality rate in patients with diabetes (Krolewski et al., 1991). 
Development of diabetic nephropathv is characterized by glomerular hyperfiltration and 
thickening of glomerular basement membranes, followed by an expansion of extracellular 
matrix in mesangial areas and increased urinary albumin excretion rate. Diabetic 
nephropathy ultimately progresses to glomerular sclerosis associated %Kith renal 
dysfunction (Sharma and Ziyadeh, 1995). 
Serum AGE levels reflect the severity of diabetic nephropathy and their measurement can 
predict the histopathological conditions (Berg et al., 1997). Circulating serum AGE level 
is so markedly increased in patients with diabetic nephropathy and renal insufficiency 
that it cannot he cleared by the kidneys (Turk, 2001). A number of studies have 
demonstrated that aminoguanidine decreased AGE accumulation and plasmaprotein 
trapping in the glomerular basement membrane (Raj et al., 2000). 
3. Diabetic neuropaihv: 
Diabetic neuropathics are a family of nerve disorders caused by diabetes. People with 
diabetes can, over time, develop nerve damage throughout the body. Diabetic neuropathy 
is associated with risk factors for other vascular complications such as poor metabolic 
control, dyslipidemia, hypertension, body mass index, smoking, microalbuminuria and 
retinopathy (Cameron et al., 2001 Forrest et al., 1997; Tesfaye ei a)., 1996). Both 
vascular and metabolic factors have been involved in the pathogenesis of diabetic 
neuropathy. Studies in human and animal models have shown reduced nerve perfusion 
and endoneurial hypoxia. which might play a role in nerve dysfunction (Ibrahim et al., 
1999). An interaction between AGE-myelin and macrophages may initiate or contribute 
to the segmental demvelination associated %%ith diabetic neuropathy (Vlassara et al., 
1984). Aminoguanidine (AG) treatment inhibits an accumulation of fluorescent AGE in 
diabetic nerves, and partially prevents demyclination and axonal atrophy probably 
through the correction of endoneurial microcirculation (Sugimoto and Yagihashi, 1997). 
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4. Diabetic atherosclerosis: 
Atherosclerotic arterial disease may be manifested clinically as cardiovascular disease 
(CVD). CVD is responsible for about 70 % of all causes of death in patients with type-2 
diabetes (Laakso. (999). Conventional risk factors, including hyped ipidemia, 
hypertension. smoking, obesity, lack of exercise, and a positive family history, contribute 
similarly to macro~'ascular complications in type-2 diabetic patients and non-diabetic 
subjects (Laakso, 1999). AGES formed on the extracellular matrix results in decreased 
elasticity of vasculatures, and quench nitric oxide, which could mediate defective 
endothelium-dependent vasodilatation in diabetes (Bucala ei al., 1991). AGE 
modification of low density lipoprotein (LDL) exhibits impaired plasma clearance and 
contributes significantly to increase LDL in-vivo, thus being involved in atherosclerosis 
(Bucala et al., 1995). Binding of AGEs to RAGE results in generation of intracellular 
ROS generation and subsequent activation of the redox-sensitive transcription factor NF-
kB which promotes the expression of a variety of atherosclerosis-related genes. Taken 
together. in diabetes. when fueled by hyperglycemia. AGEs and oxidative stress, the 
AGL-RAGE axis amplifies vascular stress and accelerates atherosclerosis and neointimal 
expansion (Naka et al., 2004). Blockade of the AGE-RAGE interaction may lead to a 
successful reduction of CVD in diabetes. Other study shows a correlation between AGE 
levels and the degree of atheroma in cholesterol-fed rabbits, and that AG has an anti-
atherogenic effect in these rabbits by inhibiting AGEs formation (Panagiotopoulos et al., 
1998). 
PROTEIN OXII)ATION IN DIABETES: 
Increasing evidence in both experimental and clinical studies suggests that oxidative 
stress plays a major role in the pathogenesis of both types of diabetes mellitus. Free 
radicals are formed disproportionately in diabetes by glucose oxidation, non-enzymatic 
glycation of proteins, and the subsequent oxidative degradation of glycated proteins. 
Abnormally high levels of free radicals and the simultaneous decline of antioxidant 
defense mechanisms can lead to damage of cellular organelles and enzymes, increased 
lipid peroxidation, and development of insulin resistance. These consequences of 
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oxidative stress can promote the development of complications of diabetes mellitus 
(Baynes and Thorpe. 1999; Ceriello ci al., 2000). 
Diabetic patients exhibit elevated levels of intracellular iron and copper ions which in the 
presence of glycated proteins, have been shown to enhance the generation of free radicals 
in-vitro (Dean er al., 1991). These highly reactive species in turn are able to induce 
oxidative degradation of protein in-vitro (Pacifici and Davies, 1991). Glycation is a major 
source of ROS i.e.. generated by oxidative pathways of glycation (Rahbar and Figarola, 
2003). Several studies support the idea that glycation and oxidation are closely linked 
processes; glucose autoxidation plays an essential role in non-enzymatic glycation of 
protein. AGEs are important source of free radicals resulting from non-enzymatic 
glycation and oxidation of proteins and lipids (Thomas et al., 2005). Free radicals and 
glycation are central to chronic diseases, degeneration and ageing. Overproduction of free 
radicals accelerates cell ageing and is counteracted by antioxidants. The analysis of 
mechanism generating free radicals and of the reaction of AGEs with cellular metabolism 
opens new avenues for the delaying of the development of chronic diseases like diabetes 
and neurodegenerative diseases (Giardino et al., 1998). 
ANTIGLYCATING AGENTS: 
The first compound that has been extensively studied in-vitro and in-vivo to be a 
powerful inhibitor of AGE formation is arninoguanidine (Brownlee et al.. 1986). AG 
prevents the formation of fluorescent AGEs and glucose derived collagen cross-linking. 
The mechanism of inhibition of AGE formation by AG involves trapping of reactive 
dicabonyl intermediates such as methylglyoxal. glyoxal and 3-dcoxyglucosone 
(Thornalley. 2003; Thornallcy et al.. 2000). In addition to chelating or antioxidant 
activity, AG also acts as true scavenger of carbonyl compounds (Thomalley et al., 2000). 
Pyradoxamine, a form of vitamin 136. found to inhibit carboxymethyl lysine formation in- 
vitro but it does not interact directly with Amadori intermediates but interfere with the 
post amadori oxidative reactions by binding catalytic metal ions (Chetyrkin et al.. 2008; 
Voziyan et al., 2003). Many studies suggested that metal catalyzed oxidation plays a 
critical role in glucose induced modification in collagen. Transition metals like Cu" ions 
can catalyze both glycation and glycoxidation in concentration dependent manner 
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(Sajithlal et al., 1999). Carnosine appears to possess antiglycating, antioxidant and free 
radical scavenging activity. Carnosine inhibits inactivation and crosslinking of enzymes 
including superoxide dismutase glycation (Ukeda et al., 2002) and oxidation (Stvolinskii 
ei al., 2003). It was found recently the imidazolium group of histadine on carnosine 
stabilizes the adduct formation at the primary amino group and hence it may play an 
important role for an anti-crosslinking agent (Hobart ci al.. 2004). Some anti-
inflammatory compounds such as acetylsalicylic acid, ibuprofen indomethacin were also 
reported to inhibit glycation by preventing the oxidative stress associated with the 
formation of AGE (Caballero et al., 2000; Shastri et al.. 1998; Sobal and Menzel, 2000). 
Aspirin was also found to inhibit pentosidine formation (Fu et al., 1994; Urios et al., 
2007). Some anti-diabetic drugs metformin and progiatazone were also reported to be 
powerful AGE inhibitors (Rahbar et al.. 2000). Recently, two new classes of aromatic 
compounds. derivatives of aryl (and heterocyclic) ureido and aryl (and heterocyclic) 
carboxamide-phenoxy-isobutyric acids and benzoic acids have been reported to be potent 
inhibitors of glycation and AGE formation (Rahhar and Figarola, 2003). In-vitro studies 
showed that they could directly interact with several reactive dicarbonyls such as glyoxal 
and methylglyoxal. The %%ere also found to be potent chelators of Cu'-  and therefore can 
suppress hydroxyl radical production during sugar autoxidation and glycation reactions 
(Rahbar and Figarola, 2003). 
Recent studies have highlighted the possible benefits of using plant extracts for 
decreasing glycation over the currently used drugs (Rates, 2001). Flavonoids like 
quercetin and rutin represent the most common and widely distributed group of plant 
phenolics and are abundant in foods. They show important antioxidant and AGE 
inhibitory properties according to their structure (Farrar et al., 2007). Quercetin has been 
shown to attenuate diabetic nephropathy in streptozotocin-diabetic rats (Anjaneyulu and 
Chopra, 2004). Bonnefont-Rousselot (2004) stated that improved antioxidant status is one 
mechanism by which dietary antioxidant treatment contributes to the prevention and 
reduction of diabetic complications (lung ci al.,2008). 
Garcinol, isolated from Garcinia indica fruit rind has been shown to possess antiglycating 
property in-vitro along with antioxidant and metal chelating properties (Yamaguchi et al., 
2000). Mizutani ei al., (2000) isolated resveratrol, a natural phytoestrogen found in 
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grapes which is found to inhibit AGE induced proliferation and collagen synthesis in 
vascular smooth muscle. Cyperus rotundus suppresses AGE formation and protein 
oxidation in a model of fructose-mediated protein glycoxidation (Ardestani and 
Yazdanparast, 2007). Regarding the significance of glycoxidative stress to diabetic 
pathology, a supplement of antioxidants to inhibit the process of protein modification 
appears to be a good strategy for preventing diabetic complications (Kahbar and Figarola, 
2003). 
FREE RADICAL BIOCHEMISTRY: 
Free radicals are the chemical species having unpaired electrons that are generated in-
vitro as well as in-vivo. They are highly reactive entities and remain so until and unless 
their valence shell electrons get paired and attain stability. They are formed from parent 
molecules via the breakage of a chemical bond keeping one electron by each of its 
fragment or by cleavage of a radical to generate another radical. Free radicals are 
fundamental to any biochemical process and represent an essential part of aerobic life and 
metabolism. Besides, they are also produced in redox reactions (Halliwell and Gutteridge, 
2007). Those reactive molecules containing oxygen are termed as reactive oxygen species 
(ROS). ROS possess modulatory roles on the physiology of body cells and also act as 
second messengers causing signal transduction (Myatt, 2010; Tavakoli and Asmis, 2012). 
It encompasses a diverse variety of chemical species including superoxide anions (O2), 
hydroxyl radicals ('OH), singlet oxygen, hydrogen peroxide (H202), alkoxyl (RO'), 
peroxyl (R00') and hypochlorous acid (HOCI) (Jakus, 2000). 
A great deal of literature indicates that free radicals especially active oxygen-centered 
ones are highly heterogeneous and highly reactive that can invade on the important 
biomolecules like proteins, lipids and DNA. This consequently can lead to enzyme 
inactivation, protein modification (deactivation or hyperactivation), lipid peroxidation, 
membrane degradation, DNA- strand breakage and base modification and so on. Hence, 
biological free radicals are potentially reactive enough to damage the neighboring 
biomolecules and can be causative agents for various diseases, aging and cancer (Back et 
al.. 2003; Hassan et al.. 2012; Valko et al.. 2004). These radicals are produced by either 
endogenous sources or by exogenous sources (Fig. 10). Endogenously, these radicals are 
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generated from physiological or bodily actions such as immune response. inflammation, 
toxicity, infection, excessive exercise. ischemia, cancer and aging etc. In analogous to 
phosphorylation modification of proteins, redox signaling is emerging in reference to 
events of oxidation of proteins and hence modification by ROS. Indeed, there are many 
sources of ROS in the cell namely, nicotinamide adenine dinucleotide phosphate oxidase 
(Block and Gorin. 2012), xanthine oxidase, uncoupling of nitric oxide synthase, 
cytochrome P450 (Cubero and Nieto, 2012; Izyumov et al., 2010). However, one of the 
main sources of ROS is the mitochondrion ithin the cell where the 02' is produced as a 
byproduct of normal oxidative phosphorylation. Exogenous sources include pollution (air 
and water), heavy metals (lead, mercury, cadmium etc.), certain drugs (gentamycin, 
cyclosporine), smoking and radiations etc. These agents after getting into the body via 
different routes are decomposed or metabolized and trigger generation of various free 
radicals (Brodin and Roed, 1984). Three major forms of ROS shall now be individually 
discussed in short. 
Superoxide (O f'): Superoxide anion is created from molecular oxygen by the addition 
of an electron. Its production mainly occurs inside the mitochondrion during the electron 
transport chain, when a small number of electrons escape from electron transport chain 
complexes I and III (Valko el al., 2007). Oz' is responsible for the dismutation and 
release of H202, which acts as precursors for *OH ion formation by the catalysis of metal 
atoms (Holley et al., 2010). It lacks the ability to penetrate lipid membranes and is 
therefore enclosed in the compartment where it was produced. The formation of 
superoxide takes place spontaneously, especially in the electron-rich aerobic environment 
with the activity of respiratory chain enzymes like flavoenzymes, lipoxygenase and 
cycloxygenase ((oughlan et a/.. 2009). The superoxide radical is produced enzymatically 
by 	the 	reaction 	with 	xanthine 	oxidase. 
Xanthine + 02 + 1-10 	 Uric acid + n,'— + H` 
Hydrogen peroxide (ff202: H202 is not a free radical but is nonetheless highly important 
much because of its ability to penetrate biological membranes and is produced by the 
dismutation of 02' or by direct reduction of 02' with two electrons (Topo et a1., 2010). 
02'— + 2H 	—, 	H202 
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It acts as an intermediate in the production of more reactive ROS molecules including 
IIOCI by the action of myeloperoxidase, an enzyme present in the phagosomes of 
neutrophils and most importantly, formation of 'OH via oxidation of transition metals. 
It's important functional role is in intracellular signaling (Sundaresan et al, 1995) and 
can be removed b at least three antioxidant enzyme systems, namely catalases, 
glutathione peroxidases and peroxiredoxins (Mates et al., 1999). 
H' + CI + H:O: 	— 	HOCI + H:O 
Hrdrox l radical ('OH): Due to its strong reactivity with biomolecules , 'OH is probably 
capable of doing more damage to biological systems than any other ROS (Betteridge, 
2000). They are produced by Fenton reaction which involves metal ions like Fee+ and Cue+  
with H202, often bound in complex with different proteins or other molecules (Liu et al.. 
2012). Transition metals thus play an important role in the formation of 'OH (Halliwell, 
1999). Transition metals may be released from proteins such as ferritin and the [4Fe-4S] 
centre of different dehydrases by reactions with 02 ' —. This mechanism, specific for living 
cells, has been called the in-vivo liaber-weiss reaction (Fridovich, 1997). 
H2O, + Cu'!Fe'' —+ "OH + OH + Cu``/Fe;.  
Nitric oxide (NO). Nitric oxide represents an odd member of the tree radical family as it 
contains unpaired electrons and it is not reactive with various biocellular molecules (Wu et 
al., 2011). Contrarily it easily reacts with other free radicals (e.g., peroxyl and alkyl 
radicals), generating mainly less reactive molecules, thus in fact functioning as a free 
radical scavenger in order to inhibit cellular oxidation of lipids in the cell membranes 
(Hogg and Kalyanaraman, 1998). The O2 - and NO react with each other to give 
OONO (peroxynitrite), which is highly cytotoxic (Beckman and Koppenol, 1996). 
OONO may react directly with diverse biomolecules in one- or two-electron reactions, 
readily react with carbon dioxide to form highly reactive nitroso peroxocarboxylate 
(ONOOCO:  ), or protonated as peroxonitrous acid (ONOOH) undergo homolvsis to form 
'OH and 'NO2 or rearrange to nitrate (NO3). Peroxynitrite, directly or via its reaction 
products, may oxidize low density lipoproteins, release copper ions by destroying 
ceruloplasmin, and generally attack tyrosine residues in different proteins, as observed in 
many inflammatory diseases (Haliiwell. 1997). NO is synthesized enzymatically from L-
arginine by NO synthase (Andrew and Mayer, 1999). 
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Fig. 10: Reactive oxygen species (ROS) generated by endogenous as well as exogenous 
sources (Brodin and Roed, 1984). 
ANTIOXIDANT DEFENSE SYSTEM: 
Free radicals exert derogatory effects on our cellular structure and functions. Ilence. 
living systems have been equipped with antioxidant defense system comprising of 
endogenous antioxidant molecules or cellular reductants Iglutathione (GSH), sulthydryl 
groups (-SH), thioredoxin] and antioxidant enzymes: 
Superoxide dismutase (SOD): It dismutates O, into 11,02 and oxygen. Superoxide 
dismutases (SODS) are metallocnzymes and their role is to protect aerobic cells against 
O 	action. They catalyze the conversion of superoxide molecules to H2O; and 02 and 
therefore form one of the cell's major defense mechanisms against oxidative stress 
(McCord and Fridovich, 1969). 
02' +02' +211—. 11202+02 
2. Catalase: C'atalase protects cells against 1120: generated inside them. It has an important 
role in the acquisition of tolerance to oxidative and nitrDsativc stress in cellular adaptive 
response. 
2H,0, —• 2H0 + 140 
3. Glututhione peroxidase: Glutathione peroxidase uses the thiol reducing power of 
glutathione to reduce oxidized lipids and protein targets of ROS. Glutathione Peroxidase 
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catalyses hydroperoxide reduction using GSN, thus protecting mammalian cells against 
oxidative damage. 
H202 + 2GSH --' GSSG + 2H20 
4. Glutalhione reduclase: Rereduction of the oxidized form of glutathiune (GSSG) is then 
catalysed by glutathione reductase. This system traps and nullifies the endogenously 
generated radicals in various metabolic reactions in virtually all the aerobic living 
systems. 
GSSG+NADI'H + ll 	—► 	2GSH+NADP4 
ANTIOXIDANTS: 
Antioxidants are substances that are able to prevent or retard oxidation of lipid, proteins 
and DNA. and to protect the compounds or tissues from damage caused by oxygen or 
free radicals. Antioxidants are key line of defense capable of trapping free radicals by 
preventing radical formation, intercepting radicals from further damage to the body 
(Cotgreave et al., 1988). Antioxidants also protect against glycation-derived free radicals 
and may have therapeutic potentials. 
Apart from endogenous antioxidants a vast number of dietary agents also act as 
antioxidants. Currently available synthetic antioxidants like butylated hydroxyanisole, 
butylated hydroxytoluene, tertiary butyl-hydroquinone, propylgallate and gallic acid 
esters are known to ameliorate oxidative damages but they are suspected to prompt 
negative health effects. Hence, strong restrictions have been placed on their application 
and there is a trend to substitute them with naturally occurring antioxidants (Amarowicz 
et al., 2000; Ghafar et al., 2010). Research on bioactive principles of essential oils 
extracted from various herbs and spices has become increasingly popular because 
essential oils have been discovered to have many functional properties such as 
antimicrobial, antioxidant and anticancer activities (Leal et al., 2003; Lee and Shibamoto. 
2002; Vardar-Unlu et al., 2003). Plants, including herbs and spices, have many 
phytochemicals which are potential sources of natural antioxidants, e.g. phenolic 
diterpenes, flavonoids, tannins and phenolic acids (Dawidowicz et al., 2006). Green tea is 
considered a rich source of phenolic compounds and its consumption is considered to be 
a factor in the lower incidence of coronary heart disease in the Chinese population 
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(Zhang et al., 2008). Similarly, parsley oil and two of its inherent bioactive phenolic 
compounds (i.e., myristicin and apiol) possess antioxidant activity (Zhang et al., 2006). 
Therefore, polyphenolic compounds' health promoting effects reduce the risk of various 
diseases (Manach et al., 2004) and inhibition of growth of pathogenic bacteria (Giroux et 
al., 2001) which are often associated with the termination of free radical propagation in 
biological systems. Thus antioxidant capacity is widely used as a parameter to 
characterize medicinal plants and their bioactive components. There is growing interest in 
natural products with combined anti-glycation and antioxidant properties as they may 
have reduced toxicity. 
PHYTOCHEMICALS: 
Aromatic herbs and spices have been used for a long time in alternative medicine, not 
only to improve or modify the flavor of foods, but also to avoid its deterioration. 
Thvmoquinone (TQ) (2-isopropyl-5-methyl-1.4-benzoquinone), is the main bioactive 
component of the volatile oil of N. sativa (Fig. 11). It has been used as antioxidant, anti-
inflammatory and antineoplastic medicines for more than 2000 years (Hosseinzadeh and 
Parvardeh, 2004: Trang et al., 1993). Generally Nigella saliva seeds contain more than 
30% fixed oil and 0.40% to 0.45% volatile oil. TQ represents 18.4 to 24% of the N. saliva 
volatile oil (Arslan et al., 2005). TQ can also be found in other plants such as Callitris 
quadrivalvis, Monarda fistulosa, Juniperus cedrus, Tetraclinis articulata, and Nepeta 
leucophylla. Quinones are ubiquitous in nature and constitute an important class of 
naturally occurring compounds found in plants, fungi, and bacteria. Current human 
exposure to quinones occurs via the diet as well as clinically. Benzoquinones are 
potentially derivable by oxidation of suitable phenolic compounds. Many of these 
benzoquinones have important biochemical functions in electron transport systems for 
respiration or photosynthesis (Dewick, 2001). The pharmacological properties attributed 
to naturally occurring quinones are thus well established. For example, thymoquinone 
presents anticonvulsant activity in the petit mal epilepsy (Hosseinzadeh and Parvardeh, 
2004). N. sativa has been traditionally used as a natural remedy for a number of illnesses 
and conditions such as diabetes, inflammation, bronchitis, fever, and influenza (Ali and 
Blunden, 2003). The antioxidant effect of TQ is associated with its potential to alter 
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I.redox state" and its scavenging activity against free radicals through modulation of 
hepatic and extra-hepatic antioxidant enzymes (Karaman et al.. 2010). TQ protects the 
kidney against itbstamide, mercuric chloride. cisplatin and doxorubicin-induced damage 
by preventing renal GSH depletion and anti-lipid peroxidation product accumulation, 
thereby improving renal functioning (13adary, 1999; Badary et al., 1997; gouda et al., 
2008). Khattab and Nagi (2007) assessed the protective effects of TQ atier chronic 
inhibition of nitric oxide synthesis with N (omega)-nitro-I-arginine methyl esters and 
found that treatment with TQ increased GSH to normal levels and inhibited the in-vitro 
production of superoxide radicals. 
Thvmol (TL) (2-isopropyl-5-methylplienol) is a natural monoterpene phenol derivative 
of cymene, isomeric with carvacrol. found in oil of thyme (Fig. 12) and has been 
commonly used in foods mainly for flavor, aroma and preservation and also in folk 
medicine since the ancient Greeks. Egyptians and Romans (Baser, 1993; Baser, 1994). 
TL can be used for the treatment of oral infectious diseases because of their inhibitory 
activity on oral bacteria (Didry et al., 1994: Kohlert et al.. 2002). Other plants that 
contain thymol are Uriganum compactum and Thymus glandulosus (Tai et al., 2002). 
Eugenol (EU) (4-ally(-2-methoxyphenol) is a methoxyphenol compound having a short 
hydrocarbon chain in its structure (Gulcin, 2011). It is found in virtually all spices but 
bay leaves and cloves are considered the best sources of it (Fig. 13) (Tai et al., 2002). It is 
one of the major components constituting about 80-95% of clove oil (Szabadics and 
Erdelyi, 2000). Pharmacologic studies have demonstrated that EU has anticonvulsant 
(Dallmeier and Carlini, 1981), local anesthetic (Brodin and Roed, 1984), antistress (Sen 
et al., 1992), bacteriostatic and bactericidal (Walsh et al., 2003) and antifungal properties 
(Lee et al., 2007). EU and its isoform, isoeugenol have been documented to be potential 
inhibitors of copper-dependent oxidation of LDL (Ito ei al., 2005). Besides, treatment of 
EU with fast decaying fruits like strawberries increased their average shelf life and also 
preserved their nutrient values of sugar and organic acids. The treatment also increased 
the content of total phenolics, anthocyanins and flavonoids (Wang et al., 2007). 
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OBJECTIVE OF THE PRESENT STUDY: 
6lycation is the sequence of non-enzymatic reactions involving interaction between 
reducing sugars and the nucleophilic groups of proteins and other biomolecules. It is 
ubiquitous in nature and occurs in the cells of all living organisms. albeit at a verN slow 
rate. The rate of glycation ho\~e%er increases remarkably during hyperglycemia, in 
diabetes and related disorders. Persistent hyperglycemia induces abnormal changes such 
as increase of AULs formation, increase of polyol pathway flux, and activation of protein 
kinase C isoforms. Glycation is also accompanied by the formation of highly reactive and 
damaging ROS. Free radicals and glycation end products are known to cause severe 
protein damage resulting in major structural alterations and loss of biological function. 
A large body of evidences indicate that glycation is a key molecular basis of diabetic 
complications. Hyperglycemia is regarded as the primary cause of diabetic microvascular 
complications that eventually contribute to diabetic macrovascular disease. Diabetic 
complications usually arise as a result of non-enzymatic protein glycation which leads to 
the formation of heterogenous, toxic, and antigenic AGES. Three routes have been 
proposed for AGEs formation: (i) autoxidative pathway (sugar gives reactive products by 
autoxidation), (ii) conventional Amadori rearrangement, and (iii) Schiff base formation. 
Reactive oxygen species (ROS) such as OZ'r, H202, and '011 contribute to these 
reactions, which require trace levels of catalytic redox-active transition metal ions. The 
process includes also oxidative steps and is therefore called glycoxidation. Regarding the 
significance of glycoxidative stress to diabetic pathology, phytochemicals that interfere 
with glycation reactions may be beneficial in restricting the complications accompanying 
diabetes and related disorders. Restriction/prevention of glycation and oxidative stress are 
therefore mooted as an effective strategy for alleviation of complications associated with 
hyperglycemia. These days, scientific interests in the functional components of food, with 
health protecting potencies, are increasing mainly due to their various biological activities 
and low cytotoxic effects. 
Since glycation- and oxidation-induced biochemical changes are known to participate in 
the overall diabetic complications, the present study was planned to determine 
antioxidant activity of TQ, TL and Eli and their protective effect against AAPI I-induced 
RBC hemolysis. The study was also extended to determine the possibility of preventing 
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the glucose-induced modification in NSA, as it being the most abundant protein in human 
blood, by these phytochemicals in concentration and time dependent manner. 
Furthermore, increase in glycoxidation products in plasma and tissue proteins suggest 
that oxidative stress increases in diabetes. Hence, the present study was further extended 
ex vivo in evaluate rho serum level of lipid peroxides, protein carbonyls, total antioxidant 
capacity and electrophnretic. pattern of albumin in healthy and diabetic patients. The 
protective effect of TQ. TL and EU on these parameters was also determined. For this, 
diabetic sevurn samples were incubated in absence and presence of TQ-2 (30 iM), TL-2 
(30 µM) or EU-2 (0.6 tM) for 21 days at 37°C. 
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Materials 
Chemicals 
Human serum albumin. thymoquinone. thymol, cugenol, aminoguanidine hydrochloride, 
diethylene triamine penta-acetic acid (DTPA), bovine serum albumin, sodium azide, 
superoxide dismutase. cytochrome c. dialysis tubing. agarose, l,l-Diphenyl-2-
picrylhy'drazyl (DPPH). 2,2'-azobis-(2-methylpropionamidine) dihydrochloride (AAPII) 
and 2,4,6-Tris(2-pyridyl)-s-triazine (TPTZ) were purchased from Sigma Chemical 
Company, USA. D-glucose, 2,4-dinitrophenyl hydrazine (DNPH), ethanol, sodium 
carbonate and formaldehyde were purchased from Merck, India. Acrylamide, bis-
acrylamide, ammonium persulphate and N,N,N',N'- tetramethyl ethylene diamine 
(TEMED) were from Bio-Rad Laboratories, USA. Nitrohluc tetrazolium (NBT), 5.5-
dithio-bis-2-nitrobenzoic acid (DTNB), sulphosalicylic acid, 2,4,6-trinitrobenzene 
sulphonic acid (TNBS). Folin-Cioculteau reagent, bromophenol blue. gallic acid, ascorbic 
acid (AA) and sodium dodecyl sulphate were from Sisco Research Laboratories, India. 
Polystyrene microtitre flat bottom ELISA plates and modules were purchased from 
NUNC, Denmark. Nitrocellulose syringe filters were purchased from AXIVA Sichem 
Biotech, India. Silver nitrate, trichloroacetic acid, methanol, sodium chloride, sodium 
acetate, isopropanol, glacial acetic acid, glycine, EDTA. ethylacetate, potassium 
ferricyanide, ferric chloride, copper sulphate, sodium potassium tartarate and sodium 
hydroxide pellets were obtained from Qualigens Fine Chemicals, India. All other 
chemicals and reagents were of the highest analytical grade available. 
Equipments 
Spectrophotometer (model, U-2910; Hitachi, Japan), Spectrofluorometer (model, RE-
5301; Shimadzu. Japan), Spectropolarinieter (model, JASCO J-815; USA), Centrifuge 
(model, 3K30; Sigma, Germany), Polyacrylamide gel electrophoresis assembly (Genei, 
India), Densitometer (model, GS-800; Bio-Rad. USA), ELISA reader (Labsystem 
Multiskan, Finland), pH meter (model, LI-120; ELICO. India), Gel-doc (Bio-Rad 
Laboratories, USA) and FT1R spectrophotometer (model, 8300; Shimadzu, Japan) were 
the major equipments used in this study. 
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Collection of blood samples 
The protocol used for the study was in accordance with guidelines of institutional ethical 
committee. Forty health- and forty type 2 diabetic patients diagnosed using World Health 
Organization criteria were included in the study. Fasting venous blood for estimation of 
MDA, protein carbonyl. FRAP and glutathione content were drawn after obtaining verbal 
consent from type 2 diabetic patients attending outpatient department (OPD) clinics at 
Rajiv Gandhi Centre for Diabetes and Endocrinology, Jawaharlal Nehru Medical College 
Hospital, Aligarh Muslim University, India. It was ensured that none of the diabetic 
patients were suffering from other autoimmune diseases. Normal human blood was 
obtained from age- and sex- matched healthy individuals (Table 1). All blood samples 
were collected in plain vials and left for clot formation. Serum was separated and stored 
in small aliquots at -20°C. 
Table 1: Clinical features and demographic profile of healthy and diabetic subjects. 
Variables Healthy controls 	I 	Type 2 diabetes 
(Mean ± SD) 	I 	(Mean ± SD) 
Sample size (n) 40 40 
Age(years) 49.9+5.71 51.6±6.91 
Gender (male/female) 18/22 21/39 
BMI (Kg/m-) 22.3 f 1.39 28.7 ± 1.6 
Fasting glucose (mgldl) 89 ± 3.14 167 ± 23.38 
Post prandial glucose (mg/dl) 126 ± 12.34 248 + 23.36 
HbA,, 4.8 ± 0.43 7.46 ± 0.54 
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1,1-Diphen►yl-2 picnyUrvdrazel (DPPH) radical scavenging Activity 
The free radical sea~enging activity of TQ, IL, EU and standard reference compound i.e, 
Gallic acid (GA) was analyzed by the DPPII assay as described by Sanchez-Moreno et 
ul., (1998) with minor modification. In this assay, I ml of varying concentrations of TQ 
(0.25-2.0 mg/ml), TL (0.25-2.0 mg/ml) and EU (1-60 pg/ml) dissolved in l ml of 
ethanol, were mixed with I ml of ethanol solution of DPPI I (0.2 mMI). The mixture was 
vortexed and incubated for 30 min. The optical density of the solution was measured at 
517 urn using Hitachi, U-2910 spectrophotometer. Gallic acid (µb/ml) has been used as a 
standard. The DPPH radical scavenging activity was calculated from the absorption value 
by the following equation: 
Radical scavenging activity (%) = [A0 11-ATFST1 x 100 
A Drn I 
Where AnPPH is the absorbance of DPPH without test compound (TQ, TL, EU and GA), 
and ATEST is the absorbance of DPPH in the presence of test compound. 
Reducing Power 
Total reducing power was determined as described by Zhu et al., (2004) with some 
modifications. TQ (0.5-2.0 mg/ml), TL (0.5-2.0 mg/ml) and EU (2.5-10 µg/ml) in I ml of 
ethanol were mixed with 2.5 ml of phosphate buffer (0.2 M, pH 6.6) and 2.5 ml of 1% 
potassium ferricyanide [K3Fe(CN)6]; the mixture was then incubated at 50°C for 30 
minute. 2.5 ml of trichloroacetic acid (10%) was then added to the mixture, which was 
then centrifuged at 3000 rpm for 10 min. 2.5 ml of supernatant was mixed with 2.5 ml of 
distilled water and 0.5 ml FeCI3 (0.1%), and the absorbance was measured at 700 nm. 
Increase in absorhance indicates increased reducing power of the phytochemical. 
Ferric Reducing Antioxidant Power (FRAP) assay 
FRAP assay is considered as a very reliable method to assess the total reducing potential 
of any biological active compound or extract. In the present study, it was carried out by 
the method of Benzie and Strain (1996) with slight modifications. The method is based 
on the reduction of a ferric 2,4,6-tripyridyl-s-triazine complex (Fe-TPTZ) to its ferrous 
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(Fe- l F l L), intensive blue colored form in the presence of antioxidant. 300 mM acetate 
buffer, pH 3.6, 10 mM TPTL and 20 mM FeCl3 were mixed in a ratio of 10:1:1 to be a 
working FRAP reagent. 100 pl of TQ. TL and EU were mixed with 3 ml of FRAP 
reagent and incubated at 37°C for 30 min. The absorbance at 593 nm was monitored. All 
reagents ere freshly prepared before use. 
Ferric reducing antioxidant power of healthy, diabetic and phytochemical treated diabetic 
serum samples was also determined by the same above protocol. Diabetic serum samples 
were incubated with three concentrations of TQ, TL and EU for 1 hour at 37°C. The 
concentrations of TQ and TL were 3 pM, 30 µM and 300 lsM while those for EU were 
0.06 µM. 0.6 µM and 6.0 µM. 20 µl of each phytochemical was incubated in 80 p) of 
serum of diabetic patients. 80 pl of healthy and diabetic serum samples incubated with 20 
pl of 20 mM phosphate buffer (pH 7.4) served as control. 3 all of FRAP reagent was 
added to each tube and incubated at 37°C for 30 min. The absorbance at 593 nm was 
monitored. Aqueous solution of known Fe (II) concentration was used for calibration (in 
a range of 100-1000 µmol:'I) ('fable 2, Fig. 14). 
Blank: FRAP reagent. 
Table 2 Standards: 1 mM standard solution of ferrous sulphate was prepared by mixing 
0.278 g of FeSO4.7H20 in I litre distilled water. They were diluted as follows to make a 
series of standards of different molarities. 
Standard concentration 
(ni11) 
FeSO4.7H20 solution 
(ml) 
Distilled water 
(ml) 
0.1 1 9 
0.2 2 8 
0.4 4 6 
0.6 6 4 
0.8 8 2 
1.0 10 0 
Freeze at -20° C in 0.2 ml aliquots in ependorfs. 
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0.9 
0.8 
0.7 
0.6 
= 0.5 
M 0.4 
0.3 
0 0.2 
0 0.1 
•
0  
0 	0.2 	0.4 	0.6 	0.8 	1 	1.2 
Concentration of FeSO4.7H20 (mM) 
L 	 -- -- 
Fig. 14: Standard curve for ferrous sulphate for the determination of FRAP equivalent. 
Metal Chelating Activity' 
The chelation of ferrous ions by TQ. TL and EU was estimated by the method of Din is et 
al., 1994 with slight modifications. Different concentrations of the TQ (12.5-200 tg/ml), 
TL (12.5-200 pglml), EU (3.125-25 pg/ml) and AA (3.125-25 }tg/ml) were added to a 
solution of l mM FeCI-, (0.05 ml). The reaction was initiated by the addition of 1 mM 
ferrozine (0.1 ml) and the mixture was finally quantified to I ml with methanol, shaken 
vigorously, and left standing at room temperature for 10 min. After the mixture had 
reached equilibrium, the absorbance of the solution was measured spectrophotometrically 
at 562 nm. 
AAPH-induced RBC hemolvsis assati' 
Blood was obtained from healthy human donor and collected into heparinized tubes 
through the Blood Bank. J. N. Medical College, Aligarh Muslim University, Aligarh. 
Erythrocytes x% ere separated from plasma and the buff)' coat, and washed three times with 
5 volumes of phosphate buffered saline (PBS), pH 7.4. During every wash, RBCs were 
centrifuged at 4000 rpm for 10 min to obtain packed cell preparation (Miki et al., 1987). 
The packed RBC was suspended in four volumes of PBS solution after the last wash. 
AAPH, a peroxyl radical initiator, was used for RBC hemolysis. Addition of AAPH to 
the suspension of washed erythrocytes induces the oxidation of membrane lipids and 
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proteins. resulting in hemolysis. 0.5 ml of the erythrocyte suspension was mixed with 0.5 
mt of PBS solution containing varying amounts of TQ. TL and EU and to this 0.5 ml of 
200 mM AAPH was added. The reaction mixture was shaken gently while being 
incubated at 37°C for 3 hours. After incubation, reaction mixture was diluted with eight 
volumes of PBS and centrifuged at 4000 rpm for 5 min. The Absorbance (A) of the 
supernatant was recorded at 540 nm. Percent inhibition was calculated by the following 
equation: 
Inhibition = [A °AP" ArESr x 100 
A AAPH 
Where AAAPH is the absorbance of AAPH at 540 nm and ATEST is the absorbance of TQ, 
TL, EU and AA at 540 nm. 
Estimation of malondialdehyde (MDA) level 
Free radicals, by their unstable and transient nature are difficult to measure directly. Their 
tendency to cause lipid peroxidation has been used as an indirect measure. Hence, 
estimation of lipid peroxides (markers of lipid peroxidation) was done by measuring 
MDA (malondialdehyde), which is a stable end byproduct of lipid peroxidation. MDA is 
one of the most reliable products to assess the extent of lipid peroxidation. Its level was 
determined by the procedure of Ohkawa ei al., (1979) with some modifications. It is 
based on reaction of Thiobarbituric acid (TBA) with MDA. One molecule of MDA reacts 
stoichiometrically with two molecules of TBA at pH 3.5. The pink color chromogen can 
be measured spectrophotometrically at 532 nm with the production of a pink pigment 
having an absorbance maximum at 532 nm. 
Preparation of TRd reagent 
TBA reagent was prepared by mixing 0.1 ml SUS (8.1% w/v), 0.75 ml acetic acid 
(20% vlv, pH adjusted to 3.5 with 5N NaOH) and 0.75 ml TBA (0.8% w/v). 
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Procedure 
Three concentrations of thymoquinone, thymol and eugenol were prepared for in-
situ study. The concentrations of TQ and "1'L were 3 pM. 30 µM and 300 µM 
while those for Eli were 0.06 NM. 0.6 pM and 6.0 µM. 20 pl of each 
phytochemical was incubated in 100 µl of serum of diabetic patients for I hour at 
37°C. 100 pI of health) and diabetic serum samples incubated with 20 pl of 20 
mM phosphate buffer (pH 7.4) served as control. Then 1.6 ml of TBA reagent 
was added to all incubated tubes. After vortexing, samples were incubated for I 
hour in 95°C and after cooling with tap water centrifuged at 4,000 rpm for 10 min. 
Supernatant was separated and measured spectrophotometrically at 532 nm. 
TBARS values were expressed as MDA equivalents. Concentration was 
calculated using extinction coefficient of the TBA reagent = 1.56 x 105 mo[tcm* 
MDA concentration is expressed in terms of nmoles/ml of serum. 
Determination of Reduced glutatlrione (GSHJ content 
Reduced glutathione (GSH) level was determined by method of Ellman, (1959) with 
slight modifications. 500 pl of serum was precipitated with 500 µl sulphosalicylic acid 
(4%). The samples were then centrifuged at 1,200 rpm for 10 min at 4°C. 400 p1 of 
supernatant was taken and 400 µl of DTNB (3 mM) and 2.2 ml of phosphate buffer (0.2 
N. pH 8.9) was added. The yellow color developed was read at 412 nm and the amount of 
reduced glutathionc was calculated using the molar extinction coefficient value of 1.36 x 
l0° cm't moF 1. 
MODIFICATION OF HUMAN SERUM ALBUMIN BY GLUCOSE: 
Commercial HSA that gave single hand in SUS-PAGE was used without purification. 
Lyophilized HS,\ was reconstituted with 20 mM phosphate buffer (pH 7.4) to make a 
stock solution of 3 mglml and stored at -20°C. In order to induce glycation, the protocol 
used by Miyazawa ei al., (1998) was adopted with slight modifications. HSA I mg/ml 
(15.15 pM), was incubated for 7, 14, 21, and 28 days at 37°C in dark with 100 mM 
glucose in 20 mM phosphate buffer (pH 7.4). The reaction mixtures were pre-filtered 
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through a nitrocellulose filter 0.2 µm pore-sizes in pre-autoclaved boxes in order to 
maintain sterile conditions during incubation. Samples incubated without sugar similarly 
served as control. After incubation, samples were extensively dialyzed against PBS in 
order to remove excess of sugars and stored at -20°C for further analysis. Protein 
concentration was measured by Lowry et al., (1951). 
IN-VITRO GLYCATION OF HSA WITH GLUCOSE ALONG WITH VARIOUS 
COMPOUNDS: 
HSA was incubated with 1mM aminoguanidine (standard anti-glycating agent) in the 
presence of 100 mM glucose. HSA was also incubated with varying concentrations of 
thymoquinone (3, 30 and 300 µM), thymol (3, 30 and 300 µM) and eugenol (0.06, 0.6 
and 6.0 µM) in presence of 100 mM glucose. They are incubated under similar conditions 
for 4 weeks. HSA incubated without sugar served as control. Before further analysis each 
sample was extensively dialyzed against the buffer in order to remove excess of sugars. 
UV-visible Spectrop/zotometrp 
The ultraviolet absorption spectra of native, glycated and phytochemical treated glycated 
HSA samples were recorded in the wavelength range 200-400 nm on a Hitachi U-2910 
spectrophotometer, using a cuvette of 1 cm pathlength. One milligram of the sample in a 
total volume of 3 ml was taken for spectral analysis. 
Fluorescence spectroscopy 
Native. glycated and phytochemical treated samples were analyzed by measuring 
intrinsic fluorescence at 25°C on Shimadzu (RF 5301-PC) spectrofluorometer. The 
fluorescence of tryptophan residue (Tryptophan-214) in all samples was monitored with 
excitation at 285 nm and emission range was taken at 290 	400 nm (Shaklai et al., 
1984). The concentration of protein samples was taken as 2 µM. 
AGE- specific Fluorescence 
AGES formation were measured by determining the fluorescence by excitation at 370 nm 
and emission between 400 - 500 nm (Lapolla, 1992) using Shimadzu (RF 5301-PC) 
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spectrofluorometer. Loss of fluorescence intensity (F1) was calculated using the 
following equation- 
°'o Loss of Fl - [FI 	-Fl`a"x`dIIS x 100 
FIname SA 
Circular dichroism (CD) studies 
CD spectra were recorded on JASCO spectropolarimeter (J-815) calibrated with D-10-
camphorsulfonic acid. The measurements were made at 25°C with a thermostatically 
controlled cell holder attached to Neslab's RTE 110 water bath with a temperature 
accuracy of ± O.M. Far-UV CD was used to measure the changes in the secondary 
structure of LISA (3.0 µM) in 20 mM phosphate buffer (pli 7.4). Protein samples were 
placed in cylindrical quartz cuvettes of pathlength lmm. Each spectrum was the result of 
average of four scans. CD measurements were performed on USA samples withdrawn 
every week from the reaction mixture under incubation for 4 weeks kept at 37°C. The 
results «ere expressed as mean residue ellipticity (MRE) in deg cm` dmo[t which is 
defined as: 
MRE = eoe cd (mdeg) 
l0x(n)xCr x1 
Where, 0°b -,d is the CD in milli-degree, n is the number of amino acid residues (585 – I 
= 584), 1 is the path length of the cell, and C, is the concentration of protein in 
moles/litre. Helical content was calculated from the MRE values at 222 nm using the 
following equation (Chen et al., 1972). 
[,NIRE222nm  -2340] % u-helix = — 	 x 100 
30300 
Fourier Transform Infra-red spectroscopy (FTIR) 
To confirm the interaction between l ISA. aminoguanidine and phytochemicals (TQ, 'I L 
and EU) in absence and presence of glucose, FTIR as conducted. FTIR spectra of 
native, glycated and phytochemical treated samples were recorded on Shimadzu-8300 
FTIR spectrophotometer (Tokyo, Japan) in the spectral range of 400 – 4000 cm't . 
Samples to be analyzed were loaded between t .o potassium bromide discs by hydraulic 
pressing. 
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Determination of Protein Concentration 
The protein conntent in all the samples as estimated b\ the method of Lowry of al., 
(1951). The protein estimation by this method utilizes alkali (to keep the pH high). Cu'-  
ions (to chelate proteins) and tartarate (to keep the Cui2 ions in solution at high pH). 
Folin-Ciocalteau reagent 
The Folin-Ciocalteau reagent was diluted 1:1 with distilled water before use. 
Alkaline copper reagent 
The components of alkali copper reagent were prepared as follows: 
• 2% sodium carbonate in 100 mM sodium hydroxide 
• 0.5% copper sulphate in 1.0% sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) and 
(ii) in the ratio of 50:1. 
Procedure 
Aliquots of protein solution were taken in separate tubes and the final volume was 
made up to I ml. To this, 5 nil of alkaline copper reagent was added. This solution 
was kept as such at room temperature for 10 minutes followed by addition of I ml 
Folin-Ciocalteau reagent. The test tubes were vortexed followed by incubation for 30 
minutes at room temperature. The resulting blue color intensity was read at 660 nm 
against the reagent blank using spectrophotometer. A standard curve was prepared 
using BSA as standard (Fig. 15). 
1 
s 0.8 
0.6 
0.4 
Q 0.2 
01  
0 	0.1 	0.2 	0.3 	0.4 	0.5 	0.6 
Amount of protein (mg) 
Fig. 15: Bovine serum albumin (BSA) standard curve using Lowry's method of protein 
estimation. 
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Ketoa►nine estimation by Nitroblueietrazolium assay 
Glycation of HSA or level of Amadori product was determined by an established 
colorimetric procedure using NI3T (Mashiba et at. 1992) with slight modifications. 
Native, glycated and phytochemical treated HSA samples (50 µl) were added to the wells 
of 96-well microtitre plate in duplicate. One hundred pl of NBT reagent (250 1iN4 in 0.1 
M carbonate buffer, pH 10.35) was added to each well and incubated at 37°C for 2 hours. 
The plate was read in a microplate reader at 550 nm. The amount of ketoamine in all 
samples was determined using 12640 cm"'M as molar extinction coefficient of 
monoformazan. 
Determination of Protein bound carbon t•1 groups 
Carbonyl content of native, glycated HSA and phytochemical treated glycated HSA was 
estimated by a published procedure of Levine et al., (1990) with slight modifications. 
Brie(l\.. 200 µl aliquot (containing 0.1 mg of protein) was mixed with 400 µl of 7 mM 
dinitrophcnyl hydrazine (DNPI-I) in 2M HCI. The mixtures were run in duplicate and the 
control protein samples were devoid of DNPH. After incubation for I hour at room 
temperature, 500µI trichloroacetic acid (4% w/v) was added to precipitate DNP-
hydrazones. Mixture was centrifuged for 5 min at 14,000 rpm. The pellet was dispersed 
in I r.il ethanol-ethvlacetate (1:1 v !v), in order to remove unreacted DNPH and 
centrifuged. After 3 such washes, the pellet was dissolved in 0.6 ml of 6M guanidinium 
hydrochloride solution in 20 mM phosphate buffer already adjusted to pH 2.3 with 
tritluoroacetic acid. The hydrazones were dissolved completely only by overnight 
freezing at -20°C and thawing. From the solution, 200 pl aliquot was taken into a 
microplate and read at 379 nm by a microplate reader. The results were expressed as the 
number of nmules of carbonyl per mg of sample protein using a molar absorption 
coefficient 22,000 \9"1cm". Samples were analyzed against a blank of I ml of 6 M 
guanidinium hydrochloride solution. 
Similar procedure was used for the estimation of protein carbonyl contents in the serum 
of healthy and diabetic patients in case of ex vivo studies. Three concentrations of 
thymoquinone, thymol and eugenol \\ere prepared for ex vivo study. The concentrations 
of TQ and TL were 3 1,M1, 30 pM and 300 pM while those for LU were 0.06 pM. 0.6 pM 
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and 6.0 µM. 100 ,d of diabetic serum was incubated with 20 ltl of each phytochemical for 
1 hour at 37°C. 100 pl of healthy and diabetic serum samples incubated with 20 .tl of 20 
mM phosphate buffer (pH 7.4) served as control. After vortexing, all serum samples 
followed the Levine ei al.. (1990) protocol. 
Determination of Free Amino Groups 
The free amino groups of native, tivcated and compound treated glycated IISA were 
measured using TNBS procedure described by Haynes et al.. (1967). To 0.2 ml of 
glycated protein, 1.8 ml of sodium tetraboratc buffer pH 9.3 was added. Further 20 µl of 
0.13 M TNBS solution was added. The reaction mixture thus formed was incubated at 
37°C for 30 min. The absorbance of the solution was read at 420 nm against a blank. 
Detection of superoxide anion radicals in glvcaied HSA in presence of pl 'mchemicalc 
Superoxide radical (U) was measured by the cytochrome c reduction method 
(Beauchamp and Fridovich, 1971). The effect of AG (1 mM) and varying concentrations 
of TQ (3. 30 and 300 µM). TL (3, 30 and 300 pM) and EU (0.06, 0.6 and 6.0 µM) on the 
generation of superoxide radicals during glycation of HSA was determined. The reaction 
tube contained HSA (15.15 pM), glucose (100 mM), DTPA (0.01 mM), cytochrome c 
(200 pM) in absence and presence of AG, TQ, TL or EU. Reaction was carried out at 
37°C for 20 min in 100 mM phosphate buffer (pH 7.4). The reduction rate was monitored 
at 550 nm. 
Sodium dodect•l sulphate po!pacriramide gel electrophoresis 
Sodium dodecyl sulphate (SUS) polvacrylamide gel electrophoresis was performed as 
described earlier by Laemmli, (1970) using slab gel electrophoresis apparatus. The 
following stock solutions were prepared: 
Acrvlamide-Bisacrvl am ide (30:0.8) 
A stock solution was prepared by dissolving 30 g of acrylamide and 0.8 mg of 
bisacrylamide in distilled water to a final volume of 100 ml. The solution was 
filtered and stored at 4°C in an amber color bottle. 
45 
Methods 
Resolving Gel Butter 
A stock solution was prepared by dissolving 9.08 g Tris base in 40 ml distilled 
water. The pH was adjusted to 8.8 and the final volume brought to 50 ml with 
distilled water. 
Electrode bu/Jer 
3 g Tris base, 14.4 g glycine and 1.0 g SDS were dissolved in distilled water, pH 
adjusted to 8.3 and final volume was made to I litre. 
Procedure for PA GE 
Thoroughly cleaned glass plates separated by 1.5 mm thick spacer were scaled 
with 1% agarose from sides and bottom. The resolving gel mixture (10%) was 
prepared by mixing the components listed in table 3 and poured between the glass 
plates and allowed to polymerize at room temperature. Protein samples mixed 
with one fourth of sample dye (10% SDS, 50% glycerol. EM Tris, pH 6.8, 5% ¢- 
mercaptoethanol and 1% bromophenol blue as a tracking dye) were boiled at 
100°C for 5 minutes and then loaded into the wells, and electrophoresis was 
carried out at 80 volts for 3-4 hours in electrode buffer. 
For ex vivo studies, diabetic serum samples were incubated in absence and presence of 
TQ-2 (30 NM), TL-2 (30 µM) or EU-2 (0.6 µM) for 14 days at 37°C. Effect was also 
compared Nvith HSA incubated in same conditions in presence of 20 mM glucose to 
check the effect on glycation reaction in excess glucose and the preventive/ inhibitory 
effect by the phytochemicals. 
Tahle-3: Recipe for 10% resolving gel 
Component Volume 
Distilled water 
Acrylamide-bisacrylamide (30: 0.8) 
4.0 ml 
3.3 ml 
Resolving gel buffer 
10% SDS  
2.5 ml 
0.1 ml 
1.5% ammonium persulphate 0.1 ml 
TEMED 4.0 pl 
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Serum of healthy individuals without any treatment served as control. They were 
analyzed by 10% SDS-PAGE in the presence of thiol-reductant 3-mercaptoethanol 
followed by silver staining. 
Silver Staining 
The procedure described by Merril et al., (1982) was followed. After electrophoresis the 
protein bands were fixed by rapidly immersing in a mixture of 40% methanol and 13.5% 
formaldehyde for 10 min with instant shaking. The gel was washed with distilled water 
twice at an interval of 5 min. Then the gel was immersed in 0.02% sodium thiosulphate 
solution for 2 min. The gel was again rinsed twice with distilled water at an interval of 20 
second. This was followed by incubation with 0.1% silver nitrate solution for 10 min. 
The gel was rinsed with distilled water briefly, immersed in developer solution (3% 
sodium carbonate solution containing 50 µl formaldehyde and 2 ml of 0.02% sodium 
thiosulphate) for 15 min or until properly stained. The reaction was stopped by 
transferring the gel to stopper solution (25% isopropanol solution containing 10% acetic 
acid glacial). The gel was washed twice with distilled water and finally stored in distilled 
water. 
Densitometric Analysis 
Image analysis of gels was performed to show the inhibition of cross-linked AGEs and/or 
fragmentation in different concentrations of TQ, TL and EU. Since protein concentration 
loaded in each well of gel remains same throughout the whole study i.e. 10 pg, therefore, 
the area selected for performing densitometry of each band was taken to be same or 
equal. Bands were compared within the same gel and sufficient background was 
included. 
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DPPH radical scavenging effects 
The scavenging effects of TQ. TL and EU on DPPH radicals are shown in Fig. 16. All the 
phytochemicals scavenged DPPH in a dose-dependent manner. As seen in Fig. 16 (a), TQ 
showed maximum DPPH radicals scavenging activity up to 78.13% at 2.0 mg/ml 
concentration while it was 82.26% at same concentration for TL (Fig. 16 b) and 88.4% 
for EU at much lower concentration (60 pg/ml) (Fig.16 c). In a similar assay, gallic acid 
(GA) as standard reference compound scavenged up to 94.67% at 18 pg/ml, having ECso 
value of 2.87 pg/ml (Fig. 16 d). ECso is the concentration of a drug/ antioxidant that gives 
half-maximal response. ECso value of TQ, TL and EU are 1.07 ± 0.03 mg/ml, 393.3 ± 
11.54 pg/ml and 10.07 ± 1.9 pg/ml respectively. Among the three phytochemicals 
examined, EU exhibited the strongest efficiency and showed over 50% scavenging effect 
of DPPH at a concentration of 10.07 pg/ml. Therefore. EU had the highest hydrogen-
donating capacity, followed by TL, while TQ rendered the weakest effect. However, the 
EC;, value of TQ. TL and EU was higher than GA revealing that these phytochemicals 
had lesser free radical scavenging potential than GA. 
Reduction Potential 
Total reducing power of TQ, TL and EU was measured by method of Zhu et al., (2004) 
that involves reduction of Fe3+(CN )6 to Fee (CN )~, leading to formation of Perl's 
Prussian blue complex determined at 700 nm. Ascorbic acid (AA) was used as standard. 
Fig. 17, shows the dose response curves for the reducing powers of TQ, TL and EU. As 
reflected in Fig. 17(c) and (d), the reducing power of EU was maximum (0.119) at 10 
pg/ml concentration which is higher than standard AA (0.109) at 50 pg/ml. The reducing 
power of all phytochemicals increased with concentration and these varied in the order of 
TQ<TL<EU. 
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Fig. 16: Percent DPPH scavenging activities of (a) TQ. (h) TI., (c) Etf and (d) GA. All 
the data has been represented as Mean ± SD of triplicate samples. 
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(d) AA. All the data has been represented as Mean ± SD of triplicate samples. 
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Ferric reducing antioxidant power (FRAP) assay 
Several assays have been introduced for the measurement of antioxidant activity of 
phytochemicals including total antioxidant capacity? by FRAP assay. FRAP method was 
used to evaluate the reducing power of TQ. TL and EU. In this method the reduction of 
ferric-tripyridyltriazine complex to its ferrous colored form is evaluated in the presence 
of phytochemicals. The FRAP values have been calculated by comparing the absorbance 
change at 593 nm in test samples with those containing ferrous ions in known 
concentrations. FRAP value was calculated from the standard graph of ferrous sulphate 
(Standard curve equation: Y= 0.71274x + 0.09092; r2= 0.999). As shown in Figure 18, 
FRAP value of TQ, TL and EU was found to be 2.73 ± 0.59, 25.31 ± 7.63 and 250.16 f 
18.92 mM Fe'' /mg of phytochemical respectively. 
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Fig. 18: Ferric reducing antioxidant power of TQ, TL and EU. All the data has been 
represented as Mean ± SD of triplicate samples. 
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Metal chelating Activity 
In the metal chelating assay, ferrozine can quantitatively form complexes with Fe'". In the presence 
of other chelating agents. the complex formation is disrupted with consequent decrease in the 
intensity of the red color of the complex. As shown in Fig. 19, TQ, TL, EU and AA were capable of 
chelating ferrous ions up to 63.55%, 73.11%. 80.96% and 83.48% at the concentrations of 200, 
200, 21.87 and 21.87 µe`ml respectively. The concentration at which TQ, Tl,. EU and AA showed 
50% chelating activity was found to be 70, 40, 13.2 and 1 1.6 µg/ml respectively. Based on these 
data, it is clear that all the phytochemicals contained high antioxidant activity and chelating 
properties. 
AAPH induced RBC hemolysis assay 
In order to compare the antioxidative activity of phytochemicals quantitatively, it is essential that 
the relationship between concentration of phytochemicals and percent inhibition is established, in 
which the appropriate time of AAPH incubation is 3 hours in this case. The results showed 
inhibition of hemolysis in the presence of TQ, TL, EU and ascorbic acid (AA) in a dose dependent 
manner (Fig. 20). TQ. TL, EU and AA inhibited AAPII-induced hemolysis at concentrations 
ranging from 12.5 to 100 gglml, 12.5 to 100 µglml, 3.125 to 25 µglml and 3.125 to 50 pglml 
respectively with varying effectiveness. TQ, TL, EU and AA showed significant inhibition up to 
86.22°ii,. 86.69°0. 89.18 and 90.72% at the concentrations of 100, 87.5, 21.875 and 50 µg/ml 
respectively. Concentration for 50% inhibition of hemolysis (IC50) of TQ, TL, EU and AA was 40, 
32, 14 and 7.5 tgIml respectively. Results were considered statistically significant at p<0.005. 
Inhibition of hemolysis was also observed at lower concentrations. 
As reflected in Fig. 21. the onset of AAPH-induced hemolysis 'as significantly delayed in the 
presence of TQ, TL, EU and AA. Erythrocytes incubated with PBS at 37°C served as control and 
were stable with little hemolysis observed within 4 hour (4.61 = 2.06%). When AAPH was added 
to the suspension of erythrocytes, hemolysis induction was time-dependent untill 3 hour and cause 
96.5°0 hemolysis. The hemolysis is lagged at initial 2 hours. Addition of TQ, TL, EU and AA 
significantly protected the erythrocyte membrane from hemolysis induced by AAPH. liemolysis 
caused by TQ, TL, EU and AA was found to be 93.1 ± 2.59%, 82.3 = 2.49%, 35.6 ± 2.4% and 30.3 
2.31% respectively. 
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Fig. 19: Metal chelating activities of (a) TQ, (b) TL, (c) EU and (d) AA. All the data has 
been represented as Mean ± SD of triplicate samples. 
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Fig. 21: Time dependent inhibition of AAPH-induced erythrocyte hemolysis by TQ. TL. 
EU and AA. 5% hematocrit was pre-incubated with TQ. TL, EU and AA at the 25 µg/ml 
of concentration for 30 min at 37'C. The cell suspension was then incubated with 200 
mM AAPII for 4 hours at 37°C. In all experiments, control erythrocytes (without any 
treatment) and AAPI I-treated erythrocytes (with AAPH) were used. All the data has been 
represented as Mean ± SD of three independent experiments. 
*p<0.05, as compared with AAPII at respective time 
#p<0.05. as compared with control at respective time 
55 
Studies on Glycation of HSA 
HSA, the most abundant protein in plasma, was selected as a model protein (Shaklai et 
al., 1984). Gly cation studies on HSA mainly focused on the reaction with glucose 
although some information with other sugars is also available. In the present study, the 
effect of glucose on HSA has been investigated for extended time period incubation. It is 
well recognized that the reaction of reducing sugars with protein can induce marked 
alterations in protein conformation. Absorption spectra continue to be used for the 
detection of sugar induced modification of protein (Yamauchi et al., 2002). The glycation 
induced alterations in HSA were further examined with respect to their chromophoric and 
fluorophoric properties. 
UV absorption spectral studies 
The UV absorption spectra of glycated HSA incubated for 7 and 14 days showed 
hyperchromicity at 280 nm. The hyperchromicity at 7 and 14 days was 27.6% and 57.3% 
respectively, whereas glycated HSA incubated for 21 and 28 days showed 
hypochromicity at 280 nm to the extent of 30.8% and 34.9%. However, no apparent peak 
shift was found in all the cases (Fig. 22). 
Fluorescence spectroscope' 
The native and glycated HSA was characterized for its fluorescence emission spectra. 
Due to high sensitivity and reproducibility, the level of fluorescence of a single 
tryptophan residue in the HSA molecule has been chosen as an index of conformational 
changes. Tryptophan specific fluorescence analysis were conducted, where both native as 
well as glycated HSA samples were excited at 285 nm and emission spectra was taken 
over a range of 290-400 nm. As shown in Fig. 23, the emission maxima of native and 
glycated LISA samples were found to be 335 and 330 nm respectively indicating a blue 
shift of 5 nm for glycated HSA. The glycated HSA incubated for 7 and 14 days showed 
an increase in the magnitude of fluorescence intensity and the percent gain in 
fluorescence was 8.24% and 18.63%, whereas glycated HSA incubated for 21 and 28 
days showed reduction in the fluorescence intensity and the loss in fluorescence intensity 
was 48.49°/i and 55.81%. 
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Fig. 22: Ultraviolet absorption spectra of native HSA (H) and glycated HSA (HG) at 7. 
14, 21 and 28 days. 
Fig. 23: Tryptophan fluorescence spectra of native HSA (H) and glycated HSA (HG) at 
7, 14, 2l and 28 days. 
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AGE specific fluorescence 
AGE specific fluorescence is widely used for the detection ofAGEs and for following the 
onset of AGE formation both in vitro and in vivo (Nagal e► al.. 2000; Valencia et al., 
2004). The fluorescence spectra recorded at an excitation wavelength of 370 nm is shown 
in Fig. 24. The glycated IISA incubated for 7 days did not show AGEs specific 
fluorescence at 370 nm (%ex). Incubation of HSA with glucose for 14 and 21 days 
showed an increase in fluorescence as compared to control. Incubation beyond 21 days 
ho«ever, resulted in no further increase in fluorescence. 
Circular dicl:roisnr (CD) spectroscopy 
The Far-UV CD spectroscopy can also be used to study the secondary structure of 
proteins and their conformational changes. The Far-UV CD spectrum of HSA exhibited 
tkco negative bands in the ultraviolet region at 208 and 222 nm which is typical for alpha-
helical structure (Fig. 25). The CD spectra obtained for native HSA and glycated HSA 
showed si-miticant differences, indicating major changes in the secondary structure of 
glycated I ISA at 7, 14,21 and 28 days compared to native HSA. Incubation of HSA with 
glucose leads to a decline in the negative CD signal on 7 days at 208 nm and 222 nm as 
compared to control (Fig. 2). This negative CD signal started decreasing slightly with 
time in l ISA samples incubated with glucose. Glycated LISA at 21 days showed further 
decrease in CD signal as compared to glycated HSA samples incubated for 14 days. 
Further incubation with glucose up to 28 days showed a gradual disappearance of the 
minima at 208 and 222 nm and appearance of minima between 210 and 220 nm occur. 
The u-helical content was 64% in native HSA. However, incubation of HSA with glucose 
showed decrease in a-helix content with time as shown in Table 4. The u-helical content 
of the protein decreased from 64% to 61%. 56%, 51% and 48% on 7, 14, 21 and 28 days 
of incubation of HSA with glucose. 
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FTIR spectroscopy 
Finally, the AGEs were characterized by FTIR spectroscopy. FTIR spectra recorded for 
native (Fig. 26a) and glycated HSA (Fig. 26b) were analyzed on the basis of shape and 
frequency of the amide I and 11 bands and other characteristic group present in their 
structures. Spectra recorded the amide I peak at 1650.87 cm'' which was consistent with 
the absorption peak of u-helix, amide 11 at 1571.51 cm- ' and epoxy ring at 813.6 cm- ' in 
1ISA. Spectra recorded for glycated HSA show shift in amide I and amide II band and 
were observed at 1646.9 cm' and 1535.8 cm-1 respectively as compared with native HSA 
peaks. The interaction of HSA with glucose is attributed by peak observed at 1158.83 cm' 
which is ascribed to the asymmetrical stretching vibration of C-4-C formed by the 
epoxy ring opening. 
Table 4: CD Characteristics of native and glycated HSA 
Groups 	 MRE at 222 nm 	Alpha helix 
Native HSA 	 I 	-17125.3 	I 	64% 
7 days 	j 	-16061.5 	y 	61% 
Glycated 	14 days 	-14824.1 	 56% 
HSA 
21 days 	-13242.6 	 51% 
28 days 	-12184.5 	f 	48% 
MRE measured in deg cm- mol 
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Fig. 24: AGE specific fluorescence spectra of native HSA (H) and glycated HSA (HG) at 
7, 14, 21 and 28 days. 
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Fig. 26: FTIR Spectra of (a) native USA (b) HSA glycated with 100 mM glucose. 
61 
Studies on Gl►rcation of HSA 
/ietoamine estimation 
Ketoamines are early non-enzymatic glycation adducts and are important precursors of 
AGEs and hydroxyl radicals (Ahmed., 2002). The ketoamine moieties formed by the 
gl cation of 1-ISA incubation for 7 days were measured colorimetrically by using NBT. 
The formation of ketoamine was found to be 61.12 ± 2.68 nmoles/mg of protein for 
glycated l ISA. The non-glycated HSA gave a negligible ketoamine concentration of 3.14 
0.26 nmoles/mg of protein (Fig. 27). 
Protein bound carbon! groups 
Carbonyl content is considered a reliable indicator of glycation and is the most 
commonly used marker of protein oxidation and glycation. Modified HSA was analyzed 
for carbonyl content by its reaction with DNPH, for assessing glycoxidative modification. 
Significant amounts of carbonyl groups were produced on glycation. The carbonyl 
contents of glvcated HSA was detected to be 3.6 ± 0.3. 5.9 ± 0.13, 8.06 ± 0.22 and 8.07 ± 
0.26 nmoles/mg of protein at day 7, 14. 21 and 28 post incubation respectively. The 
carbonyl content went on increasing till day 21 and after that there was no further 
increase (Fig. 28). HSA incubated without sugar contained very small amount of 
carbonyl groups (1.73 ± 0.58 nmoles!mg of protein). 
Determination of free amino groups 
HSA incubated with glucose for 7-28 days was also studied for loss of free amino groups. 
Free amino group content in glycated HSA decreased significantly in response to 
incubation with glucose. Percent decrease in free amino groups of glycated HSA was 
found to be 7.65 = 0.24, 9.87 ± 0.44, 15.51 ± 0.50 and 15.91 = 0.50 at 7, 14, 21 and 28 
days of incubation as compared to native HSA (Fig. 29). It clearly shows that as the time 
increases there was a decrease in free amino group of glycated HSA up to 21 days. The 
loss of free amino groups of glycated HSA was same on day 21 and 28 of incubation. 
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H 	HG 
Fig. 27: Level of ketoamines in native HSA (II) and glycated I ISA (HG) after 7 days of 
incubation time. All the data has been represented as Mean SD for samples in triplicate. 
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Fig. 28: Carbonylation of native USA (H) and glycated USA (HG) at 7, 14, 21 and 28 
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Fig. 29: Percent decrease in amino groups of HSA incubated with 100 mM glucose for 7, 
14, 21 and 28 days. All the data has been represented as Mean = SD of triplicated 
samples. 'Significantly different at p<0.05 from native HSA. 
Gel Electrophore..sis 
Native and glvcated I ISA was analyzed by 10% SDS-PAGE in the presence of the thiol 
reductant (i-mercaptoethanol. Fig. 30(a), demonstrates the SDS-PAGE analysis of HSA 
incubated with glucose from 7 days to 28 days. HSA not exposed to glucose migrated as 
a single band of about 66 kD but on incubation with glucose, clear alteration in the 
electrophoretic behavior was evident. These included broadening of the protein band 
towards high and low molecular weight suggesting the formation of high and low 
molecular weight aggregates. The second notable effect was decrease in the staining 
intensity of the original bands. These sugar-induced alterations were more obvious at 21 
and 28 days of glycation. 
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h'ig. 30 (a): SUS-PAGE off ISA incubated with glucose (100 mM) in 20 mM phosphate 
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Densitonretric analysis of SDS-PA GE gels 
the area selected for densitometric analysis of glycated 1-ISA and native HSA was same, 
so that comparison can he easily done. A portion of band selected for native HSA showed 
relative density of 608.6. while the equal portion of band selected for glycated I ISA at 7, 
14, 21 and 28 days of incubation showed 598.2, 590.3, 523.2 and 512.6 relative density 
respectively (Fig. 30b). Density of bands incubated with glucose was much less than that 
of native HSA. 
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Fig. 30 (b): Densitometric analysis of SDS-PAGE. I-ISA was incubated in absence and 
presence of glucose (100 mM) in 20 mM phosphate buffer, pH 7.4 at 37'C for 7, 14, 21 
and 28 days. 
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The aim for this investigation was to compare the inhibitory effects of various 
concentrations of phytochemicals viz. thymoquinone (1Q), thymol (TL) and eugenol 
(EU) upon LISA glycation in vitro. This information was fetched by estimating level of 
ketoamines. free lysine residues, protein carbonyl content and studying protein 
fragmentation in glycated HSA treated N%ith various concentrations of phytochemicals 
(TQ,TL and EU). 
Studies on effect ofphylochernica!s on UV-Visible Spectrophotometry 
AG (1 mM). TQ (3, 30 and 300 µM), TL (3, 30 and 300 µM) and EU (0.06, 0.6 and 6.0 
µM) showed antiglycation action after various time periods when percent chromicity of 
the samples %%as calculated at 280 nm (Table 5). Glycated HSA showed hyperchromicity 
of 27.6% and 57.3% after 7 and 14 days of incubation and 30.79% and 34.9% 
hypochromicity after 21 and 28 days of incubation respectively (Fig. 22). 
Hyperchromicity was found to be decreased for AG treated glycated USA samples as 
compared to glycated LISA after 7 and 14 days. Similarly, reduction in hypochromicity 
was also observed to AG treated glycated HSA samples after 21 and 28 days of 
incubation in comparison to glycated HSA. FU-2 showed highest reduction in hyper and 
hypochromicity in comparison to other formulations of its group. However, TQ-2 and 
T[.-2 exhibited better reduction in hyper and hypochromicity when compared to other 
preparations of their respective groups (Fig. 31-46). As compared to TQ-2 and TL-2, EU-
2 showed better results (Fig. 47). 
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Fig. 31:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
lycated l ISA treated with aminoguanidinc (HGA), TQ-I, TQ-2 and TQ-, after 
incubation for 7 days. 
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Fig. 32:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-I. TL-2 and TL-3 after 
incubation for 7 days. 
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Fig. 33:- Ultraviolet absorption spectra of native LISA (I-1), glycated HSA (HG) and 
glycated I-ISA treated with aminoguanidine (IIGA), EU-1, EU-2 and EU-3 after 
incubation for 7 days. 
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Fig. 34:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated )-{SA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL-
2) and Eugenol (EU-2) after incubation for 7 days. 
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Fig. 35:- Ultraviolet absorption spectra of native HSA (H). glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TQ-I, TQ-2 and TQ-3 after 
incubation for 14 days. 
Fig. 36:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 14 days. 
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Fig. 37:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), EU-I, EU-2 and EU-3 after 
incubation for 14 days. 
Fig. 38:- Ultraviolet absorption spectra of native HSA (II). glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL- 
2) and Eugenol (EU-2) after incubation for 14 days. 
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Fig. 39:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TQ-1, TQ-2 and TQ-3 after 
incubation for 21 days. 
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Fig. 40:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 21 days. 
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Fig. 41:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), EU-1, EU-2 and EU-3 after 
incubation for 21 days. 
Fig. 42:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL- 
2) and Eugenol (EU-2) after incubation for 21 days. 
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Fig. 43:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TQ-1, TQ-2 and TQ-3 after 
incubation for 28 days. 
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Fig. 44:- Ultraviolet absorption spectra of native HSA (H), glycatcd HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 28 days. 
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Fig. 45:- 1Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), EU-1. EU-2 and EU-3 after 
incubation for 28 days. 
Fig. 46:- Ultraviolet absorption spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL- 
2) and Eugenol (EU-2) after incubation for 28 days. 
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Fig. 47: Relative absorbance at 280 rim of native HSA (H), glvcated HSA (HG) and 
glycated HSA treated with amino uanidine I{GA , Th m uinone T 2 Th mol (TL-
2) and Eugenol (EU-2) on 7th, 14 h`, 21 and 28th day of incubation. 
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Table 5: UV Characteristics of HSA samples incubated with glucose. 
Sample Percent hyperchromicity at 280 
nm 
Percent hypochromicity at 280 
nm 
7 days 14 days 21 days 28 days 
HG 27.62 57.35 30.79 34.96 
HGA 8.41 7.43 3.62 5.64 
TQ-1 23.1 41.83 26.81 46.99 
TQ-2 20.73 34.43 22.83 44.36 
TQ-3 24.93 43.9 44.2 52.63 
TL-1 18.91 31.1 21.38 38.72 
TL-2 17.25 24.87 14.85 30.07 
TL-3 21.6 39.47 40.22 46.99 
EU-1 14.5 16.25 14.49 31.2 
EU-2 11.84 12.57 9.06 24.06 
EU-3 18.68 27.25 37.32 46.24 
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Effect of various concentrations of pitvtochemicals on the percent gain and loss in the 
tryptophan fluorescence (intrinsic) intensity ofgltcated HSA 
Percent gain and loss in the tryptophan fluorescence intensity (F.I.) of glycated HSA 
incubated with TQ. TL or EU after various time periods viz. 7, 14, 21 and 28 days was 
also analysed (Table 6). Fluorescence intensity was measured at 335 nm. Glycated HSA 
exhibited 8.24% and 18.63% gain in F.1. after 7 and 14 days and 48.49% and 55.81% loss 
in F.I. after 21 and 28 days respectively (Fig. 23). In concordance with UV results, both 
gain and loss in F.I. was observed to be decreased for AG treated HSA as compared to 
glycated HSA after each time point and the decrease seen in this case was highest 
amongst all the preparations tested. EU preparations followed AG in inducing reduction 
in gain as well as loss in F.I. EU-2 preparation exhibited highest decrease in gain and loss 
in F.I. in comparison to other formulations of its group. Similarly, TQ-2 and TL-2 
showed better reduction in F.I. loss and gain when compared to other preparations of 
their respective groups (Fig. 48-63). EU-2 again was observed to be better than TQ-2 and 
TL-2 (Fig. 64). 
Effect of varying concentration of TQ, TL and EU on the formation of AGE'S from 
HSA glvcation induced by glucose 
Table 7 shows the effect of glucose on total AGEs formation in presence of AG, TQ, TL 
and EU at different concentration during 14. 21 and 28 days of HSA incubation. As it is 
evident from Table 7, TQ, TL and EU at different concentration has significantly 
decreased the formation of AGEs at all the time points. AG at a concentration of 1 mM 
was found to exhibit highest reduction in AGEs formation at all the time points as 
compared to other agents taken. TQ at a concentration of 30 pM showed a good decrease 
in protein carbonyl levels at each time point. Both 3 pM and 300 pM of TQ although 
could induce a reduction in AGEs formation but not as effectively as TQ-2. TL 
preparations \\ere Ibund to perform better in decreasing AGE-related fluorescence as 
compared to TQ preparation. The Eli preparations at all three concentrations and at all 
the time points were found to be capable of suppressing AGEs formation better than the 
corresponding TQ and IL formulations (Fig. 65-76). In that respect, EU-2 (36.7%) is 
almost comparable to the effect of AG (42.08%). Parallel to the protein carbonyl results, 
EU-2 i.e. 0.6 pM of EU was found to reduce AGE fluorescence better than TQ-2 and TL-
2 (30 pM of TQ and TL) after each time point (14, 21 and 28 days) (Fig. 77). 
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Fig. 48:- Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TQ-1, TQ-2 and TQ-3 after 
incubation for 7 days. 
Fig. 49: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 7 days. 
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Fig. 50: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), EU-1, EU-2 and EU-3 after 
incubation for 7 days. 
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Fig. 51: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL-
2) and Eugenol (EU-2) after incubation for 7 days. 
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Fig. 52: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with arninoguanidine (HGA), TQ-I, TQ-2 and TQ-3 after 
incubation for 14 days. 
Fig. 53: f'rvptophan fluorescence spectra ol'native HSA (H). glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 14 days. 
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Fig. 54: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoeuanidine (HGA), EU-1, EU-2 and EU-3 after 
incubation for 14 days. 
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Fig. 55: 'Yryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), •fhymoquinone (TQ-2), Thymol (TL- 
2) and Eugenol (EU-2) after incubation for 14 days. 
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Fig. 56: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glNcated HSA treated with aminoguanidine (HGA), TQ-I, TQ-2 and TQ-3 after 
incubation for 21 days. 
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Fig. 57: Tryptophan fluorescence spectra of native l ISA (H). glycated HSA (HG) and 
glycated LISA treated with aminoguanidine (HGA), TL-1, 7'L-2 and TL-3 after 
incubation for 21 days. 
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Fig. 58: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
gINcated HSA treated with aminoguanidine (HGA), EU-I, EU-2 and EU-3 after 
incubation for 21 days. 
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Fig. 59: Tryptophan fluorescence spectra of native FISA (I1), glycated HSA (H6) and 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL- 
2) and Eugenol (EU-2) after incubation for 21 days. 
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Fig. 60: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (1-IGA). TQ- I. TQ-2 and TQ-3 after 
incubation for 28 days. 
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Fig. 61: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 28 days. 
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Fig. 62: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
iIvcated f IS:% treated with aminoeuanidine (f-UGA), Eli-l. EU-2 and EU-3 after 
incubation for 28 days. 
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Fig. 63: Tryptophan fluorescence spectra of native HSA (H), glycated HSA (HG) and 
• glvcated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thyrnol (TL-
2) and Eugenol (EU-2) after incubation for 28 days. 
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Fig. 64: Relative fluorescence intensity at 335 nm of native HSA (H), glycated HSA 
(HG) and glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), 
Thyrnol (TL-2) and Eugenol (EU-2) on 7 h`, 14'", 21St and 28 h` day of incubation. 
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Table 6 Percent gain and loss in the tryptophan fluorescence intensity of glycated LISA 
samples incubated with or without TQ. TL or EU alter 7 h`. 14 h`, 21 5` and 28'h day of 
incubation. 
Sample 	Percent gain in F.I. at 335 nnf 
7 days 	14 days 
Percent loss in F.I. at 335 nm 
21 days 28 days 
HG 	 8.24% 18.63 48.49 55.81 
HGA 	 1.34% 5.97 8.57 10.16 
TQ-1 	 6.01 % 14.93 38.16 48.68 
TQ-2 	 5.99% 14.42 33.95 42.59 
TQ-3 9.74% 16.16 41.49 55.52 
TL-1 5.67% 11.57 28.27 39.61 
TL-2 
TL-3 
5.38% 
6.08% 
10.49 
13.78 
24.09 
34.78 
32.56 
45.82 
EU-I 4.1 % 10.17 15.59 24.9 
EU-2 3.62% 7.93 13.36 20.11 
EU-3 	 5.08 % 12.25 22.65 48.68 
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Fig. 65: AGE specific fluorescence spectra of native I ISA (11), glycated HSA (I-1G) and 
glycated HSA treated with aminoguanidine (HGA), TQ-1, TQ-2 and TQ-3 after 
incubation for 14 days. 
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Fig. 66: AGE specific fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 14 days. 
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Fig. 67: AGE specific fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (IIGA), EU-I, EU-2 and EU-3 after 
incubation for 14 days. 
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Fig. 68: AGE specific fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (TL-
2) and Eugenol (EU-2) after incubation for 14 days. 
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Fig. 69: AGE specific fluorescence spectra of native HSA (H). glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TQ-1, TQ-2 and TQ-3 after 
incubation for 2I days. 
Fig. 70: AGE specific fluorescence spectra of native HSA (H). glycated I ISA (I iG) and 
glycated HSA treated with aminoguanidine (HGA), TL-I, TL-2 and TL-3 after 
incubation for 21 days. 
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Fig. 71: AGE specific fluorescence spectra of native HSA (H), glycated USA (HG) and 
glycated HSA treated with aminoguanidine (HGA), EU-I, EU-2 and EU-3 after 
incubation for 2I days. 
Fig. 72: AGE specific fluorescence spectra of native HSA (H). glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (I-UGA), Thymoquinone (TQ-2), Thymol (TL- 
2) and Eugenol (EU-2) after incubation for 21 days. 
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Fig. 73: AGE specific fluorescence spectra of native HSA (H). glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TO-1. TQ-2 and TQ-3 after 
incubation for 28 days. 
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Fig. 74: AGE specific fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), TL-1, TL-2 and TL-3 after 
incubation for 28 days. 
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Fig. 75: AGE specific fluorescence spectra of native HSA (H), glycated HSA (HG) and 
glycated HSA treated with aminoguanidine (HGA), EU-I, EU-2 and EU-3 after 
incubation for 28 days. 
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Fig. 76: AGE specific fluorescence spectra of native HSA (H), glycated HSA (HG) an 
glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-2), Thymol (T 
2) and Eugenol (EU-2) after incubation for 28 days. 
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Fig. 77: Relative AGE fluorescence intensity at 430 nm of native HSA (H), glycated 
HSA (HG) and glycated HSA treated with aminoguanidine (HGA), Thymoquinone (TQ-
2), Thymol (TL-2) and Eugenol (EU-2) on 7`', 14`', 2 and 28 h` day of incubation. 
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Table 7: I:tCects of I Q, TL and EL on AGES formation in the I ISA-glucose reaction in 
rin•u. 
Sample Concentration 
QiM) 
Inhibition of AGE formation (%) 
14 days 21 days 28 days 
AG 3 1000 42.08 65.38 60.96 
TQ-I 3 20.67 39.3 21.88 
TQ-' 30 24.04 44.96 24.1 
TQ- 3 300 5.13 22.6 4.82 
TL-I 3 27.74 	45.88 28.3 
TL-2 30 32.49 	49.86 33.88 
TL-3 300 16.86 29.22 17.66 
EU-I 0.06 34.69 54.97 42.03 
EU-2 0.6 36.78 59.86 48.4 
EU-3 6.0 20.67 48.93 27.35 
' Aminoguanidinc (AG) was used as positive control. 
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Fourier Transform Infrared Spectroscopy 
Addition of aminoguanidine to the reaction result in the shift of amide I peaks to 1623.11 
cm" I and the formation of new peak of group NH-CO at 1699.17 cm". A peak at 1074.68 
cm-1 showed the interaction of HSA with glucose (Fig. 78). Another peak observed at 
1238.81 cm"' shows the bond of O-CO. Addition of thymol to the reaction results in 
formation of new peak at 1058.67 cm' and 1090.70 cm- . Addition of thymoquinone to 
the reaction showed a shift in peak of epoxy ring and observed at 1178.67 cm'. Spectra 
recorded on addition of eugenol to the reaction may leads to vibration stretch in epoxy 
ring of HSA with peak observed at 1142.81 cm1  (Fig. 78). 
Effect of TQ, TL and EU on the level of ketoamines in glycated HSA 
The data show ketoamine formation in nmoles!mg of protein in various HSA samples viz. 
Native HSA, glycated HSA and aminoguanidine (AG). thymoquinone, thymol and 
eugenol treated HSA incubation with sugar for 7 days (Table 8). The glycated albumin 
treated with aminoguanidine exhibited a significant decrease in ketoamine level followed 
by EU-1 and EU-2 treated glycated albumin as compared to glycated HSA. AG had 12.3 
± 1.89 and EU- I and EU-2 had 19.6 ± 1.92 and 14.5 ± 3.77 in contrast to glycated HSA 
which had a very high ketoamine conc. of 61.1 ± 2.68 (Fig. 79c). TQ and TL treated 
glycated albumin also showed decrease in ketoamine levels but not parallel to those 
observed for AG treated albumin (Fig. 79a and b). Out of the three TQ, TL and EU 
formulations taken TQ-2, TL-2 and EU-2 showed the highest reduction in ketoamine 
levels amongst themselves. Ketoamine reduction induced by TQ-2 (28.2 ± 3.31) was 
followed by TQ-1 (35.3 ± 3.11) and TQ-3 (48.9 ± 2.07); TL-2 (24.6 ± 2.84) was followed 
by TL-1 (32.7 ± 2.48) and TL-3 (42.4 t 3.07) and EU-2 (14.5 ± 3.77) was followed by 
EU-1 (19.6 ± 1.92) and EU-3 (24.4 ± 2.82). Amongst the TQ-2, TL-2 and EU-2 
preparations, EU-2 was found to induce highest reduction in ketoamine formation (Fig. 
79d). This indicates a very high potency of eugenol as compared to thymoquinone and 
thymol in decreasing ketoamine levels since it performed better at a concentration of 0.6 
pM than 30 .tM of either TQ or TL. 
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Fig. 78: FTIR spectra of (a) HSA + Glucose + Aminoguanidine (AG); (b) HSA + 
Glucose + Thymoquinone (TQ); (c) USA + Glucose + Thymol (TL); and (d) HSA + 
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Fig. 79: (a) Level of ketoamines in native HSA (H), glycated HSA (HG) and glycated 
HSA treated with aminoguanidine (HGA), varying concentrations ofthymoquinone i.e, 
TQ-I. TQ-2 and TQ-3: (b) varying concentrations ofthymol i.e, TL-I, TL-2 and 1-1.-3; 
(c) varying concentrations of eugenol i.e, EU-1, EU-2 and EU-3. (d) thymoquinone-30 
µM (TQ-2). thymol-3O.tM (TL-2) or eugenol-0.6 pM (EU-2) at 7'h day. Each value 
represent the means ± SD for three experiments performed in duplicates. Significantly 
different at p<0.05. 
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Table 8: Level of ketoamines in native HSA (H). giveated USA (Ito) and glycated HSA 
alter being treated with aminoguanidine (FICA) or varying concentrations ui 
thyrnoquinone (I Q-1, TQ-2, T'Q-3), thy'mol (TI: I, TI.-2, TI.-3) and eugenol (P.11-I, Eli- 
2, EU-3) on 7 days. 
Sample Concentration 
(1M) 
Ketoa mine formation 
(unwlelmg of pro(rin) 
H - 3.14±0.26 
HG - 61.1f2.68 
AG 
TQ- I 3 
1000  
35.3 i 3.11 
TQ-2 30 28.2 t 3.31 
TQ-3 300 48.9+2.07 
TL-I 3 32.7±2.48 
I L-2 30 24.6+2.84 
TL-3 300 424±3.07 
EU-I 0.06 19.6 t 1.92 
EU-2 0.6 14.5 	3.77 
EU-3 6.0 24.4+2.82 
All the date has been represented as Mean ± SD for three experiments perlurmed in 
duplicates. 
Significantly different at p 00.05. 
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Comparison of the inhibitor)! effect of pM tochemicals (TQ, TL and EU) at various 
concentrations on glrcation-induced HSA oxidation 
The protein carbonyl level which is an assessment of protein oxidation was also 
determined for various HSA preparations at various time points 7, 14, 21 and 28 post 
glycation. As expected, protein oxidation markedly increased upon glycation of HSA 
(Fig. 28, Table 9). AG at a concentration of ImM was found to exhibit highest reduction 
in HSA oxidation at all the time points as compared to other agents taken. TQ at a 
concentration of 30 pM showed a good decrease in protein carbonyl levels at each time 
point and interestingly with increase in time period the gap in the protein carbonyl levels 
widened. Both 3 pM and 300 pM of TQ although could induce reduction in HSA 
oxidation but not as effectively as TQ-2 (Fig. 80a). TL formulations were found to 
perform better in decreasing protein carbonvl levels as compared to TQ preparations. EU 
formulations at all the three concentrations and at all the time points were found to induce 
better reduction than the corresponding TQ and TL formulations (Fig. 80-83). Parallel to 
the ketoamine results. EU-2 i.e. 0.6 pM of eugenol was found to reduce the carbonyl 
content better than TQ-2 and TL-2 (30 µh1 of thymiquinone and thymol) after 7, 14, 21 
and 28 days of incubation with sugar (Fig. 84). 
A comparative stud), of the percent decrease in free amino groups of glycated HSA 
treated with various concentrations of phtvochemicals 
Glycated HSA treated with various concentrations of phytochemicals for 1-4 weeks was 
also studied for loss of free amino groups. In concordance with earlier results, AG was 
found to lower the loss of free amino groups of glycated albumin significantly as 
compared to TQ, TL and EU at all the time points although each group of preparation 
could induce some reduction in loss of free amino groups (lie. 85-88). TQ-2 (30 µM) as 
observed for earlier studies, was found to decrease the loss of free amino groups better 
than the two other formulations. Similarly, 30 µM of TL i.e. TL-2 could lead to reduction 
in percent decrease of free amino group more than TL-I and TL-3 after each incubation 
period. All the EU formulations induced more reduction in loss of free amino groups than 
their corresponding TQ and TL formulations (Table 10) and in concordance with earlier 
results EU-2 was found to be better in decreasing the loss of free amino groups than TQ-2 
and TL-2 at all the time points (Fig. 89). 
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Fig. 80: Carbonylation of native HSA (H), glycated HSA (HG) and glycated HSA treated 
with aminoguanidine (HGA) or varying concentrations of thymoquinone i.e, TQ-1, TQ-2 
and TQ-3: (b) varying concentrations of thymol i.e, TL-1, TL-2 and TL-3; (c) varying 
concentrations of eugenol i.e, EU-1, EU-2 and EU-3. (d) thymoqu1none-30 pM (TQ-2), 
thymol-30 µM (TL-2) or eugenol-0.6 µM (EU-2) on 7 days. Each value represent the 
Mean ± SD for three experiments performed in duplicates. Significantly different at 
p<0.05. 
102 
Antigltication Studies 
8 
0 6 
C) E 
j 	0 4 
S3 
o2 
.0 R1 U 
0 
7 
0 
a5 
I ~ 
E4 
0 
E 
c2  
0 
(1 
U 
1I 	0 
8 
Z 7 
0
6 L 
C' S E 
04 
=3 
c2 
0 
I _. =7 
m6 
0 
0.5 
C) 
E4 
0 
=3 
>1 2 C 0 
.1 
"0 
Fig. 81: Carbonylation of native HSA (H), glycated HSA (HG) and glycated HSA treated 
with aminoguanidine (HGA) or varying concentrations of thytnoquinone i.e, TQ-1, TQ-2 
and TQ-3; (b) varying concentrations of thymol i.e, TL-I, TL-2 and TL-3; (c) varying 
concentrations ofeugenol i.e, EU-l. EU-2 and EU-3. (d) thyrnoquinone-30 µM (TQ-2), 
thymol-30 pM (TL-2) or eugenol-0.6 µM (EU-2) on 14 days. Each value represent the 
Mean -_'- SD for three experiments performed in duplicates. Significantly different at 
p<0.05. 
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Fig. 82: Carboni lation of native HSA (H), glycated PISA (HG) and glycated HSA treated 
with aminoguanidine (I IGA) or varying concentrations ofthymoquinone i.e, TQ-1, TQ-2 
and TQ-3; (b) varying concentrations of thymol i.e. TL-1. TL-2 and TL-3; (c) varying 
concentrations of eugenol i.e, EU-I, EU-2 and EU-3. (d) thymoquinone-30 µM (TQ-2), 
thymol- 30 tM (TL-2) or eugenol-0.6 NM (EU-2) on 21 days. Each value represent the 
Mean ± SD for three experiments performed in duplicates. Significantly different at 
p<0.05. 
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Fig. 83: Carbon> lation of native HSA (H) glycated IiSA (HG) 	glycated USA treated 
with aminoguanidine (HGA) or varying concentrations of thvmoquinonc i.e. TQ-1, TQ-2 
and TQ-3; (b) varying concentrations of thymol i.e, TL-1. TL-2 and TL-3; (c) varying 
concentrations of eugenol i.e, EU-l. EU-2 and EU-3. (d) thymoquinone-30 pM (TQ-2), 
thyrnol-30 µV1 (TL-2) or eugenol-0.6 pM (EU-2) on 28 days. Each value represent the 
Mean ± SD for three experiments performed in duplicates. Significantly different at 
p<0.05. 
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Fig. 84: Carbonylation of HSA incubated with 100 mM glucose in absence and presence 
of aminoguanidine (HGA), thymoquinone-30 uM (TQ-2), thvmol 30 .iM (fL-2) or 
eugenol-0.6 pM (F.0-2) up to 28 days. HSA incubated under identical conditions without 
any treatment act as control. Each value represent the Mean ± ST) for three experiments 
performed in duplicates. Significantly different at p<0.05. 
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Table 9: Protein Carboni I content (nmoles /mg protein) present in USA samples 
incubated with glucose and varvine concentrations ofTQ. Ti_ or El! at 7, 14. 21 and 28 
days. 
Sample 7 days 14 days 21 days 28 days 
H 1.73±0.58 1.9410.14 2.30±0.27 2.30±0.22 
HG 3.66±0.30 5.99*0.13 8.06±0.22 8.07±0.26 
HGA 1.94±0.32 2.26*0.15 2.31 10.12 2.37±0.23 
TQ-I 3.35±0.2 5.170.25 5.48±0.27 5.39±0.23 
TQ-2 3.05*0.17 4.01±0.19 4.63±0.3 4.87±0.17 
TQ-3 3.18±0.16 ` 	6.82±0.40 7.13±0.36 5.87 ± 0.12 
11-1 2.85±0.29 3.40=0.12 4.12=0.34 3.85±0.28 
TL-2 2.46±0.26 2.85±0.16 3.29+0.4 3.77±0.14 
"IL-3 3.3+0.21 5.91 ± 0.24 6.31±0.54 5.19 ± 0.25 
EU-1 2.18±0.24 3.07±0.10 3.6210.39 3.66±0.28 
EU-2 2.073±0.21 2.43 ± 0.14 2.6±0.33 2.90 ± 0.08 
EU-3 2.37±0.27 6.57 ± 0.15 7.05±0.68 4.35 ± 0.16 
All the data has been represented as Mean ± SD for three experiments performed in 
duplicates. 
Significantly different at p<0.05. 
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Fig. 85: (a) Percent decrease in amino groups of glycated HSA (HG) and glycated BSA 
treated with aminoguanidine (HGA) or varying concentrations of thymoquinonc i.e, TQ-
l. TQ-2 and TQ-3: (b) varying concentrations of thvmol i.e, TL-I, TL-2 and TL 3; (c) 
varying concentrations of eugenol i.e, EU-l. EU-2 and EU-3. (d) thymoquinone-30 tM 
(TQ-2). thymol-30 µM (TL-2) or eugenol-0.6 µM (EU-2) on 7 days. All the data has 
been represented as Mean f SD for three experiments performed in duplicates. 
Significantly different at p<0.05 
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Fig. 86: (a) Percent decrease in amino groups of glycated HSA (HG) and glycated LISA 
treated with aminoguanidine (HGA) or varying concentrations of thymoquinone i.e, TQ- 
l. TQ-2 and TQ-3; (b) varying concentrations of thymol i.c. 'IL-I, TL-2 and TL-3; (c) 
varying concentrations of eugenol i.e, EU-1. EU-2 and EU-3. (d) thymoquinone-30 pM 
(TQ-2), thymol-3() µM (TL-2) or eugenol-0.6 tM (EU-2) on 14 days. All the data has 
been represented as Mean f SD for three experiments performed in duplicates. 
Significantly different at p<0.05 
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Fig. 87: (a) Percent decrease in amino groups of glycated HSA (HG) and glycated HSA 
treated with aminoguanidine (HGA) or varying concentrations of thymoquinone i.e, TQ- 
1. TQ-2 and TQ-3; (b) varying concentrations of thymol i.e. TL-1. TL-2 and TL-3; (c) 
varying concentrations of eugenol i.e, EU-1, EU-2 and EU-3. (d) thymoquinone-30 tM 
(TQ-2). thyrnol-30 pM (TL-2) or eugenol-0.6 µM (EU-2) on 21 days. All the data has 
been represented as Mean ± SD for three experiments performed in duplicates. 
Significantly different at p<0.05 
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Fig. 88: (a) Percent decrease in amino groups of glycated HSA (HG) and glycated HSA 
treated %\ith aminoguanidine (HGA) or varying concentrations of thvmoquinone i.e, TQ- 
I. TQ-2 and TQ-3; (b) varying concentrations of thymol i.e. TL-l. TL-2 and TL-3: (c) 
varvinL, concentrations ofeugenol i.e. FU-I. EU-2 and EU-3. (d) thvmoquinone-30 µM 
(TQ-2). thymol-30 µM (TL-2) or eugenol-0.6 pM (EU-2) on 28 days. All the data has 
been represented as Mean ± SD for three experiments performed in duplicates. 
Significantly different at p<0.05 
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Fig. 89: Percent decrease in amino groups of HSA incubated with 100 mM glucose in 
absence and presence of aminoguanidine (HGA), thymoquinone (TQ-2, 30 µM), thymol- 
30 .tM (TL-2, 30 µM) or eugenol (EU-2, 0.6 µM) up to 28 days. All the data has been 
represented as Mean ± SD for three experiments performed in duplicates. Significantly 
different at p<0.05. 
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Table 10: Percent decrease in free amino groups of elycated USA samples incubated in 
absence and presence of varying concentrations of TQ, TL or EU at 7, 14, 21 and 28 
days. 
Sample 7 days 14 days 21 days 28 days 
HG 7.65+0.24 9.87+0.44 15.51+0.47 15.91-0.52 
HGA 	1 3.60±0.45 3.01±0.62 	2.81+0.26 3.05±0.47 
TQ-1 7.24 ± 0.46 7.9310.36 6.96+0.23 7.97±0.65 
TQ-2 6.96 ± 0.26 	6.6+0.11 6.14 ± 0.32 7.16+0.90 
TQ-3 	7.39±0.31 8.41±0.62 6.52±0.27 8.28±0.16 
TL-1 6.39+0.22 6.18±0.22 5.62±D44 6.34 ± 0.21 
TL-2 5.73±0.47 5.59±0.23 4.38+0.58 5.24±0.38 
TL-3 7.03±0.28 6.84=0.27 6.55101-7 6.74 ± 0.26 
EU-1 5.42±0.27 5.23±0.31 4.69}0.42 5.18±0.35 
EU-2 5.04 ± 0.37 4.23 f 0.21 3.31 t 0.34 3.83 ± 0.29 
EU-3 5.56+0.2 5.19+0.47 5.15[0.32 5.48±0.26 
All the data has been represented as Mean ± SD for three experiments performed in 
duplicates. 
Significantly different at p<0.05. 
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Effect of phytochenzicals on superoxide anion radical generation 
To confirm that ROS are involved in the observed propagation of protein damage, we 
measured generation of O2' from glycated HSA. Superoxide dismutase (SOD). vas used 
as the standard quencher of O-,' (Fig. 90) and showed significant inhibition in 
superoxide radical formation in glycated HSA. The amount of O[ was found to be 21.7 
1.23 nmol/ml in glycated HSA. However, addition of AG induced reduction in OZ' 
generation to 5.4 ± 1.09 nmol/ml. Out of the three TQ. TL and EU formulations taken, 
TQ-2, TL-2 and EU-2 showed the highest reduction in O[ formation amongst 
themselves. Generation of superoxide anion radical reduced by TQ-2 (8.8 ± 0.69) was 
followed by TQ-1 (9.2 ± 1.75) and TQ-3 (18.8 ± 0.93); TL-2 (7.4 ± 1.44) was followed 
by TL-1 (7.7 ± 0.78) and TL-3 (16.7 ± 1.39) and EU-2 (5.9 ± 0.69) was followed by EU-
1 (6.7 ±1.18) and EU-3 (16.5 ± 1.42) (Fig.91). EU-2 i.e. 0.6 µM of eugenol was found to 
decrease the O,' formation better than TQ-2 and TL-2 (30 µM of thymoquinone and 
thymol) (Fig.91 d). 
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Fig. 90: Inhibition of superoxide radical generation during glycation of HSA by 
superoxide dismutase. 
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Fig. 91: (a) Superoxide anion radical generation on incubation of HSA with glucose 
(HG) and its inhibition on treatment of glycated LISA with aminoguanidine (HGA) and 
varying concentrations of thyrnoquinone; (b) Inhibition of O2 generation on treatment 
with varying concentrations of thymol; (c) Inhibition of O,,'— generation on treatment 
with varying concentrations of eugenol and (d) Comparison between best concentration 
TQ-2, T1.-2 and EU-2 in inhibiting O: generation. 
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Effect of TQ, TL and EU on electrophoretic pattern of HSA in-vitro 
Hyperglycaemia. the major complication of diabetes, leads to protein glycation and 
formation of advanced glycation end products. Amadori products and glucose in the 
glycated protein undergo oxidation to form free radicals which can induce protein 
fragmentation. Phytochemicals thymoquinone (TQ), thymol (TL) and eugenol (EU) have 
been attributed with potent antioxidant property. Human Serum Albumin (HSA) was 
glycated in the presence of different concentrations of phytochemicals viz. TQ, TL and 
EU and their effect on protein fragmentation inhibition was examined by sodium dodecyl 
sulphate ployacrylamide gel electrophoresis (SDS-PAGE). 
HSA when incubated with glucose undergoes protein cross-linking and aggregate 
formation. Crosslink inhibition of glycated HSA post incubation with various 
preparations of phytochemicals viz. TQ, TL and EU was observed at various time points 
(7 days. 14 days, 21 days and 28 days). HSA incubated with glucose (Fig. 92, lane 3) 
exhibits slight fragmentation and hence intensity of band reduces with diffusion which is 
not observed for HSA incubated alone (Fig. 92, lane 2). Aminoguanidine at a 
concentration of 1 mM significantly inhibited the HSA crosslinks. All the three 
preparations of phytochemical EU showed inhibition in aggregate formation but EU-2 
(0.6 µM) was found to be the best inhibitor amongst its group at all the time points 
although it could not achieve the level observed for AG inhibition (Fig. 98, 99; lane 4). 
EU-1 was found to inhibit fragmentation better than EU-3 after incubation periods 7, 14, 
21 and 28 days (Fig. 98, 99). Similar case was observed for TQ (Fig. 92, 93) and TL (Fig. 
95, 96) phytochemicals. Amongst the three formulations of TL and TQ. TL-2 and TQ-2 
were found to inhibit HSA crosslink formation and/or fragmentation better than other 
formulations of their group after each incubation period. As observed in Fig. 100, EU-2 
significantly inhibited diffusion of glycated HSA band due to protein cross-links induced 
by protein glycation in comparison to TL-2 and TQ-2. 
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Densitomctric anahsis 
SDS-PAGE was also analyzed by gel densitometry. Density of a portion of band of equal 
area as found to be decreased on glycation of HSA. However, on treatment with 
phytochemicals, density of gel increased showing the restriction of cross-links and 
prevented HSA from glycation (Table 11). EU-2 inhibited protein fragmentation to a 
great extent. Relative density was found to be 605.8, 604.2, 590.6 and 581.0 at 7, 14, 21 
and 28 days of EU-2 incubation which is much closer to density of native HSA (608.6) 
(Fig. 100). EU-1 showed higher density as compared to EU-3 after incubation periods 7, 
14, 21 and 28 days (Fig. 100). Similar case was observed for TL and TQ phytochemicals. 
Amongst the three formulations of TL and TQ, TL-2 and TQ-2 were found to have 
greater density which is in relation to PAGE analysis of respective groups after each 
incubation period (Fig. 94, 97). Among the best concentration of phytochemicals, EU-2 
shored maximum increase in density (Fig. 102). 
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Fig. 92: (a) Sf)S-PAGE: oil ISA incubated with glucose in absence and presence of TQ- 
I. TQ-2 or TQ- 3 in 20 mh1 phosphate bunter, p11 7.4 at 37C tier 7 days: (h) 14 days. 
Lane I: 	Molecular weight Marker in kJ) 
Lane 2: 	I-ISA (1) ig protein) 
Lane 3: 	I ISA + Glucose (10O mlll) 
I.<ine 4: 	L ISA - Glucose + Arninoeuanidine (I mM ) 
Lane 5: 	I ISA Glucose + TQ-I (3 µM) 
Lane 6: 	I ISA + Glucose + 1 Q-2 (30 µM) 
Lane 7: 	I ISA - Glucose + TQ-3 ( 300 gm) 
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Fig. 93: (a) SUS-PA(11-. of HSA incubated 'id glucose in absence and presence oI TQ-
. I Q-2 or 1'Q-3 in 20 mN1 phosphate but)cr. p11 7.4 at 37`C for 21 daN s: (h) 28 days. 
Lane 1: 	Molecular weight Marker ir; ki) 
Lane 2: 	HSA (10 ug protein) 
Lane 3: 	1ISA + Glucose (100 mM 
Lane 4: 	HS,\ + Glucose + .Aminoguanidine (1 mM) 
Lane 5: 	FISA + Glucose +'EQ-I (3 pM) 
Lane 6: 	HSA + Glucose + IQ-2 (30 pM) 
Lane 7: 	HSA + Glucose + TQ-3 (300 pM) 
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Fig. 94: Densitometric analysis of SDS-PAGE. (a) Histograms represent relative mean 
band density of HSA (H), glycated HSA (HG) and glycated HSA treated with 
aminoguanidine (HGA) or varying concentrations of thymoquinone i.e, TQ-1, TQ-2 and 
TQ-3 at 7 days; (b) 14 days; (c) 21 days and (d) 28 days. 
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Fig. 95: (a) SD5-PAGE o1 l ISA incubated with glucose in absence and presence of "IL-I. 
11.-? or I L-3 in 20 mM phosphate ha tier. pH 7.4 at 37'C tor 7 days: (h) 14 days. 
Lane 1: 	Molecular weight Marker in kl) 
Lane 2: 	HSA (10 pg protein) 
Lane 1: 	USA + (ilucose ((00 mM) 
Lane 4: 	HSA + Glucose -+ Aminoguanidine (I mM) 
Lane 5: 	HSA + GIucosc I I.-I (3 MM) 
Lane 6: 	l IS.n + Glucose 'l L-? (10 f~M) 
Lane 7: 	1 IS A • Glucose + II -31300 µM► 
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Fig.96: (a) SI)S-1?AGL of HSA incubated With glucose in absence and presence of 'I'L-I, 
1-1.-2 or I L-3 in 20 mM phosphate butler. pH 7.4 at 37'C for 21 days: (b) 28 clays. 
Lane I: 	Molecular %%eight Marker in lki) 
Lane ?: 	HSA (10 pg protein) 
Lane 3: 	I ISA + Glucose (100 mM) 
Lane 4: 	11SA Glucose f Aminoguanidinc (I mM) 
Lane : 	(ISA + Glucose + I L-I (3 µM) 
Lane 6: 	11SA + Glucose t TL-2 (30 µM) 
Lane 7: 	HS.A + Glucose + TL-3 (300 NM) 
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Fig. 97: Densitometric analysis of SOS-PAGE. (a) Histograms represent relative mean 
band density of HSA (1-1), glycated USAI IG) and glycated I ISA treated with 
aminoguanidine (HGA) or varying concentrations of thymol i.e, TL-I. TL-2 and TL-3 at 
7 days; (h) 14 days: (c) 21 days and (d) 28 days. 
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Fig. 98: (a) SI)S-PA(i1: of 1IS;\ incubated with glucose in ahscnee and presence of 
aminoguanidine. Fl -I. IT-2 or HI-3 in 20 mM phosphate buffer, pH 7.4 at 37C for 7 
da%s: (b) 14 days 
Lane I : 	Molecular %~eight Marker in kO 
Lane 2: 	1IS.A (10 tg protein) 
Lane 3: 	HS A Glucose (100 mM ) 
Lane 4: 	I ISA * Glucose 7 Aminaeuanidinc (I mM) 
Lane is 	USA + Glucose+ F(' -I 1(1.06 µM) 
Lane 6: 	I ISA + Glucose + E(;-2 (0.6 pM 
Lane 7: 	I ISA + Glucose + LU-3 (6.0 I M) 
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(a) EU 21 Days 
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i 	? 4 ` 
	 1 2 3 4 5 6 7 
1Ot D lOOkD —iw` 
i$kD AD —1~"" 
—ue NiD 	s 2J—rte 
AD --~ :to~~ 
fstb  
I`l•D --ir 
Fig. 99: (a) SDS-PAG1 of I ISA incubated %%ith glucose in absence and presence of 
aminoguanidine. i- i. F• :U-2 or F•:(i-3 in 20 mM phosphate huller, pH 7.4 at 3TC for 2 i 
daNs: (h) 2l days 
Lane 1: 	Molecular weight Marker in ki) 
Lane 2: 	HSA (10 tg protein) 
Lane 3: 	I ISA I Glucose (100 mM) 
Lane 4: 	1IS.A - Glucose + Aminoguanidine (I mM) 
Lane 5: 	HSA – Glucose + FIJ-I (0.06 µM) 
Lane 6: 	I ISA -r Glucose + LLJ-2 (0.6 µM) 
Lane 7: 	HSA + Glucose + F.0-3 (6.0 µM) 
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Fig. 100: Densitometric analysis of SDS-PAGE. (a) Histograms represent relative mean 
band density of HSA (H), glycated HSA (HG) and glycated HSA treated with 
aminoguanidine (HGA) or varying concentrations of eugenol i.e. EU-1, EU-2 and EU-3 
at 7 days; (b) 14 days: (c) 21 days and (d) 28 days. 
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Fig. 101: tiI )S-PAGI I of I ISA incubated with glucose (100 mM) in presence of IQ-2. 
fl.-2 or I'U-2 in 20 mM phosphate buffer, pi 1 7.1 at 37`C for 21 days. 
Lane I: Molecular weight Marker in kD 
Lane 2: I ISA (10 jig protein) 
Lane 3: I ISA + (ilucose (100 mM) 
Lane 4: i ISA f Glucose + Arninoguanidine (I mM) 
Lane S: LISA + Glucose + TQ-2 (30 µM) 
Large 6: I ISA 	Glucose + TL-2 (30 µ\M) 
Lane 7: IISA 1 Glucose + I:U-2 (0.6 µit) 
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Fig. 102: Comparative densitometric analysis of band density of TQ-2, TL-2 and EU-2 
after 21 days of incubation. 
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Table 11: Densitometric analysis of SDS-PAGE showing effect of varying 
concentrations of TQ, TL and EU after 7, 14, 21 and 28 days of incubation. 
7 days 	14 days 21 days 28 days 
H 608.6 608.2 606.4 605.7 
HG 598.2 590.3 523.2 512.6 
HGA 606.3 605.5 599.6 591.1 
TQ-1 600.5 596.0 564.7 552.6 
TQ-2 601.8 595.2 572.4 563.8 
TQ-3 599.1 592.5 538.2 529.1 
TL-I 601.4 600.1 574.1 558.4 
TL-2 603.1 601.7 581.8 569.3 
TL-3 600.3 595.3 551.9 544.7 
EU-1 603.4 602.6 581.3 573.9 
EU-2 605.8 604.2 590.6 581.0 
EU-3 601.8 599.3 563.6 552.7 
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PROTECTIVE ROLE OF TQ, TL AND EU IN SERA OF TYPE-2 DIABETIC 
PATIENTS 
Effect was observed on sera of type-2 diabetic patients incubated with phytochemicals, 
viz. TQ. TL and EU and compared with sera incubated in same conditions in absence of 
phytochemicals for 21 days. Sera of healthy individual without any treatment served as 
control. 
Estimation of malondialdehyde (MDA) 
Lipid peroxidation is also a parameter for the evaluation of oxidative stress. Hence, 
estimation of level of MDA, lipid peroxidation product, in healthy (control) versus 
diabetic patient's serum was the obvious to investigate. The result depicted in (Fig.103) 
showed an appreciable augmentation in the MDA levels in diabetic patient's serum (7.01 
0.34 nmoles/ml. p<0.001) in comparison to control (3.31 ± 0.34 nmoles/ml). Further 
analysis of diabetic sera incubated with TQ (30 µM), TL (30 .tM) and EU (0.6 µM) 
showed significant decrease in MDA level (p<0.001) as compared to diabetic serum 
without any treatment. As shown in Table 12, the level of MDA in diabetic serum treated 
with TQ (30 µM). TL (30 µM) and EU (0.6 pM) were found to be 6.02 ± 0.28, 4.87 
0.32 and 3.73 ± 0.32 nmoles/ml respectively. 
Estimation of carbonyl contents 
Carbonyl content was determined to assess the glycoxidative stress induced protein 
oxidation. Our observation showed that serum protein carbonyl contents were 
significantly increased (p<0.001) in diabetic patients as compared to normal human 
subjects. The average carbonyl contents (± SD) of three independent assays of diabetes 
serum proteins and normal human serum proteins were 3.51 ± 0.15 and 1.95 ± 0.14 
nmoles/mg protein of the serum sample respectively (Fig. 104). Further, in vitro 
incubation with TQ (30 pM), TL (30 µM) and EU (0.6 µM) resulted in significant 
(p<0.001) decrease in the level of carbonyl group content in diabetic patients. The 
amount of protein bound carbonyl groups in diabetic serum samples treated with TQ, TL 
and EU was found to be 2.89 ± 0.15, 2.41 ± 0.11 and 2.05 ± 0.16 nmoles/mg of protein 
respectively. The treatment of EU was more effective than TL. TQ was found to be least 
effective (Table 12). 
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Fig. 103: MDA levels in serum of healthy (Control) and diabetic patients (DM) and in 
diabetic patient's serum treated with thymoquinone (DM—TQ), thymol (DM+TL) and 
eugenol (DM+EU). Data are expressed as Mean ± SD, n=40. 
p<0.00I as compared with DM. 
p<0.00I as compared '. ith Healthy. 
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Fig. 104: Protein carbonyl level in serum of healthy (Control) and diabetic patients (DM) 
and in diabetic patient's serum treated with thymoquinone (DM+TQ), thymol (DM+TL) 
and eugenol (DM+EU). Data are expressed as Mean ± SD, n=40. 
'p<0.00I as compared with DM. 
p<U.00 I as compared with Healthy. 
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Ferric Reducing Antioxidant Power (FRAP) assay 
FRAP assay as used for the determination of total antioxidants in serum samples of 
healthy and diabetic patients as well as in TQ (30 AM). TI. (30 µM) and FU (0.6 1iM) 
treated diabetic serum samples. As evident from Fig.105. FRAP value decreases 
significantly (p<0.001) in diabetic patients as compared to control. The average FRAP 
value (t SD) of three independent assays of diabetic serum and normal human scrum 
were 719.5 ± 78.8 and 1270.1 f 92.9 µM respectively. Furthermore, when the diabetic 
samples were treated with TQ (30 µM), TL (30 AM) and EU (0.6 AM), significant 
(p<0.001) increase in FRAP value was observed as compared to the diabetic samples 
without any treatment. The increment in FRAP value after treatment of diabetic samples 
with TQ, TL and EU was found to be 11%, 22.4% and 37.2% respectively (Table 12). 
The effect of in vitro incubation of diabetic patient's sera with EU is more pronounced 
than TI. and TQ. 
Estimation of reduced gluful/rione level (GSH) 
Reduced glutathione is an important antioxidant in cellular system. Table 12 summarizes 
the glutathione level in healthy and type 2 diabetic patients. The present study reports a 
decline in reduced GSII content in serum of type 2 diabetic patients (13.7 ± 1.09 AM) as 
compared to healthy controls (25.7 f 1.26 pM). In concordance to FRAP results in 
diabetic serum, phytochemical treatment ameliorates reduced GSH level significantly 
(p<0.001). Addition of EU (0.6 AM) induce highest increment in reduced glutathione 
level (23.2 = 1.09 AM) in comparison to treatment of 30 NM TL and TQ in diabetic 
patients serum (Fig. 106). 
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Fig. 105: FRAP value in serum of healthy (Control) and diabetic patients (DM) and in 
diabetic patient's serum treated with thymoquinone (DM+TQ), thymol (DM+TL) and 
eugenol (DM+EU). Data are expressed as Mean ± SD. n=40. 
~p<0.001 as compared with DM. 
p<0.001 as compared with Healthy. 
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Fig. 106: Effect of TQ-2 (DM+TQ), TL-2 (DM+TL) and EU-2 (DM+EU) treatment on 
reduced glutathione level in type 2 diabetic patients (DM). Glutathione level in healthy 
individuals served as control. Each point represents the Mean ± SD (n=40) of three 
independent assays. 
'p<0.001 as compared with DM. 
p<0.001 as compared with Healthy. 
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Effect of TQ, TL and Ell on electrophorelic pattern of 1ISA in the sera of diabetic 
patients 
One of the manifestations of diabetes is glycation of proteins. So, we observed the effect 
of phytochemicals, viz. TQ, TL and EU on crosslinking and/or fragmentation inhibition 
of HSA. Effect was observed on sera incubated with glucose and compared with sera 
incubated in same conditions in absence of glucose. As albumin is the major protein of 
human serum, hence incubated serum samples on SDS-PAGE analysis showed band of 
-66 kD. Fig. 107(a) shows SDS-PAGE profile of diabetic patient I (Dl). Serum profile 
of diabetic patient showed broadening of band towards high and low molecular weight, 
protein fragmentation and/or cross-linking but the sera incubated with TQ, TL and EU 
exhibited inhibition of diffusion of band and aggregate formation. It was further approved 
by gel densitometric analysis on SDS-PAGE of diabetic patient 1 (Dl) (Fig. 107b). 
Amongst the three phytochemicals, EU at the 0.6 µM (Fig. 107a, lane 6) concentration 
could inhibit protein cross-linking and/or fragmentation better than 30 µM of TQ (Fi and 
TL. As observed in Fig. 108, diabetic patient's sera incubated with glucose shows 
increased cross-linking and diffusion of band due to fragmentation, but in the presence of 
phytochemicals glucose incubated sera exhibited decreased fragmentation and cross-
linking. Again, EU at 0.6 pM was found to inhibit protein aggregates formation and 
cross-linking better than 30 pM of TQ and TL. Similar case was observed for other 9 
patients with EU being most effective in inhibiting HSA glycation in diabetics (Fig. 109-
126). 
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Table 12: Levels of protein carbonyl. MDA and FRAP in serum of healthy (Control), 
type 2 diabetic patients (DM) and diabetic serum samples treated with thymoquinone 30 
µM (DM+TQ), thymol 30 µM (DM+TL) and eugenol 0.6 µM (DM+EU). 
CONTROL DM DM + TQ DM + TL DM + EU 
Protein 1.96±0.14 3.51±0.16 	2.89±0.15'  2.41±0.11 2.05±0.16 
carbonyl (+44.3%)3 	(-17.74%)'' (-31.2%)b (-41.7%)b 
(nmoles/mg 
protein) 
MDA 3.31±0.34 7.01 ± 0.34 6.02±0.28' 4.87±0.32' 3.73±0.32'  
(nmoles/ml) (+52.8%) (-14.2%)f' (-30.5%)h (-46.8%)h  
FRAP (pM) 1270.1 ± 719.5 = 78.8" 808.2 ± 927.0 ± 1146.2 ± 
92.9 (-43.3%)° 47.9 68.3' 59.5' 
(+1 1%)b (+22.4%f (+37.2%)b 
GSH (pM) 25.7± 1.26 13.7 ± I.09 19.1 ± 1.48' 22.0±0.89' 	23.2 ± 1.09 
(-46.7%)a (+28.3%)b  (+37.7%)b 	(+40.9)b 
Results were expressed as Mean ± SD (n=40) of three independent assays. 
p<0.001 as compared with DM. 
"p<0.001 as compared with control. 
a = % Change from control. 
b = % Change from diabetic serum samples. 
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Diabetic patient (D1) without glucose 
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Fig.107: (a) SDS-PAGE of diabetic patient's serum (Dl, 10 pg protein) incubated with 
TQ. TI. or EtJ in 20 mM phosphate butler. pl-i 7.4 at 37`C for 21 days: (b) Densitometric 
analysis of the same ael. 
Lane 1: Molecular weight Marker in kD 
Lane 2: Serum of I-Icalthv subjects (10 pg protein) 
Lane 3: DI (10 pg protein) 
Lane 4: Dl + 'IQ (30 p M ) 
Lane 5: Dl + TL (3O pM) 
Lane 6: DI +FU(0.6µ') 
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Diabetic patient (1)1) with glucose 
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Fig.108: (a) SDS-I'A(iL ot'diahctic patients serum (1)1, It) pg protein) incubated with 
2l► mM glucose in presence of'I Q. TI. or EU in 20 mM phosphate buffer, pil 7.4 at 37'C 
for 21 days: (h) I)ensitometric analysis of the same gel. 
Lane I: 	Molecular %Height Marker in kD 
Lane 2: 	Serum of I Icalthy subjects (10 µg protein) 
Lane 3: 	Dl (10 pg protein) 
Lane 4: 	DI + Glucose (20 mM) 
Lane 5: 	DI t Glucose + IQ (30 µM) 
Lane 6: 	DI + Glucose + TI. (30 µM) 
Lane 7: 	DI + Glucose + EU (0.6 µM) 
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Diabetic patient (1)2) without glucose 
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Fig.109: SDS-I'AGL of diabetic patient's serum (D2, 10 µg protein) incubated with 1Q. 
I1. or l;U in 20 mM phosphate huller. p11 7.4 at 37`C for 21 days. Remaining captions 
.ire same as in tig107. 
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Fig.110: SI)S-PAGI: of diabetic patients serum (1)2, 10 pg protein) incubated with 20 
mM glucose in presence of IQ. "I I. or I:U in 20 mM phosphate buffer, p11 7.4 at 37`C for 
21 days. Remaining captions are same as in fig 108. 
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Diabetic patient (1)3) without glucose 
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Fig.1 11: SI)S-PA(E, of diabetic patient's serum (1)3. 10 pg protein) incubated with'I'Q. 
-11. or [V in 20 mM phosphate bulli r. pH 7.4 at 37'C liar 21 days. Remaining captions 
are same as in ticI( 
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Fig 112: SUS-PAGF, ot'diabetic patient's serum (1)3, 10 µg protein) incubated with 20 
mM glucose in presence of l'(1. Ft. or l.O in 20 mM phosphate huller. p11 7.4 at 37°C for 
_1 days. Remaining captions are same as in Iig108. 
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Diabetic patient (D4) without glucose 
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Fig.1 13: SDS-PAGI; of diabetic patient's serum (D4. 10 µg protein) incubated with 'I'Q. 
II. or ElJ in 20 mM phosphate huffer, pl 1 7.4 at 37°C for 21 days. Remaining captions 
are same as in rig. i 07. 
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Fig.114: SDS-PAGF of diabetic patient's serum (1)I. 10 gg protein) incubated with 20 
mM glucose in presence of TQ. Tl. or EI.J in 20 mM phosphate buffer, pl1 7.4 at 37°C for 
21 days. Remaining captions are same as in fig. 108. 
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Diabetic patient (1)5) without glucose 
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Fig.115: SDS-PAGI of diabetic patient's serum (U5, 10 µg protein) incubated with 1'Q. 
IL or [Ii in 20 mM phosphate buffer. p11 7.4 at 37'C. fir 21 days. Remaining captions 
..re same as in tiro. 107. 
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Figl 16: SDS-PAGE of diabetic patient's serum (1)5, 10 ig protein) incubated with 20 
mM glucose in presence of I Q. 'El. or EU in 20 mM phosphate buffer. pl1 7.4 at 37°C for 
2I days. Remaining captions are same as in fig. 108. 
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Diabetic patient (D6) without glucose 
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F ig.I 17: SDS-PAGE of diabetic patient's serum (D6, 10 µg protein) incubated with 'I'Q. 
L or I:U in 20 mM phosphate buffer. pl1 7.4 at 37°C f or 21 days. Remaining captions 
are same as in fie. 107. 
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Fig. 118: SDS-PAGF, of diabetic puUcnt"s serum ({)b. 10 pg protein) incubated with 20 
m%1 uIucosr in presence oITQ. TI. or I?tl in 21) mM phosphate buffer, pl1 7.4 at 37"C for 
21 days. Remaining captions are same as in fig. IO8. 
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Diabetic patient (1)7) without glucose 
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Fig.119: SI)S-IAGF. ot'diahetic patient's serum (1)7. 10 pg protein) incubated %%ith TQ. 
IT or l:I. 1 in 20 mM phosphate huticr. p11 7.4 at 37°C for 21 days. Remaining captions 
are same as in fig. 107. 
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Fig. 120: S1)S-PAGE of'diabetic patient's serum (1)7, 10 pg protein) incubated with 20 
mM glucose in presence of I Q. II. or VAJ in 20 mM phosphate huf er. p11 7.4 at 37`C for 
21 daNs. Remaining captions are same as in fig. 108. 
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Diabetic patient (1)8) without glucose 
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Fig.121: Sf)S-PAGF: of diabetic patient's serum (1)8. 10 pg protein) incubated with TQ, 
11. or [iU in 20 mM phosphate buffer. p11 7.4 at 37"C for 21 days. Remaining captions 
are same as in fig. 107. 
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Fig.122: SUS-PAGE of diabetic patient's serum (D8. 10 pg protein) incubated with 20 
mM glucose in presence ot'TQ. "II. or IT in 20 mM phosphate buffer. pl1 7.4 at 37`(' fi)r 
=i days. Remaining captions are same as in fig. 108. 
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Diabetic patient (D9) without glucose 
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Fit;.123: SDS-PAGE of diabetic patients serum (1)9, 10 jig protein) incubated with 'I'Q, 
I'I. or II. in 20 mM phosphate hut'ter, p11 7.4 at 37°C for 21 days. Remaining captions 
are same as in sic. 107. 
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Fig. 124: SI)S-PA(i[. ofdiahetic patient's serum (1)9, 10 ig protein) incubated with 20 
mkt glucose in presence ofTQ, II. or Et I in 20 mM. phosphate buffer. p11 7.4 at 37°C for 
2 I days. R.maining captions are sane as in fig. 108. 
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Diabetic patient (DIO)'.ithout gIucise 
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Fig.125: SDS-PA(il: of diabetic patient's serum (1)10, 10.tg protein) incubated with 
Q. I I. or I•:(! in 20 mM phosphate hotter. ph 17.4 at 37"C' I'or 21 days. Remaining 
captions are same as in tig. 107. 
Diabetic patient (D10) with glucose 
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Fig. 126: SI)S-I'A(II, of diabetic patient's serum (1)10. 10 µg protein) incubated N%ith 20 
mM glucose in presence of l C). II. or I-:ti in 2(1 mM phosphate buffer, pl 1 7.4 at 37`(' for 
21 days. Remaining captions are same as in fig. 108. 
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Discussion 
In general phenolics share the same chemical structure and composed of an aromatic 
h\droxy.l nucleus (Karaman et ul., 2010). Majority of plant based phenolic compounds 
attracted a great deal of scientific interest because of their health promoting effects 
(Hollman and Katan. 1999). Plant phenolics generally act as primary antioxidants or free 
radical terminators. Interestingly, plant polyphenols are multifunctional in the sense that 
they can act as reducing agents, hydrogen atom donors and singlet oxygen scavengers. 
Certain polyphenols are effective as antioxidants chelating transition metal ions, which 
may otherwise induce Fenton-type oxidation reactions in their free states (Rice-Evans et 
al., 1996). 
Thymoquinone (TQ) (2-isopropyl-5-methyl-1,4-benzoquinone), is the main bioactive 
component of the volatile oil of N. saliva (Fig. 11). TQ is pharmacologically active 
benzoquinone and possesses antioxidant properties (Al-Shabanah et al., 1998). It has also 
been used as anti-inflammatory and antineoplastic medicines for more than 2000 years 
(Trang et al., 1993: Hosseinzadeh and Parvardeh, 2004). Thl'mol (TL) (2-isopropyl-5-
methylphenol) is a natural monoterpene phenol derivative of cymene, isomeric with 
carvacrol, found in oil of thyme. TL can be used for the treatment of oral infectious 
diseases because of their inhibitory activity on oral bacteria (Didry et al., 1994; Kohlert et 
al., 2002). Eugenol (EU) (4-allyl-2-methoxyphenol) is a methoxyphenol compound 
having a short hydrocarbon chain in its structure (Gulcin, 2011). EU has been used as 
spice because of its strong odor and as a dental antiseptic because of its detergent-like 
effect (Tai et al., 2002). It is also used for local anesthesia (Brodin and Roed, 1984) and 
as antistress (Sen et al., 1992). 
The present stud • focuses on antioxidant potential of TQ. TL and EU. Besides there have 
also been analyzed for their activities such as inhibition of AAPH induced RBC 
hemolysis; ferric ion-reducing power (Fe -Fe-  transformation); ferric reducing 
antioxidant potential (FRAP); 1,1-diphenyl-2-picrylhydrazyl (DPPH) scavenging and 
metal chelating activities. These multiple methods are recommended to measure 
antioxidant properties of pharmacologic material that better reflect their potential 
protective effect. 
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The main mechanism responsible for antioxidants activity was considered to be the 
scavenging of free radicals, although other mechanisms may also be involved (Nenadis, 
2003). DPPH is a free radical and has been widely used to test the free radical scavenging 
activity of various antioxidants (Shimoji et al., 2002). Because of the odd electron of 
DPPH, it gives a strong absorption maximum at 517 nm by visible spectroscopy (purple 
color). As the odd electron of the radicals becomes paired off in the presence of a 
hydrogen donor, that is, a free radical scavenging antioxidant the absorption strength 
decreases, and the resulting decolorization is stiochiometric with respect to the number of 
electrons captured (Blois, 1958). Our results showed that all phytochemicals presented a 
strong concentration dependent anti-free radical activity (Fig. 16). The scavenging ability 
against DPPH radical was high even at low concentrations, especially for EU. However, 
none of the phytochemicals were as effective DPPH scavengers as the positive control 
gallic acid (EC50 = 2.87 ± 0.40 µg/ml). These results evidenced that antiradical activities 
are in the order of TQ<TL<EU indicating that TQ, TL and EU neutralize the DPPH' 
radical either by donation of electron or phenolic hydrogen to form a stable DPPH-H and 
a phenoxvl radical molecule (Gulcin, 2011). Radical scavenging capacity of each 
phytochemical might be correlated to their differential structure that favor phenolic 
hydrogen donation and the stability of the resulting phenoxyl radicals. In addition 
extension of the conjugation to the carbon chain is a molecular feature of EU which could 
participate by resonating structures leading to the stabilization of the phenoxyl radical 
(Nenadis. 2003). Conjugation seemed to enhance the antioxidant and radical scavenging 
activity of EU. It was reported that EU reduces 2 or more DPPH radicals despite the 
availability of only 1 hydrogen atom from a hydroxyl group, and different hypothesis 
have been proposed to explain the antiradical efficiencies of different monophenolic 
compounds (Mastelic etal.. 2008). Considering the absence of phenolic group in the TQ, 
its higher EC:0 value was expected. Several other reports also showed effective 
scavenging activity of EU and TQ (Ito et al., 2005; Khalife and Lupidi, 2007). In many 
studies scavenging effect of plant extracts having thymol as main component was shown 
(Nikolova, 2012). 
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Reducing power reflects the electron donating capacity of bioactive compounds and is 
associated with their antioxidant activity. In our study, the reducing power of three 
phytochemicals can be ranked in the order of TQ<TL<EU (Fig. 17). Interestingly. 
reducing power of ELI exceeds that of ascorbic acid (AA) which was used as standard 
antioxidant. Ito et al., (2005) also showed strong reducing power of EU. The reducing 
power might be due to electron/ hydrogen donating ability of bioactive compounds and 
may serve as a significant indicator of its potential antioxidant activity (Shimada, 1992). 
FRAP assay provided the absolute antioxidant values of phytochemicals. The antioxidant 
properties of phytochemicals were ranked as TQ<TL<EU. This may be explained on the 
basis of their ferric ion reducing ability and electron donor properties for neutralizing free 
radicals by forming stable products. In our study, the trend of reducing abilities for three 
phytochemicals was similar to the result of scavenging effect on DPPH radical. EU 
exhibited the best effect in all test methods as EU with lowest EC,,,, exhibited high FRAP 
value (Fig. 18). During current study. TQ. TL and EU have been reported to have 
significant potential to chelate metal ions which was elucidated by its property to 
scavenge DPPH. Metal chelation activity of EU is higher than TQ and TL but marginally 
lower than AA (Fig. 19). 
Antioxidant capacity is defined as the ability of a compound to inhibit oxidative 
degradation such as lipid peroxidation (Roginsky, 2005). Lipid peroxidation can be 
defined as oxidative deterioration of lipids containing several carbon-carbon double 
bonds. Excessive oxidative damage to cellular membranes contributes to the initiation 
and progression of numerous degenerative diseases, including certain types of cancer and 
diabetes (Pryor, 2000; Young and Woodside, 2001). Red blood cells are vulnerable to 
lipid peroxidation due to their high content of polyunsaturated lipids, their rich oxygen 
supply, and the presence of transition metals. Lipid oxidation of human red blood cell 
membrane mediated by AAPH induces membrane damage and subsequent hemolysis 
(Miki et al., 1987; Zhu et al., 2004). The free radical chain reaction is widely accepted as 
a common mechanism of lipid peroxidation. Radical scavengers may directly relate with 
and quench peroxide radicals to terminate the peroxidation chain reactions (Snares et al., 
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1997). Antioxidant intercepts the free radical chain of oxidation and donate hydrogen 
from the phenolic hydroxyl group, thereby forming a stable end product that does not 
initiate or propagate further oxidation of lipid (Soares et al., 1997). Thus, in vitro 
oxidative hemolysis of human erythrocytes was used here as a model to study the free 
radical-induced damage of biological membranes and the protective effect of TQ, TL and 
EU in the process. In the present study, all phytochemicals inhibited AAPH (an azo 
peroxyl radical initiator) mediated human RBC hemolysis in a concentration-(Fig. 20) 
and time-(Fig. 21) dependent manner. When AAPH was added to the suspension of 
erythrocytes, hemolysis induction was time-dependent until 3 hour. The hemolysis is 
lagged, indicating that endogenous antioxidants in the erythrocytes, namely glutathione, 
tocopherol, ascorbate and enzymes such as catalase and superoxide dismutase, can 
efficiently quench radicals to protect them against free radical induced hemolysis, as 
described previously (Zou el al., 2001). When production of peroxyl radicals overcomes 
the numerous antioxidant barriers of defense. an "oxidative stress" condition will 
develop. inducing oxidative damage on erythrocyte constituents, namely on membrane 
and haemoglobin, which may lead ultimately to hemolysis (Cimen, 2008). TQ, TL, EU 
and AA showed significant inhibition upto 86.22%, 86.69%, 89.18 and 90.72% at the 
concentrations of 100, 87.5, 21.875 and 50 µg/ml respectively. At a concentration of 25 
pg/ml (after 3 hours), TQ inhibited RBC hemolvsis by 6.78% which is 82%, 38% and 
80% less than L-ascorbic acid, TL and EU respectively at a similar concentration. Since, 
it is known that polyphenolics enhance red blood cell resistance to oxidative stress both 
in vitro and in vivo (Youdim et al., 2000). So, TL and EU having phenolic group in 
addition to nucleophilic benzene ring in all three phytochemicals may quench the chain 
propagating peroxyl radicals in the aquous phase to stop the peroxidation, hence 
inhibiting hemolysis more profoundly. This result is in accordance with the DPPH assay 
since EC50 of TQ was found to be much higher than that of TL and EU. 
Among three phytochemicals, EU had the most powerful antioxidant and radical 
scavenging activity followed by TL and TQ which is related to their structure. Free 
radicals are the chemical species having at least one unpaired electron in the outermost 
shell and need electrons to complete their valence shell. Hence free radicals are 
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electrophile entities and show attraction towards nucleophilic molecules. So the 
compounds having maximum electron density shows the maximum antioxidant activity. 
Benzene ring is sufficiently nucleophilic in nature and attracts electrophilic groups. 
Furthermore. by analyzing the chemical structure of TQ, TL and EU we can note that all 
three are aromatic phytochemicals having nucicophilic benzene ring. Therefore, all three 
ph~tochemicals attract and scavenge free radicals. TQ has weak electron donating groups 
contributing to less electron density to the benzene ring. However, electron density is 
found to be higher in IL and EU as compared TQ because of presence of hydroxyl group 
attached to benzene ring. Oxygen of hydroxyl group donates its lone pair of electrons to 
benzene ring, thus increasing the electron density. Among EU and TL, EU has two 
electron donating groups viz. methoxy group (—OCH3) and allyl group (—CHI 
Cl-1=CH2) at ortho- and para- position (more reactive sites as compared to meta- position) 
respectively while TL has weak electron donating groups (methyl and isopropyl) at ortho-
and meta- position respectively (Fig. 12 and 13). Electron donating groups present at 
ortho- and pars- are more reactive as compare to the meta- position. Hence it can be 
concluded that EU having maximum electron density showed best antioxidant activity 
among the three phytochemicals. Our results also indicate that TQ, TL and EU 
suppressed radical induced oxidative hemolysis of erythrocytes in vitro. To the best of 
our knowledge, this is the first report concerning the antihemolytic activity of these 
phytochemicals. The work herein indicates a high potential of application for these 
phytochemicals in food and drug products. with remarkable benefits for human health. 
Non-enzymatic glycation and oxidation of some important biomacromolecules are crucial 
in the pathogenesis of several diseases such as diabetes (Jakus, 2003; Schmitt cl al., 
2005). For example, hyperglycemia plays an important role in the pathogenesis of 
diabetic complications by inducing protein glycation with the gradual build up of AGEs 
in body tissues (Cohen et al., 2005). Protein glycation and the formation of AGEs are 
accompanied by increased free radical activity that further contributes toward the 
biomolecular damage (Ahmed et al., 2005). The elevated levels of glycoxidation products 
in plasma and tissue proteins are generally accompanied with oxidative stress in diabetes 
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(Ahmed et al., 2005). AGE formation is an inevitable process in vivo and can be 
accelerated under oxidative stress. 
Being the most abundant protein in blood constituting about 4(1 mg/ml plasma, we use 
human serum albumin as model protein (Shaklai er al., 1984). to normal individuals 
nearly 10% of the HSA is modified by glycation, while there is 2-3 fold greater 
modifications under hyperglycemic conditions such as diabetes (Guthrow et al.. 1979). 
The glycated albumin is therefore considered a useful marker for short term monitoring 
(2-7 weeks) of diabetic patients. In fact, level of the glycated albumin reflects the degree 
of hyperglycemia in diabetes (Nakajou et al., 2003). The conformational perturbation 
generated on incubation of HSA with glucose was determined by highly sensitive 
physico-chemical techniques such as spectral analysis, circular dichroism 
spectropolarimetry. FTIR, formation of ketoamine, carbonyl group, free amino group and 
polvacrvlamide gel electrophoresis. 
It is well recognized that reaction of protein with glucose results in marked alterations of 
its conformation (Ahmed et al.. 2005). The UV-absorption spectra of glycated HSA 
incubated for 7-14 days showed substantial hyperchromicity (Fig. 22). This may be due 
to unfolding of protein aggregates that are formed in the early phase of glycation process. 
The exposure of buried chromophoric groups to the polar environment leads to 
subsequent increase in the UV intensity. The glycatcd HSA incubated for 21 and 28 days 
demonstrated hypochrornicity (Fig. 22). Glycation may have caused masking of aromatic 
amino acids due to aggregation of the protein leading to subsequent decrease in UV 
intensity (Traverso etal.. 1997). There was no apparent shift in ?.max in all the incubation 
conditions. 
The intrinsic fluorophore tryptophan is an excellent parameter to monitor the tryptophan 
environment in the protein and is highly sensitive to the polarity of surrounding 
environment (Ge et al., 2011). The time-dependent plot of the tryptophan fluorescence 
intensity represents changes in protein structure in presence of glucose as revealed by 
Fig. 23. Glycated HSA incubated for 7 and 14 days depicted an increase in the 
fluorescence intensity as compared to native I ISA. This might he due to unfolding of the 
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aggregates leading to exposure of' chromophoric groups to the polar environment. 
Glycated HSA incubated for 21 and 28 days showed a decrease in the fluorescence 
intensity as compared to the native LISA indicating modification of tryptophan micro-
en~ ironmental andlor masking of these groups due to the formation of aggregates (Davies 
er al., 1987; Shaklai el al., 1984). A decrease in intrinsic protein fluorescence caused by 
tryptophan has been previously reported by Cussons er al., (1997) for glucose-modified 
HSA. Glycated HSA also showed a blue shift of 5 nm indicating that hydrophobic groups 
might be slightly more buried as compared to native HSA. 
Several investigators have shown that reaction of sugars and aldehyde with proteins leads 
to the formation of groups like pentosidine which are considered characteristic biomarker 
of glycation and accompanying autoxidation. These adduct show strong emission 
between 400-500 nm when excited at a wavelength of 370 nm (Schmidt ei al., 2001; 
"fraverso et al.. 1997). With increase in time of incubation with glucose, there was 
consistent increase in the peak value of emission in range 400-500 nrn when compared to 
control indicates the formation of glycation adducts and AGEs. As evident from the Fig. 
24, AGEs formation was maximum between 14 days and 21 days but stopped off 
subsequently. 
For further analysis of tertiary and secondary structural changes in native and glycated 
HSA, circular dichroism spectropolarimetry was carried out. It is useful for rapid 
assessment of secondary structures of proteins. In the spectral region of 200-250 nm, the 
CD signals of proteins are obtained mainly due to the amide chromophores of the 
proteins' peptide bonds (Hennessey ei al.. 1981, Manavalan et al., 1987). CD spectra also 
showed alterations in the helical behavior of HSA. Proteins rich in u-helix give negative 
bands near 208 and 222 nm whereas, proteins containing pure 3-sheets display negative 
bands near 216 nm. The incubation of USA with glucose appears to promote 
conformational change leading to instability in the secondary structure and decrease in 
percent helicity also. Incubation of HSA with glucose leads to a decline in the negative 
CD signal which started decreasing slightly with time in HSA samples incubated with 
glucose showed a gradual disappearance of the minima at 208 and 222 nm. After 28 days 
153 
Discussion 
there was disappearance of negative CD signal at 208 and 222 rim and appearance of 
minima at 217 nm Occur which indicate the 3-sheet structure (Fig. 25). The spectrum 
indicates u-helix to a-sheet transformation between 21 and 28 days. The a-helical content 
was determined for protein secondary structure analysis. and in the case of native HSA 
we found 64% a-helix which is in close agreement with the available literature value 
(Gull et al.. 2007: Liu et al., 2005). However, upon glycation with glucose, the a-helical 
content of the protein decreased from 64% to 61% after 7 days. Further incubation of 
USA with glucose up to 28 days showed marked decrease in a-helical content to 48% 
(Table 4). This signifies perturbation in the secondary structure of HSA upon glycation 
by glucose. 
Far-UV CD results were further supported by FT-IR spectroscopy, a powerful method for 
investigating the secondary structure of proteins. It helped us locate the position of 
characteristic bands in native and glycated HSA. The infra-red spectrum of protein 
exhibits a number of amide bands which represent different vibrations of peptide moieties 
(Rahmelow and Hubner, 1996). The frequencies of bands due to the amide 1, II and III 
vibrations are sensitive to the secondary structure of proteins. Amide I band is more 
sensitive to the change of protein secondary structure than amide II. The amide I peak 
position occurs in the 1600-1700 cm's  region mainly associated with the C=0 stretching 
vibration of the peptide linkage and corresponds mainly to a-helix. Amide 11 band 
position occurs from 1480-1575 cm" (C—N stretch coupled with N—H bending mode) 
(Liu et al., 2003; Zheng el al., 2010). Peaks observed in native HSA confirms the purity 
of HSA as per established standard (Ii et al., 2010) (Fig. 26a). The shifting of amide I 
and 11 bands indicate changes in intra-molecular bonding which arise from the impact on 
overall protein confirmation due to glycation. Peak observed at 1158.83 cut ` in glycated 
HSA is suggestive of opening of the epoxy ring of HSA on interaction with glucose (Fig. 
26b) (Li et al., 2010; Shibata, 2011). 
The reaction with NBT is a standard method for the detection of formed ketoamines 
which allowed characterizing the binding of glucose to the primary amino groups on the 
HSA molecules (Ahmed et al., 2002). Ketuamines are early non-enzymatic glycation 
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adducts and are important precursors of AGEs and hydroxyl radicals. It was found that 
ketoamine generation in glycated I ISA incubated for 7 days was significantly higher than 
its native form (Fig. 27). It is well recognized that carbonyl groups are introduced in 
protein as a consequence of glycation. The generation of carbonyl groups serves as a 
marker of protein glycoxidation (Baynes and Thorpe, 1999; Beat, 2002). Ketoamines 
were converted to protein bound carbonyl compounds via a protein enediol reaction 
(Baynes, 1991). Incubation of HSA with glucose resulted in a time-dependent 
introduction of carbonyl groups in the molecule up to 21 days (Fig. 28). There was no 
marked increase in carbonyl groups for further incubation up to 28 days. Number of free 
amino groups of proteins irreversibly modified due to non-enzymatic glycation (Traverso 
etal., 1997). As the time increases there was a decrease in free amino group of glycated 
HSA as shown by percent decrease in free amino groups as compared to native HSA 
(Fig. 29). 
Another parameter used for the study of protein glycation was the formation of protein 
cross-links. Electrophoretic migration allows the evaluation of such modifications in a 
protein (Chesne et al., 2006). '1 he SUS-PAGE of glycated HSA showed a decrease in the 
band intensity (as indicated by gel densitometric analysis) as well as broadening of the 
hand towards high and low molecular weights (Fig. 30a), which can he attributed to 
extensive inter- and intramolecular cross-linking due to glycation, resulting in the 
formation of aggregates (Bouma er al.. 2003; Rosca et al., 2005). Interestingly, samples 
incubated with glucose migrated as highly diffused bands with the increase in incubation 
time up to 28 da>s and showed the presence of aggregates and fragmentation. The 
changes were more obvious at 21 and 28 days of incubation. This could also he seen in 
the densitometric analysis of gels showing a decrease in density due to protein 
fragmentation (Fig. 30b). 
On the basis of above observations we can infer that incubation with glucose for up to 28 
days resulted in a time-dependent modification of HSA. The changes were more 
prominent in HSA incubated with glucose for 21 days. Thus, prolonged exposure of HSA 
to glucose exerts greater deleterious effects on its structure and formation of aggregates. 
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Preliminary data in the present study indicates formation of glycated HSA involving 
covalent linkage of free amino groups to glucose. It '.as shown earlier that while amino 
groups are primary targets. the extent of glycation does not directly depend on the 
number of glycation-prone residues but on the solvent accessible surface area of such 
residue (GhoshMoulick el al., 2007). 
The accumulation of various protein glycation products in living organisms lead to 
functional modifications of tissue protein. Many studies have shown a significant role for 
glycation in the pathogenesis of diabetic complications (Brownlee, 1995; Basta el al., 
2004). Thus the discovery and design of glycation inhibitors offer a promising 
therapeutic approach for its prevention (Rahbar and Figarola, 2003). Although, the 
synthetic glycation inhibitor aminoguanidine, attenuates the development of a range of 
diabetic complications, some toxicity problems have been encountered in clinical trials 
with this drug ( fhornaliey, 2003). For last decade, attention has been focused on 
preventing protein glycation by antioxidants from plant sources (Rudnicki el al., 2007). 
Glycation and AGE-induced toxicity are also known to be associated with increased free 
radical production. Recent studies have demonstrated the benefits of using compounds 
with combined antioxidant and antiglycation properties (Nakagawa ei al., 2002; Ahmad 
and Ahmed, 2006). Such compounds not only prevent AGE formation but also reduce 
free radical-mediated toxicity. 
There are several reports that various plant products show remarkable AGE inhibitory 
activity. These include resveratrol, a natural stilbenoid phenol present in grapes, 
curcumin found in turmeric. S-allyl cysteine a constituent of garlic. rutin found in 
tomatoes and many polyphenolic compounds in Lea mays. Green tea contains tannins 
having significant antiglycation properties (Mizutani et al., 2000; Nakagay.a el al., 2002). 
It is well known that phenolic compounds are constituents of many plants (Rice-Evans, 
1997). Some antioxidants also act as inhibitors of glycation (Urios et al.. 2007). The 
antioxidant properties of the phenolic compounds can be attributed to their potential as 
hydrogen- or electron-donating agents and metal ion chelating properties mediated 
considerably free radical scavenging properties (Rice-Evans et at 1996). 
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Most of the givcation inhibitory phytochemical constituents of plants have been reported 
to possess polyphenolic nature (Rudnickira et al.. 2007). The present study explores and 
compares the effect of co-incubation of TQ. TL and EU on glucose mediated glycation of 
model protein HSA up to 28 days. Besides, structural changes interaction of HSA %tiith 
glucose cause marked alterations in its conformation (Ahmed, 2005). The resulting 
covalent cross-linking may induce stress in the molecule, triggering the overall 
conformational changes as revealed by hyperchromicity and gain of intrinsic fluorescence 
up to 14 days (Table 5, 6) (Khan et al.. 2011). This may he explained by protein 
unfolding in the initial phase of glycation reaction that led to exposure of buried groups 
to the external milieu (Traverso et al., 1997). After 14 days of incubation there was 
hypochromicity and loss of intrinsic fluorescence that may be due to protein folding and 
aggregation that cause exposure of aromatic amino groups. Interestingly, incubation of 
HSA with glucose in presence of varying concentrations of TQ, 'IL and EU was found to 
alleviate conformational changes in the protein (Fig. 31-64). The protective property of 
these phytochemicals could be explained on the premise that these phytochetnicals may 
act as quenchers of glucose/carbonyl compounds thereby inhibiting their interaction with 
protein leading to prevention of glycation-induced conformational changes in HSA. 
AGEs cause various types of protein modifications resulting in structural and functional 
impairments such as intra- and inter cross-linking, absorption and fluorescence at specific 
wavelength (Bucala and Cerami. 1992; Fu et al.. 1994). It has been proposed that 
oxidation plays a crucial role in the formation of fluorescence and the molecular bridge 
which are characteristic feature of AGEs (Fu et al., 1994). The AGES complications are a 
direct result of protein alteration which results in irreversible tissue damage. Thus, 
inhibition of the formation of AGE is believed to play a role in the prevention of diabetes 
related complications. Therefore, the identification of antiglycation compounds is 
considerably an attracting interest. The known AGEs inhibitors act either as quenchers of 
dicarbonyl intermediates, as metal ion chelators or as antioxidants (Verbeke et al., 2000; 
Rahbar and Figarola, 2003). Some herbal extracts and natural products have proven to be 
somewhat effective for inhibiting AGE formations (Kim and Kim. 2003). Based on the 
fluorescence properties, we studied the influence of TQ. TL and FU on the formation of 
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AGEs and employed AG, a well-known AGE inhibitor. Our results demonstrated that all 
three phytochemicals efficiently inhibited AGEs formation as observed by a reduction in 
the AGE-associated fluorescence (Table 7). Moreover, a strong inhibitory activity against 
the formation of AGEs was shown by EU followed by TL and TQ (Fig. 65-77). This 
could be explained by structure-activity relationship. Glucose reacts with amino groups 
of proteins forming ketoamines which ultimately leads to AGEs formation. Further, 
oxidation processes are also important in the formation of many AGEs (Fu etal., 1994). 
There are two mechanisms through which oxidative processes take palce. The first 
involves autoxidation of glucose, leading to formation of ketoaldehydes, more reactive 
dicarbonyl compounds, which react with proteins to form highly reactive ketoamine, 
finally leading to AGEs formation. The second mechanism involves oxidative breakdown 
of amadori products to form highly reactive protein-enediols and protein dicarbonyls 
which can generate AGEs. Therefore, both the Amadori formation and glucose 
autoxidation may contribute to the development of diabetic complications via free 
radical-induced protein oxidation and promotion of AGEs formation (Takagi et al., 
1995). Recent studies have indicated that some radical species, including H202. 0['~ and 
singlet oxygen participate in AGEs formation (Chace et al., 1991; Yim et al., 1995), and 
that antioxidant and radical scavengers inhibit these processes (Oya et al., 1997). Since 
the formation of AGEs is facilitated under oxidative reactions, all the three 
phytochemicals used in the study inhibit their formation by decreasing the ROS 
formation or by trapping the ROS formed in vitro by autoxidation of glucose and/or 
oxidative degradation of Amadori products. This hypothesis is reinforced by the results 
of our antioxidant parameters which have shown that TQ. TL and EU have potent 
antioxidant and radical scavenging effect (TQ<TL<EU) which has been shown by 
reducing power. FRAP assay and DPPH scavenging assay, inhibition of generation of 
02 along with metal chelating properties. Moreover, the above hypothesis is also 
strengthened and well supported by the observation that these phytochemicals also 
suppress oxidative protein damage in terms of protein carbonyl formation which is 
believed to cause decrease in the glycoxidation processes. Further, the FTIR studies 
showed that phytochemical treatment causes shift in the peaks of amide I and II bands. 
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Interestingly, some new peaks were also observed (Fig. 78) confirming the formation of 
nee% bonds. This suggests the interaction of all three phytochemicals with either HSA or 
glucose thereby limiting their interaction. 
Ketoamines are early non-enzymatic glycation adducts. It was shown earlier that while 
amino groups are primary targets. however, the extent of glycation does not directly 
depend on the number of glycation prone residues but on the solvent accessible surface 
area of such residues (GhoshMoulick et al., 2007). The treatment of glycated HSA at 7 
days of incubation with TQ, TL or EU showed slightly lower levels of ketoamine (Fig. 
79, Table 8) as compared to untreated glycated HSA. Although the exact mechanism of 
inhibition of ketoamine formation is at present unknown, this could be explained by the 
possibilities of mechanisms such as quenching of glucose/carbonyl compounds, thereby 
limiting the reactivity towards the amino groups of protein or phytochemicals may also 
bind with HSA. Binding to glucose or protein would inhibit ketoamine production and 
subsequent AGE tormation. 
It is well recognized that glycation reactions contribute to protein damage. Further. 
autoxidation of glucose as well as oxidative degradation of Amadori product enhance the 
chemical modifications of proteins by ROS (Wolff and Dean, 1987; Bucala, 1992). In 
fact, carbonyl groups are introduced in the proteins as a consequence of glycation (Beal, 
2002). In addition, oxidation of protein is also accompanied by the formation of carbonyl 
protein. Thus protein carbonyl content is considered to be a reliable measure of 
glycoxidation (Telci et al., 2000). Regarding the presence of free radicals and oxidative 
steps in the glycoxidation process compounds with antioxidant activities have been tested 
in order to reduce or stop glycoxidation. In this study, we examine antioxidant viz., TQ, 
TL and EU mediated protection of HSA against glycoxidation. We found that exposure 
of HSA to glucose could enhance the protein oxidation levels in terms of protein carbonyl 
formation, while all three phytochemicals inhibits glucose-induced glycoxidative 
damages to protein as indicated by reduction in protein carbonyl formation (Fig. 80-84, 
Table 9). This clearly suggest that three phytochemicals have potential to alleviate 
oxidative stress by inhibiting oxidative processes may be effective in preventing 
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glycoxidative protein damage. Potency of the protein carbonyl inhibitory activity was in 
the order of 1 Q< T] L<EU suggesting the relationship between carbonyl inhibitory activity, 
free radical scavenging activity with the chemical structure of phytochemicals. 
At an early stage of Maillard reaction, both free as well as c-amino groups of lysine 
residues of I iSA reacts with the carbonyl groups of reducing sugars. Moreover, reactive 
carbonyl species can react with lysine and arginine residues forming specific AGEs 
(Chace et al., 1991). Some AGEs are formed on the same lysine residue that was initially 
modified by glucose, whereas others can form intra- and intermolecular covalent cross-
links with unmodified lysine or arginine residues, thus propagating initial modifications 
(Gunusen et al., 2010). The measurement of free lysine residues indicates that in the 
glycated HSA samples, there were significantly less free lysine residues than in the 
control. The presence of phytochemicals inhibits the modification of lysine residues 
indicating that in their presence glucose cannot react with the lysine residues of HSA. 
This may be due to quenching of glucose or carbonyl compounds. Moreover, an increase 
in free lysine residues in presence of these phytochemicals confirms that none of them 
chemically react with amino groups in the lysine residues of I ISA (Fig. 85-89, Table 10). 
Moreover, the phytochemicals inhibit AGEs formation thereby inhibiting intra- and 
intermolecular cross-links with unmodified lysine or arginine residues that eventually 
ensued in increase in free lysine residues. 
It is well known that ROS are produced at many steps during sequential glycation 
cascade. Schiff 's base. Amadori product and AGEs etc. generated during this process led 
to the formation of free radicals. Several reports indicate the production of radicals and 
highly reactive oxidants from glycated proteins under physiological conditions (Wolff er 
al., 1991). It has also been reported that glycated proteins generate fifty times more 
superoxide radicals in vitro than unmodified proteins and cause a two-fold increase in 
peroxidation of lipid vesicles (Mullarkey et al., 1990). Superoxide radical is generated 
when the Amadori product takes on an enaminol structure. These free radicals in turn will 
induce further oxidative protein degradation (Wolff and Dean, 1987). Recent studies have 
indicated that some radical species including H2O, superoxide anion radicals and singlet 
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oxygen participates in AGEs formation (Chace et al., 1991) while antioxidant and radical 
sca,.engers inhibit these processes (Yokozawa and Nakagawa, 2004). To evaluate 
whether TQ, TL and EL could affect superoxide radical formation during glycation, we 
employed cytochromc c reduction assay on day 7 of incubation. There was a significant 
increase in the amounts of superoxide radical in glycated HSA. Addition of TQ, TL and 
EU inhibited the increase in superoxide radical (Fig. 91). The observed effect on 
inhibition of superoxide radical generation in phytochernical treated glycated HSA could 
be explained on the basis of their antioxidative or free radical scavenging properties 
(TQ<TL<EU). EU has a methoxyphenolic structure that plays an important role in 
antioxidant functions (Fujisawa el al., 2002) while TL lacks methoxy group. TL and EU 
being the phenolic compounds exhibited considerable free radical scavenging activities, 
through their reactivity as hydrogen- or electron-donating agents and metal chelating 
properties (Rice-Evans ei al., 1996). However, TQ showed least superoxide anion radical 
scavenging activity due to the presence of less reactive and weak electron donating 
groups attached to ortho- and meta- position. 
Reactive carbonyl species formed during glycation can react with protein forming 
specific AGEs (Chace et al., 1991). These AGEs can form intra- and intermolecular 
covalent crosslinks leading to formation of high molecular aggregates (Liggins and Furth, 
1996; Ahmad et al., 2007). Moreover, glycation is also accompanied by autoxidation of 
glucose and Amadori products to produce free radicals capable of protein fragmentation 
(Wolff and Dean, 1987; Bucala and Cerami, 1992). HSA was glycated by glucose in 
presence of different concentrations of TQ. TL and EU with subsequent analysis of 
glycation-derived crosslinking and/or protein fragmentation using SDS-PAGE (Fig. 92-
102). Phytochemicals restricted glycation-induced protein crosslinking and/or protein 
fragmentation to some extent. The photographed gels were also analyzed through 
densitometry and showed the increase in density in presence of phytochemicals 
confirming the above finding (Table 11). These phytochemicals probably act by 
preventing autoxidative glycation and glycoxidative reactions. This could also be 
attributed to their ability to prevent, multiple changes associated with the accumulation of 
AGEs, i.e., reduction in carbonyl stress and prevention of oxidative stress etc. 
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In conclusion. our findings herein showed that all three phytochemicals are powerful 
antioxidant and have potent inhibitory effect on protein glycation and glycoxidation 
thereby preventing glucose mediated HSA modification in vitro. It seems these 
phytochemicals may act at multiple steps involved in glycation process and AGE 
formation. Interestingly, antiglycating activities were relevant and directly related to their 
free radical scavenging capability TQ<TL<EU. Inhibition of free radical produced from 
protein glycation and subsequent inhibition of protein modification is one of the 
mechanisms of glycation prevention (Farrar ei al., 2007). EU-2 was found to be the best 
inhibitor amongst various phytochemicals at all the time points. The high antioxidative 
efficacy of all three phytochemicals is more apparent from the fact that in comparison to 
AG that acts at magnitude of millimolar, the three phytochemicals are effective at 
micromolar concentration. 
Diabetes mellitus is a metabolic disorder which is characterized by hyperglycaemia and 
insufficiency of secretion or action of endogenous insulin. Protein glycation and 
fragmentation of AGEs are accompanied by increased free radical activity (Ahmed et al., 
2005). The elevated levels of glycoxidation products in plasma are greatly accompanied 
with oxidative stress in diabetes (Ahmed et a1., 2005). Increased free radical production 
and reduced antioxidant defense responses, encountered in the diabetic state may give 
rise to oxidative stress (Baynes and Thorpe. 1999; Ceriello et al.. 2000). MDA, measured 
as TBARS, is the most commonly used marker of lipid peroxidation (Nishigaki et al., 
1981; Altomare et al.. 1992). Carbonyl groups are generated on protein side chains 
especially of arginine, lysine, proline and threonine in the oxidation reaction. Since these 
moieties are chemically stable and formed relatively early hence are exploited for 
detection. In addition, carbonyl groups may be introduced into proteins by secondary 
reaction of the nucleophilic side chains of Cvstcine. Histidine, and Lysine residues, with 
aldehydes (4-hydroxy-2-nonenal, malondialdehyde) produced during lipid peroxidation 
(Dalle-Donne. 2003). 
Antioxidants play a vital role as preventive factors in the pathogenesis of diabetes 
(Kaneto et al.. 1999). Therefore, much attention has been focused on the use of natural 
antioxidants/phytochemicals to inhibit lipid peroxidation, or to protect the damage from 
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free radicals. The present study, provide further evidence for the strong antioxidant effect 
of TQ. TL and EU in serum from diabetic patients. 
In the present study. samples from diabetic patients had been found to possess 
significantly higher (p<0.001) serum levels of MDA than healthy subjects (Fig. 103). 
Several other reports also showed that due to oxidative stress, lipid peroxidation increases 
in diabetic patients (Nacitarhan el u!.. 1995). It might be due to increase in the levels of 
oxygen free radicals which suggest their increased production. This increased level of 
MDA could be because of increased free radical production via glycated protein 
autoxidation of glucose as well as oxidative degradation of Amadori products in diabetes 
mellitus (Wolff and Dean, 1987; Bucala and Cerami, 1992). ROS formed causes 
peroxidative breakdown of phospholipid fatty acids and accumulation of MDA (Jain el 
al.. 1989). However, on incubation with TQ. TL or Ell the MDA level decreases up to 
certain extent in diabetic patients (Table 12). This could be attributed to their ability of 
scavenging ROS. 
We estimated the protein carbonyl content as a marker of protein glycoxidation. Our 
results showed that there is significant increase in the carbonyl group content in diabetic 
patients as compared to the control groups (Fig. 104, Table 12). Increased ROS 
production in diabetes via glycated protein autoxidation of glucose and oxidative 
degradation of Amadori product enhance the chemical modification of protein (Wolff and 
Dean, 1987; Bucala and Cerami, 1992). Carbonyl groups are introduced in the proteins as 
a consequence of glycation and oxidation (Beal, 2002). Our result is in concordance with 
earlier reports. Odetti et al., (1999) showed higher carbonyl content in type 2 diabetic 
patients and that impaired glycemic control is connected to protein oxidation. On 
incubation with TQ. TL and EU the protein carbonyl content decreased up to 17.7%, 
31.2% and 41.7% in diabetic patient's serum respectively. However, protein carbonyl 
level in diabetic samples on treatment with EU reaches very close to the normal value as 
shown in Fig. 104. Thus these phytochemicals showed antioxidative property by 
scavenging ROS, thereby protecting protein from free radical damage due to increase in 
oxidative stress. 
163 
Discussion 
On the other hand, total antioxidant capacity reflected by FRAP and GSH value was 
found to be significantly reduced in type 2 diabetic patients as compared to health} 
individuals. The observed decrease in the level of FRAP and GSH in diabetic patients are 
an indicator of oxidative stress condition. It can also be considered as compensatory 
mechanism for minimizing the overwhelming stress and restoring the normal condition. 
Protein carbonyl content showed a direct relationship with MDA level in diabetic patients 
whereas FRAP assay and GSH level showed negative relation with protein carbonyl and 
MDA which was also observed in many reports (Tvacitarhan et al., 1995). Kuppusamy et 
al.. (2005) observed a significantly lower FRAP level in type 2 diabetic patients in both 
Malay and Indian ethnics. Colak et al., (2005) documented a similar decrease in type 2 
diabetic patients with cardiovascular complications. According to Kim et al., (2007) 
study, the plasma levels of reduced GSH were significantly diminished in diabetic 
patients as compared to controls. 
Treatment with TQ, TL and EU resulted in significant increment in FRAP value in type 2 
diabetic patients (Fig. 105). TQ incubation showed lowest increment in the FRAP value 
(11%) while TL showed 22.4% increase in type 2 diabetic serum samples which is in 
concordance with their antioxidant and antiglycating properties. As compared to TQ and 
TL. EU showed excellent effect. Similarly, the level of GSI-t increased in type 2 diabetic 
patients on TQ. TL and EU treatment (Fig. 106). It showed that these phytochemicals 
protect cell components from damage due to oxidative stress and lower the level of free 
radicals in the body by their high reducing power and scavenging ability. 
Glycation of proteins has been shown to result in protein degradation and/or crosslinking 
(Singh, 2001; Rosca ei al., 2005). Further, diabetic serum samples were also subjected to 
SOS-PAGE and showed the decrease in intensity and broadening of band towards high 
and low molecular weight. This could be attributed to fragmentation, extensive inter and 
intra-molecular cross-linking due to glycation, resulting in the formation of aggregates. 
Interestingly, diabetic serum samples incubated with glucose migrated as highly diffuse 
bands and showed fragmentation and the presence of aggregates. Further, decrease in 
density of bands in diabetic samples as compared to healthy subjects as showed in gel 
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densitometry (Fig. 107b, 108b), proved protein cross-linking and/or fragmentation due to 
glycation confirming the above finding. 
However, electrophoretic pattern of diabetic serum samples treated with phytochernical 
in presence and absence of glucose are shown in Fig. 107-126. Our finding herein 
showed the reduced formation of glycation adduct in presence of TQ, TL or EU. The 
results suggested the potential of these phytochemicals in reducing the glycation-induced 
protein damage in the order. viz. TQ<TL<EU by reduction in carbonyl stress and 
prevention of oxidative stress. Inhibition of free radical generation derived from protein 
glycation and subsequent inhibition of protein modification is one of the mechanisms of 
prevention of glycation (Farrar et al., 2007). These results are in accordance with earlier 
data pertaining to antioxidant and antiglycation parameters and provide further evidence 
for their strong antioxidant and antiglycation effect. 
In order to analyze the antioxidant and antiglycative effect in vivo, it is important to 
evaluate the bioavailability of these phytochemicals. Plasma concentrations of EU were 
reported to be about 5 pM in human 2 hours after the administration of 150 mg EU 
(Fischer and Dengler. 1990). And the concentration of EU that can prevent glycation of 
HSA effectively as demonstrated in this study was 0.6 tM, indicating that EU can act as 
a physiological antioxidant and antiglycating agent in vivo. Although, the exact 
mechanism by which TQ. TL and EU function in the human body is not clear, however, 
the data of present study may have important therapeutic implications in view of 
increasing evidence that oxidative stress may be the underlying cause for most of the 
diabetic complications (Baynes and Thorpe, 1999) and the protection provided by these 
phytochemicals is a convincing reason for the possibility of using these phytochemicals 
in tackling of diabetic complications, as another mode of diabetes treatment not 
dependent on the control of blood glucose level. They may also help to reduce oxidative 
stress and concomitant free radical damage in diabetic patients. However, the in vitro 
results may not reflect the effects of these agents in vivo, as their antioxidative properties 
may decrease during cooking process as well as the liver-first pass effect, which 
invariably affect the content, activity and bioavailahility of hioactive compounds. Hence, 
further investigation is needed to establish whether these phytochemicals attenuate 
glucose mediated protein modification in vivo. 
165 

Bibliography 
• Ahmad. M. S., and Ahmed, N. (2006). Antiglycation properties of aged garlic extract: 
possible role in prevention of diabetic complications. J Nutr, 136(3 Suppl), 796S-
799S. 
• Ahmad. M. S.. Pischetsrieder, M., and Ahmed, N. (2007). Aged garlic extract and S-
allyl cysteine prevent formation of advanced glycation endproducts. Eur .1 
Pharmacol. 561(1-3), 32-38. 
• Ahmed, N. (2005). Advanced glycation endproducts--role in pathology of diabetic 
complications. Diabetes Res Clin Pract, 67(1), 3-21. 
• Ahmed, N., Argirov, 0. K., Minhas, H. S., Cordeiro, C. A., and Thornalley, P. J. 
(2002). Assay of advanced glycation endproducts (AGEs): surveying AGEs by 
chromatographic 	assay 	with 	derivatization 	by 	6-aminoquinolyl-N- 
hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine-
and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J, 364(Pt 1), 1-14. 
• Ahmed. N., Babaei-Jadidi. R., Howell, S. K.. Beisswenger, P. J., and Thornalley, P. J. 
(2005). Degradation products of proteins damaged by glycation, oxidation and 
nitration in clinical type I diabetes. Diabetologia, 48(8), 1590-1603. 
• Ahmed, N., and Thornalley, P. J. (2005). Peptide mapping of human serum albumin 
modified minimally by methylglyoxal in vitro and in vivo. Ann N YAcadSci, 1043, 
260-266. 
• Al-Shabanah, 0. A., Badary, 0. A., Nagi, M. N., al-Gharably, N. M., al-Rikabi, A. 
C., and al-Bekairi, A. M. (1998). Thymoquinone protects against doxorubicin-
induced cardiotoxicity without compromising its antitumor activity. J Exp Clin 
Cancer Res, 17(2), 193-198. 
• Ali, B. H., and Blunden, G. (2003). Pharmacological and toxicological properties of 
Nizella sativa. Phvtother Res, 1 1(4), 299-305. 
• Altomare, E., Vendemiale, G., Chicco, D., Procacci, V., and Cirelli, F. (1992). 
Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabete 
Metab, 18(4). 264-271. 
166 
Bibliograplr ' 
• Amarowicz. R., Naczk, M., and Shahidi, F. (2000). Antioxidant activity of various 
fractions of non-tannin phenolics of canola hulls.. J Agric Food Chem, 48(7), 2755-
2759. 
• Andrew. P. J., and Mayer, B. (1999). Enzymatic function of nitric oxide synthases. 
Cardiovasc Res, 43(3), 521-531. 
• Anjaneyulu, M., and Chopra, K. (2004). Quercetin, an anti-oxidant bioflavonoid, 
attenuates diabetic nephropathy in rat. Clin Exp Pharmacol Physiol, 31(4), 244-248. 
• Arakawa, T., and Timasheff, S. N. (1982). Stabilization of protein structure by sugars. 
Biochemistry, 21(25), 6536-6544. 
• Ardestani, A., and Yazdanparast, R. (2007). Cyperus rotundus suppresses AGE 
formation and protein oxidation in a model of fructose-mediated protein 
glycoxidation. lnt J Biol M cromol, 41(5), 572-578. 
• Arslan, S. 0.. Gelir, E., Armutcu, F., Coskun, 0., Gurel, A., Sayan, H., et at., (2005). 
The protective effect of thymoquinone on ethanol-induced acute gastric damage in 
the rat. Nutrition Research, 25(7), 673-680. 
• Badary, 0. A. (1999). Thymoquinone attenuates ifosfamide-induced Fanconi 
syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol, 
67(2), 135-142. 
• Badary, 0. A., Nagi, M. N., al-Shabanah, 0. A., al-Sawaf, H. A., al-Sohaibani, M. 0., 
and al-Bekairi, A. M. (1997). Thymoquinone ameliorates the nephrotoxicity induced 
by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol 
Pharmacol, 75(12), 1356-1361. 
• Badenhorst, D., Maseko, M.. Tsotetsi, 0. J., Naidoo, A., Brooksbank, R., Norton, G. 
R., et al., (2003). Cross-linking influences the impact of quantitative changes in 
myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. 
Cardiovasc Res, 57(3), 632-641. 
• Back, S. M., Kwon, C. H., Kim, J. H., Woo, J. S., Jung, J. S., and Kim, Y. K. (2003). 
Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell 
death in renal proximal tubular epithelial cells. J Lab Clin Med, 142(3), 178-186. 
167 
Bibliography 
• Baser, K. H. C. (1993). Essential oils of Anatolian Labiatae: a profile. Acta 
Horticulture, 333, 217-238. 
• Baser. K. H. C. (1994). Essential oils of Labiatae from Turkey: Recent results. 
Lamiales Newslett., 3, 6-11. 
• Basta, G., Schmidt, A. M., and De Caterina, R. (2004). Advanced glycation end 
products and vascular inflammation: implications for accelerated atherosclerosis in 
diabetes. Cardiovasc Res, 63(4), 582-592. 
• Baydanoff, S., Nicoloff, G., and Alexiev, C. (1987). Age-related changes in the level 
of circulating elastin-derived peptides in serum from normal and atherosclerotic 
subjects. Atherosclerosis, 66(1-2), 163-168. 
• Baynes, J. W. (1991). Role of oxidative stress in development of complications in 
diabetes. Diabetes, 40(4), 405-412. 
• Baynes. J. W., and Thorpe, S. R. (1999). Role of oxidative stress in diabetic 
complications: a new perspective on an old paradigm. Diabetes, 48(1), 1-9. 
• Baynes. J. W., Thorpe, S. R., and Murtiashaw, M. H. (1984). Nonenzymatic 
glucosylation of lysine residues in albumin. Methods Enzymol, 106, 88-98. 
• Beal, M. F. (2002). Oxidatively modified proteins in aging and disease. Free Radic 
Biol Med, 32(9), 791-803. 
• Beauchamp, C., and Fridovich, I. (1971). Superoxide dismutase: improved assays and 
an assay applicable to acrylamide gels. Anal Biochem, 44(1), 276-287. 
• Beckman, J. S., and Koppenol, W. H. (1996). Nitric oxide, superoxide, and 
peroxynitrite: the good, the bad, and ugly. Ain JPhysiol, 271(5 Pt 1), C 1424-1437. 
• Beisswenger, P. J., Makita, Z., Curphey, T. J., Moore, L. L., Jean, S., Brinck-Johnsen, 
T., et al.,. (1995). Formation of immunochemical advanced glycosylation end 
products precedes and correlates with early manifestations of renal and retinal disease 
in diabetes. Diabetes, 44(7), 824-829. 
• Benzie, 1. F., and Strain, J. J. (1996). The ferric reducing ability of plasma (FRAP) as 
a measure of "antioxidant power": the FRAP assay. Anal Biochem, 239(1), 70-76. 
168 
Bibliography 
• Berg, T. J., Bangstad, H. J., Torjesen, P. A., Osterby, R., Bucala, R.. and Hanssen, K. 
F. (1997). Advanced glycation end products in serum predict changes in the kidney 
morphology of patients with insulin-dependent diabetes melt itus.Metaholism, 46(6). 
661-665. 
• Betteridge, D. J. (2000). What is oxidative stress? Metabolism, 49(2 Suppl 1), 3-8. 
• Bhattacharya, A. A., Curry, S., and Franks, N. P. (2000). Binding of the general 
anesthetics propofol and halothane to human serum albumin. High resolution crystal 
structures. JBiol Chem, 275(49), 38731-38738. 
• Block, K., and Gorin, Y. (2012). Aiding and abetting roles of NOX oxidases in 
cellular transformation. Nat Rev Cancer, 12(9), 627-637. 
• Blois, M. S. (1958). Antioxidant Determinations by the Use of a Stable Free Radical. 
Nature, 181. 1199 - 1200. 
• Bonnefont-Rousselot, D. (2004). The role of antioxidant micronutrients in the 
prevention of diabetic complications. Treat Endocrinol, 3(1), 41-52. 
• Bookchin, R. M., and Gallop, P. M. (1968). Structure of hemoglobin AIc: nature of 
the N-terminal beta chain blocking group. Biochem Biophys Res Commun, 32(l), 86-
93. 
• Bouma, B., Kroon-Bater,burg, L. M., Wu, Y. P., Brunjes, B., Posthuma, G., 
Kranenburg, 0., et al., (2003). Glycation induces formation of amyloid cross-beta 
structure in albumin. .J Biol Chem, 2 78(43), 41810-41819. 
• Bourdon, E.. Loreau, N., and Blache, D. (1999). Glucose and free radicals impair the 
antioxidant properties of serum albumin. FA.SEB J, 13(2), 233-244. 
• Bousova, I., Vukasovic, D., Juretic, D., Palicka, V., and Drsata, J. (2005). Enzyme 
activity and AGE formation in a model of AST glycoxidation by D-fructose in vitro. 
Acta Pharm, 55(1), 107-114. 
• Brodin. P.. and Roed, A. (1984). Effects of eugenol on rat phrenic nerve and phrenic 
nerve-diaphragm preparations. Arch Oral Biol, 29(8), 611-615. 
Bibliography 
• Brown, J. R. a. S., P. (1982). Serum Albumin- Structzn•e and Characterization of its 
Ligand Binding Sites (Vol. 1). New York: Wiley. 
• Brownlee. M. (1995). Advanced protein glycosylation in diabetes and aging. Ann:, 
Rev .%fed. 4h. 22 3-2 34. 
• Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic 
complications. Nature. 414(6865). 813-820. 
• Brownlec, M., Vlassara, H., Kooney, A., Ulrich, P., and Cerami, A. (1986). 
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. 
Science, 232(4758), 1629-1632. 
• Bucala, R. (1992). Polyclonal activation of B lymphocytes by lipopolysaccharide 
requires macrophage-derived interleukin-I.Immunolok,*t'. 77(4), 477-482. 
• Bucala, R.. and Cerami, A. (1992). Advanced glycosylation: chemistry, biology, and 
implications for diabetes and aging. At& Pharniucol. 23, 1 -34. 
• Bucala, R.. Mitchell, R., Arnold. K.. Innerarity, T., Vlassara, H., and Cerami, A. 
(1995). Identification of the major site of apolipoprotein B modification by advanced 
glycosylation end products blocking uptake by the low density lipoprotein receptor. J 
Riol Chem, 270(18). 10828-10832. 
• Bucala, R., Tracey. K. J., and Cerami, A. (1991). Advanced glycosylation products 
quench nitric oxide and mediate defective endothelium-dependent vasodilatation in 
experimental diabetes. JClin Invest. 87(2), 432-438. 
• Bulteau, A. L., Verbeke, P., Petropoulos, 1., Chaffotte, A. F., and Friguet, B. (2001). 
Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated 
glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro. J Biol 
Chem, 276(49), 45662-45668. 
• Bunn, 1-1. F., and Briehl, R. W. (1970). The interaction of 2,3-diphosphoglycerate 
with various human hemoglobins. JClin Invest, 49(6), 1088-1095. 
• Bunn, H. F., Gabbay, K. H., and Gallop, P. M. (1978). The glycosylation of 
hemoglobin: relevance to diabetes mellitus. Science. 200(4337), 21-27. 
170 
Bibliography 
• Bunn, H. F., and Higgins, P. J. (1981). Reaction of monosaccharides with proteins: 
possible evolutionary significance. Science, 213(4504), 222-224. 
• Caballero, f., Gcrcz, E., Battle, A., and Vazquez, E. (2000). Preventive aspirin 
treatment of streptozotocin induced diabetes: blockage of oxidative status and 
revertion of heme enzymes inhibition. Chem Biol Interact, 126(3), 215-225. 
• Cameron, N. E., Eaton, S. E., Cotter, M. A., and Teslaye, S. (2001). Vascular factors 
and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 
44(11), 1973-1988. 
• Ceriello, A., Morocutti, A., Mercuri, F., Quagliaro, L., Moro, M., Damante, G., and 
Viberti. G. C. (2000). Defective intracellular antioxidant enzyme production in type I 
diabetic patients with nephropathy.Diahetes, 49(12), 2170-2177. 
• Chace, K. V., Carubelli, R., Nordquist, R. E., and Rowsey, J. J. (1991). Effect of 
oxygen free radicals on corneal collagen. Free Radic Res Commun, 12-13 Pt 2. 591-
594. 
• Chace, K. V., Carubelli, R., and Nordquist, R. E. (1991). The role of nonenzymatic 
glycosvlation, transition metals, and free radicals in the formation of collagen 
aggregates. Arch Biochern Biophvs, 238(2), 473-480. 
• Charonis, A. S., Reger, L. A., Dege, J. E., Kouzi-Koliakos, K., Furcht, L. T., 
Wohlhueter. R. M., and Tsilibary, E. C. (1990). Laminin alterations after in vitro 
nonenzymatic glycosylation. Diabetes, 39(7), 807-814. 
• Chen, Y. H., Yang, J. T., and Martinez, H. M. (1972). Determination of the secondary 
structures of proteins by circular dichroism and optical rotatory dispersion. 
Biochemistry, 11(22), 4120-4131. 
• Chesne, S.. Rondeau, P., Armenta, S., and Bourdon, E. (2006). Effects of oxidative 
modifications induced by the glycation of bovine serum albumin on its structure and 
on cultured adipose cells. Biochimie, 88(10), 1467-1477. 
171 
Bibliogruphy 
• Cheivrkin, S. V., Mathis, M. E.. Ham, A. J., Hachey, D. L.. Hudson, B. G.. and 
Voziyan, P. A. (2008). Propagation of protein glycation damage involves 
modification of tryptophan residues via reactive oxygen species: inhibition by 
pyridoxamine Free Radic Biol Mcd. 44(7), 1276-1285. 
• Cimcn, M. Y. (2008). Free radical metabolism in human erythrocytes. Clin ('him 
Acta, 390(1-2), 1-11. 
• Cohen, M. P., Chen, S., Ziyadeh, F. N., Shea, E., Hud, E. A., Lautenslager, G. T., and 
Shearman, C. W. (2005). Evidence linking glycated albumin to altered glomerular 
nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney in!, 
68(4). 1554-1561. 
• Colak, E., Majkic-Singh, N., Stankovic. S., Sreckovic-Dimitrijevic, V., Djordjevic, P. 
B.. Lalic. K., and Lalic, N. (2005). Parameters of antioxidative defense in type 2 
diabetic patients N%ith cardiovascular complications. Ann Med, 37(8), 613-620. 
• Coradello, H.. Lubec, G., Pollak, A., and Sternberg, M. (1982). Enzyme activities of 
native non-enzymatically glucosylated trypsin, chymotrypsin and papain. Padiair 
Padol, 17(2), 457-464. 
• Cotgreave. I.A.. Moldeus, P., and Orrenius, S. (1988). Host biochemical defense 
mechanisms against prooxidants. Annu Rev Pharmacol Toxicol, 28, 189-212. 
• Coughlan, M. T., Thorburn, D. R.. Penfold, S. A., Laskowski, A., Harcourt, B. E., 
Sourris, K. C.. et al., (2009). RAGE-induced cytosolic ROS promote mitochondrial 
superoxide generation in diabetes. JAin Soc Nephrol, 20(4). 742-752. 
• Coussons, P. J., Jacoby, J., McKay, A., Kelly, S. M., Price. N. C., and Hunt, J. V. 
(1997). Glucose modification of human serum albumin: a structural study. Free Radic 
Biol Mcd 22(7), 1217-1227. 
• Cubero, F. J., and Nieto, N. (2012). Arachidonic acid stimulates TNFalpha production 
in Kupffer cells via a reactive oxygen species-pERK 112-Egrl -dependent mechanism. 
Am J Physiol Gastrointest Liver Physiol, 303(2), G228-239. 
172 
Biblioxraphr 
• Dallc-Donne I. R. R., Giustarini D, Milzani A. and Colombo R. (2003). Protein 
carbonyl groups as biomarkers of oxidative stress. Clinic-ti Chirnica Acta., 329(1-2), 
23-38. 
• Dallmeier. K.. and Carlini, E. A. (1981). Anesthetic, hypothermic. myorelaxant and 
anticomvlsant effects of synthetic eugenol derivatives and natural analogues. 
1'hurmacoluvt•, 22(2). 113-127. 
• Davies. K. J., Delsignore. M. E.. and Lin, S. W. (1987). Protein damage and 
degradation by oxygen radicals. 11. Modification of amino acids. J Biol Chem. 
262(20), 9902-9907. 
• Dawidowicz, A. L., Wianowska, D., and Baraniak, B. (2006). The antioxidant 
properties of alcoholic extracts from Sarnbucus nigra L. (antioxidant properties of 
extracts). LJVT - Food Science and Technology. 39(3), 308-315. 
• Dean, R. T.. Hunt, J. V., Grant, A. J., Yamamoto, Y., and Niki, E. (1991). Free 
radical damage to proteins: the influence of the relative localization of radical 
generation, antioxidants, and target proteins. Free Rudic Biol Mud, 11(2), 161-168. 
• Dewick, P. M. (2001). Medicinal Natural Products. A Biosynthetic Approach., 2nd 
ed., 158-164. 
• Didry, N., Dubreuil, L., and Pinkas, M. (1994). Activity of thymol, carvacrol, 
cinnamaldehyde and eugenol on oral bacteria. Pharm Acta Hely, 69(1). 25-28. 
• Dinis, T. C., Maderia, V. M., and Almeida, L. M. (1994). Action of phenolic 
derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of 
membrane lipid peroxidation and as peroxyl radical scavengers. Arch Biochem 
Biophvs. 315(1), 161-169. 
• Dolhofer, R.. and Wieland, 0. H. (1979). Preparation and biological properties of 
glycosylated insulin. FERS Lett, 100(1), 133-136. 
• Dolhofer, R., and Wieland, 0. H. (1980). Increased glycosylation of serum albumin 
in diabetes mellitus. Diabetes, 29(6), 417-422. 
• Dyer, D. G., Blackledge, J. A., Katz, B. M., Hull, C. J.. Adkisson, H. D., Thorpe, S. 
R., et al., (1991). The Maillard reaction in vivo. Z Ernahrcmg.vwiss, 30(1), 29-45. 
173 
Bibliography 
• Elgawish, A.. Glomb, M., Friedlander, M.. and Monnier, V. M. (1996). Involvement 
of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J 
Biol Chem. 271(22). 12964-12971. 
• Ellman, G. L. (1959). Tissue sulfhydryl groups. Arch Biochem Biophys, 82(l), 70-77. 
• Era, S., Kuwata, K., Imai, H., Nakamura, K., Hayashi, T., and Sogami, M. (1995). 
Age-related change in redox state of human serum albumin. Biochim Biophys Ada, 
1247(1), 12-16. 
• Evans, J. L., Goldfine, 1. D., Maddux, B. A., and Grodsky, G. M. (2002). Oxidative 
stress and stress-activated signaling pathways: a unifying hypothesis of type 2 
diabetes. Endocr Rev, 23(5), 599-622. 
• Farrar, J. L., Hartle, D. K., Hargrove, J. L., and Greenspan, P. (2007). Inhibition of 
protein glycation by skins and seeds of the muscadine grape. Biofactors. 3((3), 193-
200. 
• Fischer, I. L'., and Dengler, H. J. (1990). Sensitive high-performance liquid 
chromatographic assay for the determination of eugenol in body fluids. [Research 
Support, Non-U.S. Gov't). JChromatogr, 525(2). 369-377. 
• Forrest. K. Y., Maser, R. E., Pambianco. G., Becker, D. J., and Orchard, T. J. (1997). 
Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes, 
46(4), 665-670. 
• Fouda, A. M., Daba, M. H., Dahab, G. M., and Sharaf El-Din, O. A. (2008). 
Thymoquinone ameliorates renal oxidative damage and proliferative response 
induced by mercuric chloride in rats. Basic Clin Pharmacol Toxicol, 103(2), 109-118. 
• Fridovich. I. (1997). Superoxide anion radical (02-.). superoxide dismutases, and 
related matters. JBiol Chem. 272(30), 18515-18517. 
• Fu, M. X., Wells-Knecht, K. J., Blackledge, J. A., Lyons, T. J., Thorpe, S. R., and 
Baynes, J. W. (1994). Glycation, glycoxidation, and cross-linking of collagen by 
glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. 
Diabetes, 43(5). 676-683. 
174 
Bibliography 
• Fujisawa, S.. Atsumi. T., Kadoma, Y., and Sakagami, H. (2002). Antioxidant and 
prooxidant action of eugenol-related compounds and their cytotoxicity. Toxicology, 
l 77(I ). 39-54. 
• Ge. F., Jiang. L., Liu, D., and Chen, C. (2011). Interaction between alizarin and 
human serum albumin by fluorescence spectroscopy. Anal Sci. 27(1), 79-84. 
• Ghafar. M. F., Prasad, K.N., Weng, K.K., and Ismail, A. (2010). Flavonoid, 
hesperidine, total phenolic contents and antioxidant activities from Citrus species. 
African Journal of Biotechnology, 9(3), 326-330. 
• GhoshMoulick, R., Bhattacharya, J., Roy, S., Basak, S., and Dasgupta, A. K. (2007). 
Compensatory secondary structure alterations in protein glycation. Biochim Biophys 
Ac/a. 1774(2). 233-242. 
• Giardino, 1., Edelstein, D., and Brownlee, M. (1994). Nonenzymatic glycosylation in 
vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A 
model for intracellular glycosylation in diabetes. J Clin Invest, 94(l), 1 10-1 17. 
• Giardino, L. Fard. A. K., Hatchell, D. L.. and Brownlee, M. (1998). Aminoguanidine 
inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced 
apoptosis. Diabetes, 47(7), 1114-1120. 
• Giroux, M., Ouattara, B., Yefsah, R., Smoragiewicz, W., Saucier. L., and Lacroix, M. 
(2001). Combined effect of ascorbic acid and gamma irradiation on microbial and 
sensorial characteristics of beef patties during refrigerated storage. J Agric Food 
Chem, 49(2), 919-925. 
• Greene, D. A. (1983). Metabolic abnormalities in diabetic peripheral nerve: relation 
to impaired function. Metabolism, 32(7 Suppl 1). 118-123. 
• Gulcin, 1. (2011 . Antioxidant activity of cugenol: a structure-activity relationship 
study. J Med Food, 14(9), 975-985. 
• Gull, N., Sen. P., Kabir Ud, D., and Khan, R. H. (2007). Effect of physiological 
concentration of urea on the conformation of human serum albumin. J Biochem, 
141(2), 261-268. 
175 
Bibliography 
• Gunusen. 1., Karaman, S., Ertugrul, V.. and Firat, V. (2010). Effects of fluid preload 
(crystalloid or colloid) compared with crystalloid co-load plus ephedrine infusion on 
hypotension and neonatal outcome during spinal anaesthesia for caesarean delivery. 
Anaesth Intensive Care, 38(4), 647-653. 
• Guthrow, C. F,., Morris, M. A.. Day, J. F., Thorpe, S. R., and Baynes, J. W. (1979). 
Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. 
Proc Nail Acad Sci US A, 76(9), 4258-4261. 
• Halliwell, B. (1997). Antioxidants and human disease: a general introduction. Nuir 
Rev, 55(I Pt 2), S44-49 
• Halliwell, B. (1999). Antioxidant defence mechanisms: from the beginning to the end 
(of the beginning). Free Radic Res, 31(4), 261-272. 
• Halliwell, B., and Gutteridge, J. M. (1990). Role of free radicals and catalytic metal 
ions in human disease: an overview. Methods Enzymol, 186, 1-85. 
• Halliwell, B.. and Gutteridge, J.M.C. (2007). Free radicals in biology and medicine. 
(4th ed.). Oxford, UK: Clarendon Press. 
• Hammes, H. P., Strodter, D., Weiss, A., Bretzel, R. G., Federlin, K., and Brownlee, 
M. (1995). Secondary intervention with aminoguanidine retards the progression of 
diabetic retinopathy in the rat model. Diabetologia, 38(6), 656-660. 
• Hassan, I., Chibber, S., Khan, A. A., and Naseem, 1. (2012). Riboflavin ameliorates 
cisplatin induced toxicities under photoillumination. PLoS One, 7(5), e36273. 
• Haynes, R., Osuga, D. T., and Feeney, R. E. (1967). Modification of amino groups in 
inhibitors of proteolytic enzymes. Biochemistry, 6(2), 541-547. 
• Heath. M. M., Rixon, K. C., and Ilarding, J. J. (1996). Glycation-induced inactivation 
of malate dehydrogenase protection by aspirin and a lens molecular chaperone, alpha-
crystallin. Biochim Biophys Acta, 1315(3), 176-184. 
• Hennessey, J. P., Jr., and Johnson, W. C., Jr. (1981). Information content in the 
circular dichroism of proteins. Biochemistry, 20(5), 1085-1094. 
176 
Bibliography 
• Hobart, L. J., Seibel, l., Yeargans, G. S., and Seidler, N. W. (2004). Anti-crosslinking 
properties of carnosine: significance of histidine. Life Sci, 75(11), 1379-1389. 
• Hogg, N.. and Kalyanaraman, B. (1998). Nitric oxide and low-density lipoprotein 
oxidation. Free Radic Res, 28(6), 593-600. 
• Holley, A. K., Dhar, S. K., and St Clair, D. K. (2010). Manganese superoxide 
dismutase vs. p53: regulation of mitochondrial ROS. Mitochondrion, 10(6), 649-661. 
• Hollman, P. C., and Katan, M. B. (1999). Dietary tlavonoids: intake, health effects 
and bioavai lability. Food Chem Toxicol, 37(9-10), 937-942. 
• Hosseinzadeh, H., and Parvardeh, S. (2004). Anticonvulsant effects of thymoquinone, 
the major constituent of Nigella sativa seeds, in mice. Phytomedicine, 11(1), 56-64. 
• Hudson. B. I., Hofmann, M.A., Bucciarelli, L., Wendt, T., Moser, B., Lu, Y., et al., . 
(2002). Glycation and Diabetes: The RAGE connection. Current Science, 83(12), 
1515-1521. 
• Hutson. S. M.. Stinson-Fisher. C., Shiman, R., and Jefferson, L. S. (1987). Regulation 
of albumin synthesis by hormones and amino acids in primary cultures of rat 
hepatocytes. Am J Physiol, 252(3 Pt 1), E291-298. 
• Ibrahim. S., Harris, N. D., Radatz, M., Selmi, F., Rajbhandari, S., Brady, L., et al., 
(1999). A new minimally invasive technique to show nerve ischaemia in diabetic 
neuropathy. Diabetologia, 42(6), 737-742. 
• Ito, M.. Murakami, K., and Yoshino, M. (2005). Antioxidant action of eugenol 
compounds: role of metal ion in the inhibition of lipid peroxidation. Food Chem 
Toxicol, 43(3). 461-466. 
• lzyumov. D. S., Domnina, L. V., Nepryakhina, O. K., Avetisyan, A. V., Golyshev, S. 
A., Ivanova, O. Y. et al., (2010). Mitochondria as source of reactive oxygen species 
under oxidative stress. Study with novel mitochondria-targeted antioxidants--the 
"Skulachev-ion" derivatives. Biochemistry (Mosc,), 75(2), 123-129. 
• Jabeen, R., Mohammad, A. A., Elefano, E. C., Petersen, J. R., and Saleemuddin, M. 
(2006). Antibodies and Fab fragments protect Cu,Zn-SOD against methylglyoxal-
induced inactivation. Biochim Biophys Acta, 1760(8), 1167-1174. 
177 
Bibliography 
• Jain, S. K., McVie, R., Duett, J., and Herbst, J. J. (1989). Erythrocyte membrane lipid 
peroxidation and glycosylatcd hemoglobin in diabetes. Diabetes, 38(12), 1539-1543. 
• Jakus, V. (2000). The role of free radicals. oxidative stress and antioxidant systems in 
diabetic vascular disease. Brutisl Lek Lisir. 101(10), 541-551. 
• Jakus, V. (2003). The role of nonenzymatic glycation and glyco-oxidation in the 
development of diabetic vascular complications. Cesk Fvsiol, 52(2), 51-65. 
• Jung, H. A., Yoon. N. Y., Kang, S. S., Kim, Y. S., and Choi, J. S. (2008). Inhibitory 
activities of prenylated flavonoids from Sophora flavescens against aldose reductase 
and generation of advanced glycation endproducts]. J Pharm Pharmacol, 60(9), 
1227-1236. 
• Kaneto, H., Kajimoto, Y., Miyagawa, J., Matsuoka, T., Fujitani, Y., Umayahara, Y., 
et al., (1999). Beneficial effects of antioxidants in diabetes: possible protection of 
pancreatic beta-cells against glucose toxicity. Diabetes. -18(12), 2398-2406. 
• Karaman, S., Tutem, E., Baskan, K.S., and Apak, R. (2010). Comparison of total 
antioxidant capacity and phenolic composition of some apple juices with combined 
HPLC—CUPRAC assay. Food Chem, 120(4), 1201-1209. 
• Kasper, D. L., Fauci, A. S., Longo, D. L., Braunwald, E.. Hauser, S. L., an Jameson, 
J. L. (2005). Harrison's Principles of Internal Medicine. New York: Mcgrow Hill. 
• Khattab, M. M., and Nagi, M. N. (2007). Thymoquinone supplementation attenuates 
hypertension and renal damage in nitric oxide deficient hypertensive rats. Phyiother 
Re.s. 21(5), 410-414. 
• Khalife. K. H., and Lupidi, G. (2007). Nonenzymatic reduction of thymoquinone in 
physiological conditions. Free Radic Res, .1/(2), 153-161. 
• Khan, T. A., Saleemuddin, M., and Naeem, A. (2011). Partially Folded Glycated 
State of Human Serum Albumin Tends to Aggregate. !nt J Pept Res Ther, 17, 271-
279. 
178 
Bibliography 
• Kim, H. W., Ko, Y. J., Rhee, W. I., Lee, J. S., Lim, J. E., Lee, S. J., et al., (2007). 
Interexaminer reliability and accuracy of posterior superior iliac spine and iliac crest 
palpation for spinal level estimations. J Manipulative Physiol Ther, 30(5), 386-389. 
• Kim. H. Y.. and Kim, K. (2003). Protein glycation inhibitory and antioxidative 
activities of some plant extracts in vitro. JAgric Food Chern, 51(6), 1586-1591. 
• Kirstein. M.. Brett, J.. Radoff, S.. Ogawa, S.. Stern, D.. and Vlassara, H. (1990). 
Advanced protein glycosylation induces transendothelial human monocyte 
chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of 
diabetes and aging. Proc Natl Acad Sci USA, 87(22), 9010-9014. 
• Klein, R., Klein, B. E., Moss, S. E.. Davis. M. D., and DeMets, D. L. (1984). The 
Wisconsin epidemiologic study of diabetic retinopathy. 11. Prevalence and risk of 
diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol, 
102(4). 520-526. 
• Koenig. R. J.. Peterson, C. M., Jones, R. L., Saudek, C'.. Lehrman, M., and Cerami. A. 
(1976). Correlation of glucose regulation and hemoglobin Ale in diabetes mellitus. N 
Engl J Med, 295(8), 417-420. 
• Kohlert, C.. Schindler, G., Marz, R. W., Abel, G., Brinkhaus, B., Derendorf, H., et al., 
(2002). Systemic availability and pharmacokinetics of thymol in humans. J Clin 
Pharmacol, 42(7), 731-737. 
• Koschinskv, T.. He, C. J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., et al., 
(1997). Orally absorbed reactive glycation products (glycotoxins): an environmental 
risk factor in diabetic nephropathy. Proc Natl Acad Sci USA, 94(12), 6474-6479. 
• Krolewski, A. S., Warram, J. H., Valsania, P., Martin, B. C., Laffel, L. M., and 
Christlieb. A. R. (1991). Evolving natural history of coronary artery disease in 
diabetes mellitus. Am J Med, 90(2A), 56S-61 S. 
• Kuppusamy. U. R., Indran, M., and Rokiah, P. (2005). Glycaemic control in relation 
to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients. 
Diabet Mcd, 22(10). 1343-1346. 
179 
Bibliography 
• L'Esperance, F. A., James, W.A., and Judson, P.H. (1990). The eve and diabetes 
mellitu.v. New York: Elsevier. 
• Laakso, Ni. (1999). Hyperglycemia and cardiovascular disease in type 2 diabetes. 
Diabetes, 48(5), 937-942. 
• Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature, 227(529), 680-685. 
• Lapolla, A., Gerhardinger, C.. Baldo, L., Fedele, D. (1992). Pyrolysis/gas 
chromatography/mass spectrometry in the analysis of glycated poly-L-lysine. 
Organic Mass Spectrometry, 27(3), 183-187. 
• Lapolla, A., Traldi, P., and Fedele, D. (2005). Importance of measuring products of 
non-enzymatic glycation of proteins. Clin Biochem, 38(2), 103-115. 
• Leal, P. F.. Braga. Ni. E., Sato. D. N., Carvalho, J. E., Marques, M. O., and Meireles, 
M. A. (2003). Functional properties of spice extracts obtained via supercritical fluid 
extraction. J Agric Food Chem, 51(9), 2520-2525. 
• Lee, K. G., and Shibamoto, T. (2002). Determination of antioxidant potential of 
volatile extracts isolated from various herbs and spices. J Agric Food Chem, 50(17), 
4947-4952. 
• Lee, S. J., Han, J. I., Lee, G. S., Park, M. J., Choi, I. G., Na, K. J., and Jeung, E. B. 
(2007). Antifungal effect of eugenol and nerolidol against Microsporum gypseum in a 
guinea pig model. Biol Pharm Bull, 30(1), 184-188. 
• Levine, R. L., Garland, D., Oliver, C. N.. Amici, A., Climent, I., Lenz, A. G., et al., 
(1990). Determination of carbonyl content in oxidatively modified proteins. Methods 
Enzvmol, 116. 464-478. 
• Li, Y.. Ren, H., and Ragauskas, A.J. (2010). Rigid polyurethane foam reinforced with 
cellulose whiskers: Synthesis and characterization. Nano-Micro Letters, 2(2), 89-94. 
• Liggins, J., and Furth, A. J. (1996). Mixed dimers formed by crosslinking of native 
and glycated proteins in the absence of free sugar. Biochem Biophys Res Canmun, 
219(1), 186-190. 
I:1 
BiblioRraplzV 
• Liu, R., Yang, J., Ha, C. E., Bhagavan, N. V., and Eckenhoff, R. G. (2005). Truncated 
human serum albumin retains general anaesthetic binding activity. Biochem J, 388(Pt 
1), 39-45. 
• Liu, X., Chen. Z.. Mao. N.. and Xie, Y. (2012). The protective of hydrogen on stress-
induced gastric ulceration. lnt Immunopharmacol, 13(2), 197-203. 
• Liu, Y., Xie, M. X., Kang, J., and Zheng, D. (2003). Studies on the interaction of total 
saponins of panax notoginseng and human serum albumin by Fourier transform 
infrared spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc, 59(12), 2747-2758. 
• Lowry. O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein 
measurement with the Folin phenol reagent. JBiol Chem, 193(1), 265-275. 
• Lundsgaard-Hansen, P. (1986). Physiology and pathophysiology of colloid osmotic 
pressure and albumin metabolism. Cur Stud Hematol Blood Transf us(53), 1-17. 
• Maillard, L. C.. and Gautier, M.A. (1912). C. R. Seances Acad. Sc!. 111, 154, 66-68. 
• Manach. C., Scalbert, A., Morand, C., Remesy, C.. and Jimenez, L. (2004). 
Polyphenols: food sources and bioavailability. Am J Clin Nutr, 79(5), 727-747. 
• Manavalan, P., and Johnson, W. C., Jr. (1987). Variable selection method improves 
the prediction of protein secondary structure from circular dichroism spectra. Anal 
Biochem, 167(1), 76-85. 
• Mashiba, S., Uchida, K., Okuda, S., and Tomita, S. (1992). Measurement of glycated 
albumin by the nitroblue tetrazolium colorimetric method. Clin Chirn Acta, 212(1-2), 
3-1S. 
• Mastelic, J., Jerkovic, 1., Blazevic, l., Poljak-Blazi, M., Borovic, S., Ivancic-Baee, I., 
et al., (2008). Comparative study on the antioxidant and biological activities of 
carvacrol, thymol, and eugenol derivatives. J Agric Food Chem, 56(11), 3989-3996. 
• Mates. J. M., Perez-Gomez, C., and Nunez de Castro, 1. (1999). Antioxidant enzymes 
and human diseases. Clin Biochem, 32(8), 595-603. 
• McCord, J. M., and Fridovich, 1. (1969). Superoxide dismutase. An enzymic function 
for erythrocuprein (hemocuprein). J Biol Chem, 244(22), 6049-6055. 
181 
Biblio,'raphr 
• McDonald. M. J., Bleichman, M., Bunn. H. F., and Noble, R. W. (1979). Functional 
properties of the glycosylated minor components of human adult hemoglobin. J Biol 
Chem, 54(3), 702-707. 
• McLellan. A. C., Thornallev. P. J., Benn. J., and Sonksen, P. H. (1994). Glyoxalase 
system in clinical diabetes mellitus and correlation with diabetic complications. Clin 
Sci (Loral), 87(l), 21-29. 
• Mera, K., Anraku, M., Kitamura, K., Nakajou, K., Maruyama, T., and Otagiri, M. 
(2005). The structure and function of oxidized albumin in hemodialysis patients: Its 
role in elevated oxidative stress via neutrophil burst. Biochem I3iophys Res Commun, 
334(4), 1322-1328. 
• Merril. C. R., Goldman, D., and Keuren, M.L.V. (1982). Simplified silver protein 
detection and image enhancement methods in polyacrylamide gels. Electrophoresis, 
3(1). 17-23. 
• Miki. M., Tamai, H., Mino, M., Yamamoto, Y., and Niki, E. (1987). Free-radical 
chain oxidation of rat red blood cells by molecular oxygen and its inhibition by alpha-
tocopherol. Arch Biochem Biophys, 258(2), 373-380. 
• Miller, J. A., Gravallese, E., and Bunn, H. F. (1980). Nonenzymatic glycosylation of 
erythrocyte membrane proteins. Relevance to diabetes. JClin Invest, 65(4), 896-901. 
• Miyazawa, N., Kawasaki, Y., Fujii, J., Theingi, M., Hoshi, A., Hamaoka, R., et al., 
(1998). Immunological detection of fructated proteins in vitro and in vivo. Biochem J, 
336 (Pt 1), 101-107. 
• Mizutani, K., Ikeda, K., Nishikata, T., and Yamori, Y. (2000). Phytoestrogens 
attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone 
spontaneously hypertensive rats. J Hypertens, 18(12), 1833-1840. 
• Moebus, S., Balijepalli, C., Losch, C., Gores, L., von Stritzky, B., Bramlage, P., et al., 
(2010). Age- and sex-specific prevalence and ten-year risk for cardiovascular disease 
of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional 
stud. Cardiovasc Diahetol, 9. 34. 
182 
Bibliograph y 
• Monnier, V. M. (2005). Bacterial enzymes that can deglycate glucose- and fructose-
modified lysine. Biochem J, 392(Pt 2), 
• Monnier. V. M., and Cerami, A. (1981). Noncnzvmatic browning in vivo: possible 
process for aging of long-lived proteins. Science, 211(4481). 491-493. 
• Mullarkey, C. J., Edelstein, D., and Brownlee, M. (1990). Free radical generation by 
early glycation products: a mechanism for accelerated atherogenesis in diabetes. 
Biochem Biophys Res Common, 173(3), 932-939. 
• Myatt, L. (2010). Review: Reactive oxygen and nitrogen species and functional 
adaptation of the placenta. Placenta, 31 Suppl, S66-69. 
• Nacitarhan. S., Ozben, T., and Tuncer, N. (1995). Serum and urine malondialdehyde 
levels in NIDDM patients with and without hyperlipidemia. Free Radic Biol Med, 
19(6), 893-896. 
• Nagai, R., Matsumoto, K., Ling, X., Suzuki, 11., Araki, T.. and 1-loriuchi, S. (2000). 
Glycolaldehyde. a reactive intermediate for advanced glycation end products, plays 
an important role in the generation of an active ligand for the macrophage scavenger 
receptor. Diabetes, 49(10). 1714-1723. 
• Naka, Y.. Bucciarelli, L. G., Wendt, 1'., Lee, L. K.. Kong, L. L., Ramasamy, R., et al., 
(2004). RAGE axis: Animal models and novel insights into the vascular 
complications of diabetes. Arterioscler Thromb Vasc Biol, 24(8), 1342-1349. 
• Nakagawa, T., Yokozawa, T., Terasawa, K., Shu, S., and Juneja, L. R. (2002). 
Protective activity of green tea against free radical- and glucose-mediated protein 
damage. .!Agric Food Chem, 50(8), 2418-2422. 
• Nakajou, K., Watanabe, H., Kragh-Hansen, U.. Maruyama. T., and Otagiri, M. 
(2003). The effect of glycation on the structure, function and biological fate of human 
serum albumin as revealed by recombinant mutants. Biochim Biophys Acta, 1623(2-
3), 88-97. 
• Nenadis, N., Boyle, S., Bakalbassis, E.G., and Tsimidou, M. (2003). An experimental 
approach to structure-activity relationships of caffeic and dihydrocaffeic acids and 
related monophenols. Journal of the American Oil Chemists'Society, 80(5), 451-458. 
183 
Bibliox'raphV 
• Neumann, A.. Schinzel. R., Palm. D.. Riederer, P., and Munch, G. (1999). High 
molecular weight hvaluronic acid inhibits advanced glycation endproduct-induced 
NF-kappat3 activation and cytokine expression. FED.S Lett. .153(3), 283-287. 
• Newkirk, M. Ni.. Goldbach-Manske, R.. Lee, J., Hoxworth, J., McCoy, A., Yarboro, 
C., et al., (2003). Advanced glycation end-product (AGE)-damaged IgG and 1gM 
autoantibodics to LEG-AGE in patients with early synovitis. Arthritis Res Ther, 5(2), 
R82-90. 
• Nikolova, M., Zhekova, G., and Dzhurmanski, A. (2012). Preliminary investigation 
of free radical scavenging activity and total phenolic content of three cultivated 
Thymus chemotypes from Bulgaria. Biologica Nyssana, 3(1), 11 -15. 
• Nishigaki, L, Hagihara, M., Tsunekawa, H., Maseki, M., and Yagi, K. (1981). Lipid 
peroxide levels of serum lipoprotein fractions of diabetic patients. Riochem Meal 
25(3). 373-378. 
• Odetti, P., Garibaldi, S., Noberasco, G.. Aragno. 1., Valentini, S., Traverso, N., and 
Marinari, U. Ni. ( l999). Levels of carbonyl groups in plasma proteins of type 2 
diabetes mellitus subjects. Acta Diabetol. 36(4), 179-183. 
• Ohkawa, 11., Ohishi, N., and Yagi, K. (1979). Assay for lipid peroxides in animal 
tissues by thiiobarbituric acid reaction. Anal Biochem, 95(2), 351-358. 
• Oya, T., Osawa, T., and Kawakishi, S. (1997). Spice constituents scavenging free 
radicals and inhibiting pentosidine formation in a model system. Biosci Biotechnol 
Biochem. 61(2). 263-266. 
• Pacitici, R. L.. and Davies, K. J. (1991). Protein, lipid and DNA repair systems in 
oxidative stress: the free-radical theory of aging revisited. Gerontology, 37(1-3), 166-
180. 
• Palm. F., Cederberg, J., Hansell, P., Liss, P., and Carlsson, P. O. (2003). Reactive 
oxygen species cause diabetes-induced decrease in renal oxygen tension. 
Diabetologia, 46(8), 1153-1160. 
184 
Bibliographt 
• Panagiotopoulos, S., O'Brien, R. C., Bucala, R., Cooper, M. E., and Jerums, G. 
(1998). Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. 
Atherosclerosis, 136(1). 125-131. 
• Peters. T.. Jr. (1970). Serum albumin. Adv Clin Chem, 13. 37-1 II. 
• Pryor. W. A. (2000). FORUM: oxidation and atherosclerosis. Free Radic Biol R1ed, 
28(12). 1681-1682. 
• Rahbar. S., and Figarola, J. L. (2003). Novel inhibitors of advanced glycation 
endproducts. Arch Biochem Biophys, 419(1), 63-79. 
• Rahbar, S., Yemeni, K. K., Scott, S., Gonzales, N., and Lalezari, I. (2000). Novel 
inhibitors of advanced glycation endproducts (part II). Mol Cell Biol Res Commun, 
3(6), 360-366. 
• Rahmelow, K.. and Hubner, W. (1996). Secondary structure determination of proteins 
in aqueous solution by infrared spectroscopy: a comparison of multivariate data 
analysis methods. Anal Biochem. 24](1). -13. 
• Raj. D. S., Choudhury, D., Welbourne, T. C., and Levi, M. (2000). Advanced 
glycation end products: a Nephrologist's perspective. Am J Kidney Dis, 35(3), 365-
380. 
• Ramachandran, A., Snehalatha, C., Kapur, A., Vijay, V., Mohan, V., Das, A. K., et 
al., Diabetes Epidemiology Study Group in, 1. (2001). High prevalence of diabetes 
and impaired glucose tolerance in India: National Urban Diabetes Survey. 
Diabetologia, 44(9), 1094-1101. 
• Rates. S. M. (2001). Plants as source of drugs. Toxicon, 39(5), 603-613. 
• Rice-Evans. C. A., Miller, N. J.. and Paganga, G. (1996). Structure-antioxidant 
activity relationships of flavonoids and phenolic acids. Free Radic Bin! Med, 20(7). 
933-956. 
• Rice-Evans, C. A., Miller, N.J.. and Paganga, G. (1997). Antioxidant properties of 
phenolic compounds. Trends Plant Sci, 2(4), 152-159. 
185 
Bibliograplt y 
• Rigamonti. C., Mottaran, E., Reale, E., Rolla, R., Cipriani, V., Capelli, F et al.. 
(2003). Moderate alcohol consumption increases oxidative stress in patients with 
chronic hepatitis C. Hepatologt', 38(1). 42-49. 
• Roginsk%. V.. and Lissi. E.A. (2005). Review of methods to determine chain-breaking 
antioxidant activity in food. Food Chemistry, 92(2), 235-254. 
• Rosca, M. G., Mustata. T. G., Kinter, M. T.. Ozdemir, A. M., Kern, T. S., Szweda, L. 
l., et al., (2005). Glycation of mitochondrial proteins from diabetic rat kidney is 
associated with excess superoxide formation. Am J Physiol Renal Physiol, 289(2), 
F420-430. 
• Rudnicki, M., Silveira, M. M., Pereira, T. V., Oliveira, M. R., Reginatto, F. H., Dal-
Pizzol, F.. and Moreira, J. C. (2007). Protective effects of Passiflora alata extract 
pretreatment on carbon tetrachloride induced oxidative damage in rats. Food Chem 
Toxicol, 45(4), 656-661. 
• Sajithlal, G. B., Chithra, P., and Chandrakasan, G. (1999). An in vitro study on the 
role of metal catalyzed oxidation in glycation and crosslinking of collagen. IVfol Cell 
Biochem. 194(1-2), 257-263. 
• Sanchez-Moreno, C., Larrauri, J.A., and Saura-Calixto, F. (1998). A procedure to 
measure the antiradical efficiency of polyphenols. .Journal of the Science of Food and 
Agriculture, 76(2), 270-276. 
• Sato, T., Iwaki, M., Shimogaito, N., Wu, X., Yamagishi, S., and Takeuchi, M. (2006). 
TAGE (toxic AGEs) theory in diabetic complications. Curr Mot Med, 6(3), 351-358. 
• Schleicher, E. D., Wagner, E., and Nerlich, A. G. (1997). Increased accumulation of 
the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in 
diabetes and aging. J Clin Invest, 99(3), 457-468. 
• Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2001). The multiligand 
receptor RAGE as a progression factor amplifying immune and inflammatory 
responses. J Clin Invest, 108(7), 949-955. 
186 
Bibliorrapl:r 
• Schmitt. A., Schmitt, J.. Munch, G., and Gasic-Milencovic, J. (2005). 
Characterization of advanced glycation end products for biochemical studies: side 
chain modifications and fluorescence characteristics. Anal Biochem, 338(2), 201-215. 
• Seidler, N. \V.. and Seibel, 1. (2000). Glycation of aspartate aminotransferase and 
conformational flexibility. Biochem Biophys Res Commun, 277(1), 47 -50. 
• Sell, D. R.. Nagaraj, R. H.. Grandhee, S. K., Odetti, P., Lapolla, A., Fogarty, J., and 
Monnier, V. M. (1991). Pentosidine: a molecular marker for the cumulative damage 
to proteins in diabetes, aging, and uremia. Diabetes Metab Rev, 7(4), 239-251. 
• Sen, P., Maiti, P. C., Puri, S., Ray, A., Audulov, N. A., and Valdman, A. V. (1992). 
Mechanism of anti-stress activity of Ocimum sanctum Linn, eugenol and Tinospora 
malabarica in experimental animals. Indian J Exp Biol, 30(7), 592-596. 
• Shaklai, N.. Garlick, R. L., and Bunn, H. F. (1984). Nonenzymatic glycosylation of 
human serum albumin alters its conformation and function. J Biol Chem, 259(6), 
3812-3817. 
• Sharma, K.. and Ziyadeh, F. N. (1995). Hyperglycemia and diabetic kidney disease. 
The case for transforming growth factor-beta as a key mediator. Diabetes, 44(10), 
1139-1146. 
• Shastri, G. V., Thomas, M., Victoria, A. J., Selvakumar, R., Kanagasabapathy, A. S., 
Thomas, K., and Lakshmi. (1998). Effect of aspirin and sodium salicylate on cataract 
development in diabetic rats. Indian J Exp Biol, 36(7), 651-657. 
• Shibata, M. (2011). Bio-Based Nanocomposites Composed of Photo-Cured Soybean- 
Based Resins and Supramolecular Hydroxystearic Acid Nanofibers. Japan: InTech. 
• Shimada, K., Fujikawa, K., Yahara, K., and Nakamura, T. . (1992). Antioxidant 
properties of xanthan on the autoxidation of Soybean oil in cyclodextrin emulsion. J. 
.4g>ric . Food Chem., 40(6). 945-948. 
• Shimoji, Y.. Tamura, Y., Nakamura, Y., Nanda, K., Nishidai, S., Nishikawa, Y., et 
al., (2002). Isolation and identification of DPPH radical scavenging compounds in 
Kurosu (Japanese unpolished rice vinegar). .I Agric Food Chem, 50(22), 6501-6503. 
187 
Bibliogruph p 
• Shinohara, M., Thornalley, P. J.. Giardino. 1.. Beisswenger. P., Thorpe. S. R., 
Onorato, J., and Brownlee, M. (1998). Overexpression of glyoxalase-I in bovine 
endothelial cells inhibits intracellular advanced glycation endproduct formation and 
prevents hyperglycemia-induced increases in macromolecular endocytosis. .1 Clin 
Invesi, 101(5). 1142-1147. 
• Singh. R., Barden. A., Mori, T., and Beilin, L. (2001). Advanced glycation end-
products: a review. Diabetulogia, 44(2), 129-146. 
• Skolnik, E. Y.. Yang, Z., Makita. Z., Radoff, S.. Kirstein, M., and Vlassara, H. 
(1991). Human and rat mesangial cell receptors for glucose-modified proteins: 
potential role in kidney tissue remodelling and diabetic nephropathy. J Erp Med, 
174(4), 931-939. 
• Smedsrod, B., Melkko, J., Araki. N., Sano, H., and Horiuchi, S. (1997). Advanced 
_Ivcation end products are eliminated by scavenger-receptor-mediated endoc}tosis in 
hepatic sinusoidal Kupffer and endothelial cells. Biuchem J, 322 (P/ 2). 567-573. 
• Soares. J. R.. Dinis. T. C., Cunha, A. P.. and Almeida, L. M. (1997). Antioxidant 
activities of some extracts of Thymus zygis. Free Radic Res, 26(5), 469-478. 
• Sobal, G., and Menzel, J. (2000). The role of antioxidants in the long-term glycation 
of low density lipoprotein and its Cu2+-catalyzed oxidation. Free Radic Res, 32(5), 
439-449. 
• Soriani, M.. Pietraforte, D., and Minetti, M. (1994). Antioxidant potential of 
anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon 
radicals. Arch Biocheni Biophyc, 312(1), 180-188. 
• Stevens, V. J., Rouzer, C. A., Monnier, V. M., and Ceranti, A. (1978). Diabetic 
cataract formation: potential role of glycosylation of lens crystallins. Proc Nail Acad 
Sci USA, 75(6), 2918-2922. 
• Stvolinskii, S. L.. Fedorova, T. N., Yuneva, M. 0., and Boldyrev, A. A. (2003) 
Protective effect of carnosine on Cu,Zn-superoxide dismutase during impaired 
oxidative metabolism in the brain in vivo. Bull Exp Biol Med, 135(2), 130-132. 
188 
Bibliograph 
• Sugimoto, K., and Yagihashi, S. (1997). Effects of aminoguanidine on structural 
alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. 
Microvasc Res, 53(2), 105-112. 
• Sugio. S., Kashima, A.. Mochizuki, S., Noda, M.. and Kobayashi. K. (1999). Crystal 
structure of human serum albumin at 2.5 A resolution. Protein Eng, 12(6), 439-446. 
• Sundaresan. M., Yu, Z. X., Ferrans. V. J., Irani. K., and Finkel, T. (1995). 
Requirement for generation of 1-1202 for platelet-derived growth factor signal 
transduction. Science, 270(5234), 296-299. 
• Suzuki, E., Yasuda, K., Takeda, N., Sakata, S., Era, S., Kuwata, K., et al., (1992). 
Increased oxidized form of human serum albumin in patients with diabetes mellitus. 
Diabetes Res Clin Pract, 18(3), 153-158. 
• Szabadics. J., and Erdelyi, L. (2000). Pre- and postsynaptic effects of eugenol and 
related compounds on Helix pomatia L. neurons. Acta Biol Hung, 51(2-4), 265-273. 
• Tai, K. W.. Huang, F. M., Huang, M. S., and Chang, Y. C. (2002). Assessment of the 
genotoxicity of resin and zinc-oxide eugenol-based root canal sealers using an in vitro 
mammalian test system. J Biomed Muter Res, 59(l). 73-77. 
• 'Takagi, Y., Kashiwagi, A., Tanaka, Y., Asahina, T., Kikkawa, R., and Shigeta, Y. 
(1995). Significance of fructose-induced protein oxidation and formation of advanced 
glycation end product. J Diabetes Complications, 9(2), 87-91. 
• Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y., and 
Yamamoto, H. (2000). The receptor for advanced glycation end products is induced 
by the glycation products themselves and tumor necrosis factor-alpha through nuclear 
factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial 
cells. .1 Biol Chem, 275(33), 25781-25790. 
• Tavakoli, S., and Asmis, R. (2012). Reactive oxygen species and thiol redox signaling 
in the macrophage biology of atherosclerosis. Antioxid Redox Signal, 17(12), 1785-
1795. 
• Telci, A., Cakatay, U., Kayali, R., Erdogan, C., Orhan, Y., Sivas, A., and Akcay, T. 
(2000). Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab 
Res, 32(l). 40-43. 
Bibliograph1,  
• Tesfaye, S., Stevens, L. K., Stephenson, J. M.. Fuller, J. H., Plater, M.. lonescu-
Tirgoviste, C.. et al., (1996). Prevalence of diabetic peripheral neuropathy and its 
relation to glycaemic control and potential risk factors: the EURODIAB IDDM, 
Complications Study. Diabetologia. 39(11). 1377-1384. 
• I homas, M. C., Forbes. J. M., and Cooper, M. E. (2005). Advanced glycation end 
products and diabetic nephropathy. Am J Iher, 12(6). 562-572. 
• Thornalley, P. J. (1998). Glutathione-dependent detoxification of alpha-oxoaldehydes 
by the glyoxalase system: involvement in disease mechanisms and antiproliferative 
activity of glyoxalase I inhibitors. Chem BiolInteract, 111-112, 137-151. 
• Thornallcy. P. J. (2003). Glyoxalase I--structure, function and a critical role in the 
enzymatic defence against glycation. Biochem Soc Trans, 3/(Pt 6), 1343-1348. 
• Thornalley, P. J., Langborg, A., and Minhas, H. S. (1999). Formation of glyoxal, 
fnethyIglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. 
Biochem J. 344 Pr 1. 109-116. 
• Thornalley. P. J., Yurek-George, A.. and Argirov. 0. K. (2000). Kinetics and 
mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, 
rnethylglyoxal. and 3-deoxyglucosone under physiological conditions. Biochem 
Phururacol, 60(1), 55-65. 
• Topo, E.. Fisher, G., Sorricelli, A.. Errico, F., Usiello, A., and D'Aniello, A. (2010). 
Thyroid hormones and D-aspartic acid. D-aspartate oxidase, D-aspartate racemase, 
H202. and ROS in rats and mice. Chen r Biodivers, 7(6), 1467-1478. 
• Trang. N. T., Wanner, M. J., Phuong le, V. N., Koomen, G. J., and Dung. N. X. 
((993). 'Ihy- moguinone from Eupatorium ayapana. Planru .1fed, 59(t), 99. Turk, Z. 
(2001). Glycation and complications of diabetes. Diabetol Croat, 30, 49-54. 
• Traverso, N.. Menini, S., Cottalasso. D.. Odetti, P., Marinari, U. M., and Pronzato, M. 
A. (1997). Mutual interaction between glycation and oxidation during non-enzymatic 
protein modification. Biochim Biophys Ada, 1336(3), 409-4 18. 
• Turk. Z. (2001). GIycation and complications of diabetes. Diabetol Croat, 30, 49-54. 
190 
Bibliography 
• "1'urko, 1. V.. Marcondes, S., and Murad, F. (2001). Diabetes-associated nitration of 
tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol 
Heart Circ Pinvsiol, 281(6). H2289-2294. 
• tikeda. H.. l lasegawa, Y., Harada, Y., and Sawamura, M. (2002). Effect of carnosine 
and related compounds on the inactivation of human Cu,Zn-superoxide dismutase by 
modification of fructose and gtvcolaidehvde. Biosci Biotechnol Biochem, 66(l), 36- 
43. 
• Ulrich, P., and Cerami, A. (2001). Protein glycation, diabetes, and aging. Recent Frog 
Horm Res, 56, 1-21. 
• Urios, P., Grigorova-Borsos, A. M., and Sternberg, M. (2007). Aspirin inhibits the 
formation of pentosidine, a cross-linking advanced glycation end product, in collagen. 
Diabetes Res Clin Pract, 77(2), 337-340. 
• Valencia, J. V.. Weldon, S. C., Quinn, D.. Kiers, G. I-I., DeGroot, J., TeKoppele, J. 
M., and Hughes, T. E. (2004). Advanced glycation end product ligands for the 
receptor for advanced glycation end products: biochemical characterization and 
formation kinetics. [Comparative Study]. Anal Biochem, 324(1), 68-78. 
• Valko, M., Izakovic, M., Mazur, M., Rhodes, C. J., and Telser, J. (2004). Role of 
oxygen radicals in DNA damage and cancer incidence. Nfol Cell Biochern, 266(1-2), 
37-56. 
• Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., and Telser, J. (2007). 
Free radicals and antioxidants in normal physiological functions and human disease. 
Int J Biochem Cell Biol. 39(l).44-84. 
• Vardar-Unlu. G., Candan, F., Sokmen. A.. Daferera, D., Polissiou, M., Sokmen, M., 
et al... (2003). Antimicrobial and antioxidant activity of the essential oil and methanol 
extracts of Thymus pectinatus Fisch. et Mey. Var. pectinatus (Lamiaceae). J Agric 
Food Chem, 51(1), 63-67. 
• Verbeke, P., Siboska, G. E., Clark, B. F., and Rattan, S. 1. (2000). Kinetin inhibits 
protein oxidation and glycoxidation in vitro. [Research Support, Non-U.S. Gov't]. 
Biochem Biophvs Res Common, 276(3), 1265-1270. 
191 
Bibliojruphy 
• \'lassara, H. (2001). The AGE-receptor in the pathogenesis of diabetic complications. 
Diabetes Metab Res Rev, 17(6), 436-443. 
• Vlassara. H., Brownlee, M.. and Cerami, A. (1984). Accumulation of diabetic rat 
peripheral nerve myelin by macrophages increases with the presence of advanced 
glycosylation endproducts. J Rxp :bled, 160(1), 197-207. 
• Vlassara, H.. Fuh. H., Donnelly. T.. and Cvbulsky. M. (1995). Advanced glvcation 
endproducts promote adhesion molecule (VCAM- I. ICAM- I) expression and 
atheroma formation in normal rabbits. Mo! Med, 1(4), 447-456. 
• Voziyan, P. A., Khalifah, R. G., Thibaudeau, C., Yildiz, A., Jacob, J., Serianni, A. S., 
and Hudson, B. G. (2003). Modification of proteins in vitro by physiological levels of 
glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced 
glycation end-products through binding of redox metal ions. .1 Biol Chem. 278(47), 
46616-46624. 
• Walsh, S. E., Maillard, J. Y., Russell. A. D., Catrenich, C. E.. Charbonneau. D. L., 
and Bartolo. R. G. (2003). Activity and mechanisms of action of selected biocidal 
agents on Gram-positive and -negative bacteria. JAppl Microbiol, 94(2), 240-247. 
• Wang, C. Y., Wang, S. Y., Yin, J. J., Parry, J., and Yu, L. L. (2007). Enhancing 
,-.ntioxidant, antiproliferation, and free radical scavenging activities in strawberries 
with essential oils. JAgric Food Chem, 55(16), 6527-6532. 
• Wautier, J. L., and Schmidt, A. M. (2004). Protein glycation: a firm link to 
endothelial cell dysfunction. Circ Res, 95(3), 233-238. 
• Weber. G. (1975). Energetics of ligand binding to proteins. Adv Protein Chem, 29, 1-
83. 
• Whiting. D. R., Guariguata, L., Weil, C'., and Shaw. J. (2011). IDF diabetes atlas: 
global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin 
Pract. 94(3). 311-321. 
• Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27(5), 
1047-1053. 
192 
Bibliography 
• Wolff, S. P.. and Dean, R. T. (1987). Glucose autoxidation and protein modification. 
The potential role of'autoxidative glycosylation' in diabetes. Biochem J, 245(1), 243-
250. 
• Wolff, S. P.. Jiang, Z. Y., and Hunt. J. V. (1991). Protein glycation and oxidative 
stress in diabetes mellitus and ageing. Free Radic Biol Mcd, 10(5), 339-352. 
• % olftenbuttel. B. H., Giordano, D., Founds, H. W., and Bucala, R. (1996). Long-term 
assessment of glucose control by haemoglobin-AGE measurement. Lancet, 
347(9000), 513-515. 
• Wu, M. J., O'Doherty, P. J., Murphy. P. A., Lyons, V., Christophersen, M., Rogers, P. 
J., et al., (2011). Different Reactive Oxygen Species Lead to Distinct Changes of 
Cellular Metal Ions in the Eukaryotic Model Organism Saccharomyces cerevisiae. lnt 
.I Mo! Sci. 12(11). 8119-8132. 
• Yamaguchi, F., Ariga, T., Yoshimura, Y., and Nakazawa, H. (2000). Antioxidative 
and anti-glycation activity of garcinol from Garcinia indica fruit rind. J Agric Food 
Cheer, 48(2), 180-185. 
• Yamauchi, Y., Ejiri. Y., and Tanaka, K. (2002). Glycation by ascorbic acid causes 
loss of activity of ribulose-1,5-bisphosphate carboxylase/oxygenase and its increased 
susceptibility to proteases. Plant Cell Physiol, 43(11), 1334-1341. 
• Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y. S., et al., 
(1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end 
products with their receptors/binding proteins. J Biol Chem, 269( 13), 9889-9897. 
• Yim, H. S., Kang, S. 0., Hall, Y. C., Chock, P. B., and Vim, M. B. (1995). Free 
radicals generated during the glycation reaction of amino acids by methylglyoxal. A 
model study of protein-cross-linked free radicals. J Biol Chem, 270(47), 28228-
28233. 
• Yokozawa, T., and Nakagawa, T. (2004). Inhibitory effects of Luobuma tea and its 
components against glucose-mediated protein damage. Food Chem Toxicol, 42(6), 
975-981. 
193 
Bibliography 
• Youdim, K. A.. Shukitt-Hale. B.. MacKinnon. S., Kalt. W.. and Joseph, J. A. (2000). 
I'olyphenolics enhance red blood cell resistance to oxidative stress: in vitro and in 
vivo. Biochim Biophiw Acta. 1523(1). 117-122. 
• Young, I. S.. and Woodside. J. V. (2001). Antioxidants in health and disease. J ('tin 
1'athol, 54(3). 176-186. 
• Zeng. J.. and Davies, M. J. (2005). Evidence for the formation of adducts and S-
(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol 
groups on amino acids, peptides. and proteins. Chem Res Toxicol, 18(8). 1232-1241. 
• Zhang, H., Chen, F., Wang, X.. and Yao, H.Y. (2006). Evaluation of antioxidant 
activity of parsley (Petroselinum crispum) essential oil and identification of its 
antioxidant constituents. Food Research International. 39(8). 833-839. 
• Zhang, X. H.. Lu, Z. L.. and Liu. L. (2008). Coronary heart disease in China. Heart, 
94(9), 1126-1131. 
• Lheng, h., Yang. "l .. Liang. M., Zhang, H., Li, L., Sunnassee, A., and Liu. L. (2010). 
Characterization of protein in old myocardial infarction by FTIR micro-spectroscopy. 
J Huazhong Univ Sci Technolog Med Sci, 30(4), 546-550. 
• Zhu, J. X., Wang, Y., Kong. L. D., Yang, C., and Zhang, X. (2004). Effects of Biota 
orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid 
levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase 
activities in mouse liver. JEthnopharmacol, 93(1), 133-I40. 
• Zill, H., Gunther, R., Erbersdobler, H. F.. Folsch, U. R., and Faist, V. (2001). RAGE 
expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochern 
Biophyys Res Co►mmun, 288(5), 1 108-1 1 1 1. 
• Lou, C. G., .Agar, N. S., and Jones, G. L. (2001). Oxidative insult to human red blood 
cells induced by free radical initiator AAPH and its inhibition by a commercial 
antioxidant mixture. Life Sci, 69(1), 75-86. 
194 

List ofPub(icatlams 
I, Aman, S., and Moin, S. (2077). Antioxidant activity of Ihymuyuinone and its 
pmlective effect against oxidative lie' olvsis. lrnernuriuno/ . IT) e,rnal nJ S'ci,mti/ir 
Rescmch, 2(1).26-30. 
_. Aman, S., Moin, S., Ovaic. M. and Sicdiqui. M.11. (2013). Antioxidant activity 
of drynol: protective rile is AAPH-induced hemolysis in diahet c erythrocytes. 
h terna7onua jo,v'naf o(Pltar'rnacein!tnl.Science Drventlan, 2(3), 55-60. 
3. Muhtnood, T., Moin, S., Faia}, A.F.. Fascan, S., and .Auran, S. (2013). Nix(lu 
.Y.d,u as an anliglyoatin4 agent For Homari Serum Albumin. Inrernulional Journal 
of S'cienh.c Research, 2(4). 25-27. 
4. Parasurampuria. P. Khan, AA.. Ashraf. M.. Arian, S., and Moln. S. (2013). 
Study of serum nitric oxid, lees in senile culataet pat ient> and in normal 
individuals. hrlcrnotiona/Jou,vaal of Scienl,ic Research. ?(QL -417-419. 
195 
Volume • 2 ( Issue : 4 [ Apr 2013 • ISSN No 2277 • R179 
Antioxidant Activity of Thymoquinone 
and its Protective Effect Against Oxidative 
Hemolysis 
f~ 	 - 
~L C 1 f vet It DS: 	. r < • tie 
i 
Shazia Aman 	 Research Scholar, Department of Biochenliitry, ).N.M.C.ti., Ali arh Muslim 
University, Aligarh, U.P„ India-202002 
Shagufta Moin 	 . crrciatr Professor. Department of Bicchr-ni sr.' ] 1N \1.0.11., Aligarh Muslim 
U:iitcrsity, A)igarh, )J P., India-202002 
e 	 .. .. ... - .. • (.r: •I ,((ICs '..?(. ,::.7 1?'.: .' , c r, tr,[n ;p: 	o'"'r ;;:r ra 110 rol,. t,. ..•,r~ r. 	r; ir: 4k0' 
f,t tr 	 r:fele'ne'rtt 	,nuaoie/i(rtni}'<h.vase>rt:':  :et rrrjt-ut'nn../'au;l e: r.';  ii' o.r3y.•n 
ntrr 'r. ' 	r; e or:,,: :urger,}'rt oaturallyomorrIny anttroxidaris are warranted for better ilamtagemcnt of disecses, 1n this 
rudr. ::' ; ,r t. ' l y r., rlhI Jrazyl (DPPNJ radical scavenging assay; reducing patver and Ferric Reducing Antioxidart Power assay 
were used Jot citing the anCcoxedant activity. It was also tested that whether TQ rn vitro protects red blood coils from (AAPH)-
induced heinoly,s in diabetic and healthy subjects. It scar erg es opro 78.13( TQ demonstrated signs kart ferric reducing ability of 
very low <ancentrutmns in healthy and diabetic pfasrnu samples. Furthermore. TQ was able to inhibit Rf1C hentottysis L 86.2296 and 
710401 in norrnat and diabetic patients respectively. Our findings reveal that tlrymoqutnore possess exccllcnt antioxidant properties 
and cculd rert c as a Iree radtiaf scavenger, and thislustities its uses rn alternative inedicrneg. 
1.INTRODUC LION 
R0S are formed and degraded by all aerobic organisms, lead. 
ing to rrthrr physiuIugitul runientrations required for normal 
cell function, or excessive quantities, the state called oxidative 
stress. Intracellular production of those oxygen intermediates 
threatens the integrity of various biontolectiles including pro. 
teins (1). lipids as well as lipoproteins and DNA. ROS are the 
most lethal byproducts of metabolism that mediate many dio. 
eases including cancer, diabetes, Immunodeficiency diseases 
and ageing (2.3). There should be a balance between antioxi-
dants and prooxedants to maintain the body 's optimal physio-
logical conditions. Synthetic anttoxtdants, such as Bill' and LMA 
have recently been suspected to cause negative health effects 
and therefore their applications have been rest icted [4). 
Many studies have demonstrated a correlation between the 
oxnlatuve stress defense and the antioxidant properties of phy• 
tocon5tituents (5,61. Phenolic phytocherntcals found in sing- 
nthcartt quantities in vegetables, fruits, spices and seeds. They 
have been regarded as possible anuox:dar::s their roles in food 
industry and in chemoprevention of dise,(.es resulting due to 
oxidative stress have become an area of active research [7.8). 
TQ (2•isnpropyl-5-methyl' 14-ben'oquinnne). is the main hio-
active component of the volatile oil of the black seed or black 
cumin (Ntgella saliva. Ranunculoccae family). It has been used 
is antioxidant. anti-iowa,rooatorv• and antineoplastic medicines 
fur ,mute than 2(100 years (9,10). Generally Nigella saliva seeds 
contain more than 30°/%fixed oil and 0.40% to 0.45%volatile or) 
(11). TQ represents 18.4 to 24% of the N. sanva volatile oil (12).  
The pharmacological investigations ofthe seed extracts reveal a 
broad spectrum of activities including antidiabetic (i3(. nr•uro• 
protective (14). antiasthntatic (15[. ant i•intlammatory (16] and 
antimicrobial 117). In this study, we investigated the antioxidant 
properties of TQ and Its effect on AAPH-induced hemolysis in 
et ythrnu ytes ed'tatned from dt hrt(c patients and healthy sots' 
Ire IS 
I.MATERIALSAND IIIFTHODS 
1'll)nxxluurn re ('rQ). :• 1'diPheny1.2•purylhcdrazyl ((11'PH). 
22 Azobrs(2 amrdinopi ,pane) dihydrochlonde (AAPSS) v. ere 
purchased from trpm.rAldnch, USA. Rests of the general chemt-
cals used were of an.ilyucal grade bought from Sisco (India), 
HiMedta (India) aad Qualigens (India). 
2,2•Diphenyl•2•picrvlhydrazyl (DPPH) radical scavenging 
Activity 
The free radical scavenging act sir; of TQ and standard refer-
ence compound i.e. Gallic acid was analyze-1 by the DPPII assay 
as described by Sanchez•Moreno at al. (1'198)) 18) with minor 
modification. In this assay. I nil of van'mg concentrations of 
TQ (i12 S 2 0 rrrgr nnI) dissolved in I nil of ethanol. were mixed 
with 1 ml of ethanol solution of DPPII (0.2 niM). The mixture 
was vortexed and incubated for 30 min. The optical density of 
the solution was measured at S 17 nm using Hitachi 2010 spec• 
trophotometer. Gallic acid (pg/nil) has been used as a standard. 
The DPPII radical scavenging activity ivas calculated from the 
absorption value by the following equation: 
Radical scavenging activity (cyu) _ ((013 control - OD sample)/ 
Of) control] X 100 
Reducing Power 
Total rectucmg power wasdeterttuned as described by ThuCl at., 
(2002)) 191 with some modifications. 7Q (0.5-2.0 rngjrnl) in 1 
nil ofethanol were rntxed with 2 Still of pltasphate buffer (0.2 M, 
pH 6.6) and 2.5 nil of 1.i, potassium ferricyanidc (K3Fc(CN)6]; 
the mixture was then incubated at 50°C for 30 minute. 2.5 nil 
of sruhtoroateoc acid (10°/v) was then added to the mixture, 
which was then centrifuged at 3000 rpm for 10 min. 2.5 ml of 
supernatant was mixed with 2.5 nil of distilled water and 0.5 
nil FeC13 (0.1('k), and the absorbance was measured at 700 rim. 
Ferric Reducing Antioxidant Power (FRAP) assay 
FRAP asssay was carried out by the method of 8enzre & Strain 
(1(196)(20] with slight tnodiftcatton. The method is based on the 
reduction of a ferric 2,4.b-tapyridyl's'triozine complex (Fe3* 
-TPTZ) to its ferrous (Fe2c TPTZ), intensive blue colored form 
in the presence of antioxidant. 300 mM acetate buffer, pH 3.6, 10 
mM TPTZ and 20 mM FeCl3 were ,nixed in a ratio of 10:1:1 to 
be a working FRAP reagent. 100 td of TI) was ,nixed with 3ml of 
FRAP reagent and incubated at 37°C for 30 min. The absorbance 
at 593 nrn was monitored. All reagents were freshly prepared 
before used Aqueous s,trmun of known Fe (II) concentration 
was used iii: r it iemtion (in a r,urge of 100.1(100 tnnnl/I). 
AAPH-induced RBC hemolysis assay 
Blood was obtained from healthy human donor and collected 
into hepannacd tubes through the Itluud Nank. I- N Mediral 
College, Aligarh Muslim Uni:ers ty, Aligarh. Erythrocytes were 
separated front plasma and the bully coat. and washed three 
times with S volumes of phosphate buffered salne (PBS), pH 
7.4 During every wash. ABCs were centrifuged at 4000rpm for 
10 min to obtain packed cell preparation (21). The packed RBC 
was suspended in four volumes of PBS solution after the last 
wash. AAPII• a peroxyl radical nvici.itoi, was used for RBC hentol• 
ysrs [211. Addition of AAPH to the suspension of washed eryth-
rocvtes induces the oxidation of membrane lipids and proteins, 
resulting in hernolysis 0.5 ml oftheerythrocyte suspension was 
rntxed with O.S ml of PBS snuhwirn containing varying amounts 
of TQ. 0.5 nil of 200 mM AAPH was added. The reacttoo mixture 
.gas shaken gently while being incubated at 37°C for 3 hr. After 
uncuhation, reaction mixture was diluted t.-,Ih eight volumes of 
PRS and centrduge'd at 4000 rpm for S min The Absorbance (A) 
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ABSTRACT: In the aeruhtr ervironmenr, rea:7nr axigen species are the must lethal by-products ci 
iretabDGwti that nediare ruant diseases includingcancer• diabetes, immune deficiency diseases and ageing. 
Present study is aimed it, assc's.s the cnuioxirlant artivitt at Thorn/ and its implication in diabetes in vitro. 
Thymol rras evaluated he ferric reducing antiamdant potser (FR:IPI assay and measurement of its total 
reducing poster, iota! phenolic content and 1.1-diphenrl 2-picri lhy dra _t/ (DPl'N) scavenging activity. 
Furthermore. the extract in vitro was also checked if it protects red Mood cells (R8('s) from 2.2-a_o-hi.s(2-
amidinopropane) dihydrochloride f.4.IPHI-induced henolisis in the samples of diabetic patients and healthy 
subjects 
TIymo! dentunstraied good Jerrzc reducing abrlitr and high reducing power that can he attributed to its higher 
amount of phenolic con(ents. ,1Icreoter. it scavenges upto a great extent. Tht•mol rras able to inhibit RBC_' 
hemolvsc:r hr N6 6912.34% wit! '?.04s2.1 % in normal and diabetic patients respectively 
Our findings reveal that dn'mol possess antioxidant properties and could serve as a tree radical scavenger• and 
ibis Just i/ies its uves in jolAloric me•clie•ines 
Keywords: Tltrmol. /)ruhr; 	Irrr >.rul:cnts and Rl ).t 
1. 	It vI'ltODIif"1'1ON 
In the aerobic cmtronn•ernt. reactive os er species are the most lethal byproducts of metabolism that 
mediate marts diseases inclidin2 cancer, diabetes, imrnunodeticiencs diseases and ageing. There should he a 
halance hetsseen antioxidants and prooxidants to maintain the body's optimal physiological conditions. 
Ss nthetic antioxidants. such as BHT and DHA have recently been suspected to cause negative health effects and 
therefore their application have been restricted [ 1 J. 
?Ian} studies have demonstrated a correlation betuecn ttic oxidative stress defense and the antioxidant 
properties of phytoconstituents 12.3). Phenolic phvtochemicals found in singnificant quantities in vegetables. 
fruits. spices and seeds. The have been regarded as possible antioxidants. Their roles in food industry and in 
chemopresention of diseases resulting due to oxidatise stress have become an area of active research (4.5,6,7,8]. 
Thane has been cumntonl used in foods mainl for the flavor. aroma and preservation arid also in folk 
medicine since the ancient Greeks. Egyptians and Romans. Thymol. carsacrol and terpinine are major 
constituents of the oils of the me [9.10). Th,,mol can be used for the treatment of oral infectious diseases because 
of - their inhibitor- activity on oral bacteria [ 11.12 
In this study, we investigated the antioxidant properties of thymol and its effect on :\,\PH-induced 
herttolysis in ernlbrocctes obtained fiom diabetic p,ui  err ts and health\ suhjrct1. 
ll. 	MATERIALS AND 1lIF11l0o)S 
2.1. 	tIuterial, 
Pure th~mul. er.urulc,rnd ssltilc snlirl >uhaance. tium Irari.t .', - Iihcml-I-PicnlMJr.tnl 1l)PPH) 
and L'-aevhis ('-mnethvl propion-amidine) dihydrochtoride rAAPH) from Aldrich. 
2.2. 	Methods 
2.2.1. 	lIctcrmination of Total Phenolic (•ontcnt 
Total phenolic content was determined by the method of (13J with slight modification. In each analysis. 
.i8 nil of distilled %rater was pipette) into test tubes• follosted by addition of 20 Ill of standard solution, sample 
solution, or water. Vortex all tubes. Then 100 µl of Folin-Ciocaltcau's (PC) reagent was added to each test tube, 
and the solutions were mixed again. After 30s and before S minute, 300t1 of 20% sodium carbonate solution 
was added. The solutions sere left at room temperature for 2 hour. Then the absorbance of the developed blue 
colour was determined at 765 nm. Gallic acid was used as a standard for the calibration curve and reported as 
gallic acid equivalents (mg) using the follossing equation based on (lie calibration curve. 
A = (1.001 .s + (I 01)409 	it = (I ')'J- 
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